| 1 |
Bylicki O, Tomasini P, Radj G, Guisier F, Monnet I, Ricordel C, Bigay-Game L, Geier M, Chouaid C, Daniel C, Swalduz A, Toffart AC, Doubre H, Peloni JM, Moreau D, Subtil F, Grellard JM, Castera M, Clarisse B, Martins-Lavinas PH, Decroisette C, Greillier L; GFPC. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. Eur J Cancer 2023;183:38-48. [PMID: 36801605 DOI: 10.1016/j.ejca.2023.01.014] [Reference Citation Analysis]
|
| 2 |
Krishnan SM, Friberg LE, Mercier F, Zhang R, Wu B, Jin JY, Hoang T, Ballinger M, Bruno R, Karlsson MO. Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study. Clin Pharmacol Ther 2023;113:851-8. [PMID: 36606486 DOI: 10.1002/cpt.2838] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Shen Y, Lu J, Hu F, Qian J, Zhang X, Zhong R, Zhong H, Chu T, Han B. Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial. J Cancer Res Clin Oncol 2023;149:1417-24. [PMID: 35482076 DOI: 10.1007/s00432-022-03964-9] [Reference Citation Analysis]
|
| 4 |
Mei Y, Khan H, Shishikura M, Ishiyama S, Khan A, Orita H, Brock MV. pfeRNAs-A Novel Class of Small Non-coding RNAs With Real Translational Potential. J Surg Res 2023;284:237-44. [PMID: 36599285 DOI: 10.1016/j.jss.2022.12.002] [Reference Citation Analysis]
|
| 5 |
Tanizaki S, Matsumoto K, Tamiya A, Taniguchi Y, Matsuda Y, Uchida J, Ueno K, Kawachi H, Tamiya M, Yanase T, Suzuki H, Okishio K. Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study. Eur J Clin Pharmacol 2023;79:503-11. [PMID: 36773042 DOI: 10.1007/s00228-023-03452-0] [Reference Citation Analysis]
|
| 6 |
Zou Y, Xu Y, Chen X, Zheng L. Advances in the application of immune checkpoint inhibitors in gynecological tumors. International Immunopharmacology 2023;117:109774. [DOI: 10.1016/j.intimp.2023.109774] [Reference Citation Analysis]
|
| 7 |
Gridelli C, Peters S, Velcheti V, Attili I, de Marinis F. Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). ESMO Open 2023;8:101192. [PMID: 36965261 DOI: 10.1016/j.esmoop.2023.101192] [Reference Citation Analysis]
|
| 8 |
Landi L, Delmonte A, Bonetti A, Pasello G, Metro G, Mazzoni F, Borra G, Giannarelli D, Andrikou K, Mangiola D, Gori S, D'Andrea MR, Minuti G, Resuli B, Laudisi A, Vidiri A, Conti L, Cappuzzo F. Combi-TED: a new trial testing Tedopi(®) with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. Future Oncol 2023. [PMID: 36946237 DOI: 10.2217/fon-2022-0913] [Reference Citation Analysis]
|
| 9 |
Zhao B, Wu B, Feng N, Zhang X, Zhang X, Wei Y, Zhang W. Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. J Hematol Oncol 2023;16:28. [PMID: 36945046 DOI: 10.1186/s13045-023-01426-4] [Reference Citation Analysis]
|
| 10 |
Hisakane K, Seike M, Sugano T, Matsuda K, Kashiwada T, Nakamichi S, Matsumoto M, Miyanaga A, Noro R, Kubota K, Gemma A. Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. Gene 2023;857:147177. [PMID: 36623674 DOI: 10.1016/j.gene.2023.147177] [Reference Citation Analysis]
|
| 11 |
Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J, Jerusalem G, Penel N, Saada-Bouzid E, Garrido P, Helwig C, Locke G, Ojalvo LS, Gulley JL. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. Oncologist 2023;28:258-67. [PMID: 36571770 DOI: 10.1093/oncolo/oyac253] [Reference Citation Analysis]
|
| 12 |
Assaf ZJF, Zou W, Fine AD, Socinski MA, Young A, Lipson D, Freidin JF, Kennedy M, Polisecki E, Nishio M, Fabrizio D, Oxnard GR, Cummings C, Rode A, Reck M, Patil NS, Lee M, Shames DS, Schulze K. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med 2023. [PMID: 36928816 DOI: 10.1038/s41591-023-02226-6] [Reference Citation Analysis]
|
| 13 |
Ohashi K, Nishito Y, Fukuda H, Sadahiro R, Yoshida Y, Watanabe S, Motoi N, Sonobe Y, Mizuno H, Tsunoda H, Tatsumi K, Suzuki T, Ochiai A, Aoki K. Neutrophil-to-lymphocyte ratio is a prognostic factor reflecting immune condition of tumor microenvironment in squamous cell lung cancer.. [DOI: 10.21203/rs.3.rs-2618362/v1] [Reference Citation Analysis]
|
| 14 |
Reck M, Popat S, Grohé C, Corral J, Novello S, Gottfried M, Brueckl W, Radonjic D, Kaiser R, Heymach J. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. Lung Cancer 2023;179:107173. [PMID: 36940614 DOI: 10.1016/j.lungcan.2023.03.009] [Reference Citation Analysis]
|
| 15 |
Sridhar A, Singh PK, Parikh K. Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions. International Journal of Cancer Care and Delivery 2023. [DOI: 10.53876/001c.72631] [Reference Citation Analysis]
|
| 16 |
Uprety D, Surapaneni M. Lung cancer management in low and middle-income countries - current challenges and potential solutions. International Journal of Cancer Care and Delivery 2023. [DOI: 10.53876/001c.73042] [Reference Citation Analysis]
|
| 17 |
Bruno R, Marchand M, Yoshida K, Chan P, Li H, Zou W, Mercier F, Chanu P, Wu B, Lee A, Li C, Jin JY, Maitland ML, Reck M, Socinski MA. Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clin Cancer Res 2023;29:1047-55. [PMID: 36595566 DOI: 10.1158/1078-0432.CCR-22-2323] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
L. Russell B, T. Malindisa S, A. Sooklal S, Ntwasa M. Current Advances in Immune Checkpoint Therapy. Immune Checkpoint Inhibitors - New Insights and Recent Progress 2023. [DOI: 10.5772/intechopen.107315] [Reference Citation Analysis]
|
| 19 |
Escudero-Vilaplana V, Collado-Borrell R, De Castro J, Insa A, Martínez A, Fernández E, Sullivan I, Flores A, Arrabal N, Carcedo D, Manzaneque A. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. J Med Econ 2023;:1-16. [PMID: 36883193 DOI: 10.1080/13696998.2023.2188844] [Reference Citation Analysis]
|
| 20 |
Bertaglia V, Morelli AM, Solinas C, Aiello MM, Manunta S, Denaro N, Tampellini M, Scartozzi M, Novello S. Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. Crit Rev Oncol Hematol 2023;184:103954. [PMID: 36878396 DOI: 10.1016/j.critrevonc.2023.103954] [Reference Citation Analysis]
|
| 21 |
Lei H, Tao D, Zhang N, Sun M, Sun L, Yang D, Jiang Y, Zhou W, Xie Y, Wang Y. Nomogram prediction for the risk of venous thromboembolism in patients with lung cancer. Cancer Cell Int 2023;23:40. [PMID: 36872336 DOI: 10.1186/s12935-023-02882-1] [Reference Citation Analysis]
|
| 22 |
Bai X, Guo ZQ, Zhang YP, Fan ZZ, Liu LJ, Liu L, Long LL, Ma SC, Wang J, Fang Y, Tang XR, Zeng YJ, Pan X, Wu DH, Dong ZY. CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nat Commun 2023;14:1247. [PMID: 36871040 DOI: 10.1038/s41467-023-36892-4] [Reference Citation Analysis]
|
| 23 |
Ko MM, Jeong MK, Choi CM, Lee SH, Chun J, Yi JM, Jang H, Lee SY. Safety and Efficacy of Bojungikki-Tang in Advanced NSCLC Patients Receiving Treatment with Immune Checkpoint Inhibitors: Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Trial. Int J Environ Res Public Health 2023;20. [PMID: 36901517 DOI: 10.3390/ijerph20054507] [Reference Citation Analysis]
|
| 24 |
Rudin CM, Cervantes A, Dowlati A, Besse B, Ma B, Costa DB, Schmid P, Heist R, Villaflor VM, Spahn J, Li S, Cha E, Riely GJ, Gettinger S. Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. ESMO Open 2023;8:101160. [PMID: 36871392 DOI: 10.1016/j.esmoop.2023.101160] [Reference Citation Analysis]
|
| 25 |
Hofmann I, Baum A, Hofmann MH, Trapani F, Reichel-Voda C, Ehrensperger D, Aichinger M, Ebner F, Budano N, Schweifer N, Sykora M, Depla E, Boucneau J, Gschwind A, Kraut N, Hilberg F, Künkele KP. Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition. J Pharmacol Exp Ther 2023;384:331-42. [PMID: 36241203 DOI: 10.1124/jpet.122.001255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Berlin, 7. Dezember 2022 – Aktuelle Empfehlungen zum Lieferengpass von Nanopartikel-Albumin-gebundenem Paclitaxel (nab-Paclitaxel). Senologie - Zeitschrift für Mammadiagnostik und -therapie 2023;20:22-24. [DOI: 10.1055/a-1994-9296] [Reference Citation Analysis]
|
| 27 |
Molife C, Brnabic A, Stefaniak VJ, Belger MA, Gruver K, Chen JV, Souri S, Blumenschein GR Jr. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. Immunotherapy 2023;15:293-309. [PMID: 36748406 DOI: 10.2217/imt-2022-0252] [Reference Citation Analysis]
|
| 28 |
Villacampa G, Cresta Morgado P, Navarro V, Viaplana C, Dienstmann R. Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy. Cancer Treatment Reviews 2023. [DOI: 10.1016/j.ctrv.2023.102542] [Reference Citation Analysis]
|
| 29 |
Provencio M, Ortega AL, Coves-Sarto J, Calvo V, Marsé-Fabregat R, Dómine M, Guirado M, Carcereny E, Fernández N, Álvarez R, Blanco R, León-Mateos L, Sánchez-Torres JM, Sullivan IG, Cobo M, Sánchez-Hernández A, Massuti B, Sierra-Rodero B, Mártinez-Toledo C, Serna-Blasco R, Romero A, Cruz-Bermúdez A. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncol 2023;9:344-53. [PMID: 36520426 DOI: 10.1001/jamaoncol.2022.5959] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 30 |
Shantzer LB, Dougherty SC, Bolte F, Melson JW, Reed DR, Lynch AC, Gentzler RD, Novicoff W, Hall RD. Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report. Clin Lung Cancer 2023;24:e60-4. [PMID: 36526550 DOI: 10.1016/j.cllc.2022.11.006] [Reference Citation Analysis]
|
| 31 |
Yang F, Xu K, Zhou YG, Ren T. Insight into autophagy in platinum resistance of cancer. Int J Clin Oncol 2023;28:354-62. [PMID: 36705869 DOI: 10.1007/s10147-023-02301-5] [Reference Citation Analysis]
|
| 32 |
Sattler M, Mambetsariev I, Fricke J, Tan T, Liu S, Vaidehi N, Pisick E, Mirzapoiazova T, Rock AG, Merla A, Sharma S, Salgia R. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. J Clin Med 2023;12. [PMID: 36902723 DOI: 10.3390/jcm12051936] [Reference Citation Analysis]
|
| 33 |
Negrao MV, Papadimitrakopoulou VA, Price AC, Tam AL, Furqan M, Laroia ST, Massarelli E, Pacheco J, Heymach JV, Tsao AS, Walker GV, Vora L, Mauro D, Kelley H, Wooldridge JE, Krieg AM, Niu J. Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. JTO Clin Res Rep 2023;4:100423. [PMID: 36925644 DOI: 10.1016/j.jtocrr.2022.100423] [Reference Citation Analysis]
|
| 34 |
Zaim R, Redekop K, Uyl-de Groot CA. Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer. J Cancer Policy 2023;35:100382. [PMID: 36592861 DOI: 10.1016/j.jcpo.2022.100382] [Reference Citation Analysis]
|
| 35 |
Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat Rev Clin Oncol 2023;20:143-59. [PMID: 36639452 DOI: 10.1038/s41571-022-00718-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 36 |
O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, Eccles LJ, Varol N, Waser N, Penrod JR, Goring S. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis. Lung Cancer 2023;177:11-20. [PMID: 36669321 DOI: 10.1016/j.lungcan.2023.01.006] [Reference Citation Analysis]
|
| 37 |
Mortezaee K, Majidpoor J. Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progresses. Heliyon 2023;9:e14566. [PMID: 36950599 DOI: 10.1016/j.heliyon.2023.e14566] [Reference Citation Analysis]
|
| 38 |
Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 2023;22:213-34. [PMID: 36509911 DOI: 10.1038/s41573-022-00615-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 39 |
Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Oki M, Tachihara M, Fujimoto D, Hayashi H, Yamaguchi K, Yamamoto S, Iwama E, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. Lung Cancer 2023;177:44-50. [PMID: 36731290 DOI: 10.1016/j.lungcan.2023.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 40 |
Kim SY, Costa DB, Shibahara D, Kobayashi S, Halmos B. EGFR-Directed Therapy in Lung Cancer. 2023. [DOI: 10.1017/9781009342285] [Reference Citation Analysis]
|
| 41 |
Mitsuhashi A, Koyama K, Ogino H, Afroj T, Nguyen NT, Yoneda H, Otsuka K, Sugimoto M, Kondoh O, Nokihara H, Hanibuchi M, Takizawa H, Shinohara T, Nishioka Y. Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. Cell Rep 2023;:112162. [PMID: 36870329 DOI: 10.1016/j.celrep.2023.112162] [Reference Citation Analysis]
|
| 42 |
Fujimoto A, Koutake Y, Hisamatsu D, Ookubo N, Yabuuchi Y, Kamimura G, Kai T, Kozono A, Ootsu T, Suzuki H, Matsuo K, Kuwahara K, Oiwane Y, Nagata Y, Tanimoto K, Sato E, Suenaga M, Uehara T, Ikari A, Endo S, Hiraki Y, Kawamata Y. Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study. Cancer Immunol Immunother 2023. [PMID: 36849845 DOI: 10.1007/s00262-023-03408-4] [Reference Citation Analysis]
|
| 43 |
Nitta N, Morimoto Y, Tani N, Shimamoto T. Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation. Cureus 2023. [DOI: 10.7759/cureus.35545] [Reference Citation Analysis]
|
| 44 |
Montrone M, Rosati G, Longo V, Catino A, Massafra R, Nardone A, Pesola F, Montagna ES, Marech I, Pizzutilo P, Galetta D. Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. J Clin Med 2023;12. [PMID: 36902620 DOI: 10.3390/jcm12051833] [Reference Citation Analysis]
|
| 45 |
Amoroso V, Gallo F, Alberti A, Paloschi D, Ferrari Bravo W, Esposito A, Cosentini D, Grisanti S, Pedersini R, Petrelli F, Berruti A. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies. ESMO Open 2023;8:100787. [PMID: 36842300 DOI: 10.1016/j.esmoop.2023.100787] [Reference Citation Analysis]
|
| 46 |
So WV, Dejardin D, Rossmann E, Charo J. Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. J Immunother Cancer 2023;11. [PMID: 36822668 DOI: 10.1136/jitc-2022-006464] [Reference Citation Analysis]
|
| 47 |
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 2023;22:40. [PMID: 36810079 DOI: 10.1186/s12943-023-01740-y] [Reference Citation Analysis]
|
| 48 |
De Castro J, Insa A, Collado-Borrell R, Escudero-Vilaplana V, Martínez A, Fernandez E, Sullivan I, Arrabal N, Carcedo D, Manzaneque A. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulm Med 2023;23:69. [PMID: 36809990 DOI: 10.1186/s12890-023-02356-0] [Reference Citation Analysis]
|
| 49 |
Takeuchi S, Kubota K, Sugawara S, Teramukai S, Noro R, Fujikawa K, Hirose T, Atagi S, Minami S, Iida S, Kuraishi H, Aiba T, Minegishi Y, Matsumoto M, Seike M, Gemma A, Kawahara M; Japan-Multinational Trial Organization (JMTO). Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01). Cancer Med 2023. [PMID: 36807519 DOI: 10.1002/cam4.5652] [Reference Citation Analysis]
|
| 50 |
Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T; POSEIDON investigators. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol 2023;41:1213-27. [PMID: 36327426 DOI: 10.1200/JCO.22.00975] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 51 |
Sato M, Maishi N, Hida Y, Yanagawa-Matsuda A, Alam MT, Sakakibara-Konishi J, Nam JM, Onodera Y, Konno S, Hida K. Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy. Cancer Med 2023. [PMID: 36808261 DOI: 10.1002/cam4.5696] [Reference Citation Analysis]
|
| 52 |
Tang H, Yang D, Luo G, He J, Yi G, Chen Z, Li H, Luo Q, Huang N, Luo H. Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report. Medicine (Baltimore) 2023;102:e32924. [PMID: 36800614 DOI: 10.1097/MD.0000000000032924] [Reference Citation Analysis]
|
| 53 |
Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, Finley GG, Kaul MD, Yu W, Paranthaman N, Bara I, West HJ. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncol 2023. [PMID: 36795388 DOI: 10.1001/jamaoncol.2022.7711] [Reference Citation Analysis]
|
| 54 |
Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer 2023. [PMID: 36797503 DOI: 10.1038/s43018-023-00515-0] [Reference Citation Analysis]
|
| 55 |
Russano M, La Cava G, Cortellini A, Citarella F, Galletti A, Di Fazio GR, Santo V, Brunetti L, Vendittelli A, Fioroni I, Pantano F, Tonini G, Vincenzi B. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. Curr Oncol 2023;30:2366-87. [PMID: 36826142 DOI: 10.3390/curroncol30020181] [Reference Citation Analysis]
|
| 56 |
Zhang C, Zhou W, Zhang D, Ma S, Wang X, Jia W, Guan X, Qian K. Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. Open Med (Wars) 2023;18:20220574. [PMID: 36820064 DOI: 10.1515/med-2022-0574] [Reference Citation Analysis]
|
| 57 |
Moliner L, Spurgeon L, Califano R. Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? ESMO Open 2023;8:100879. [PMID: 36791668 DOI: 10.1016/j.esmoop.2023.100879] [Reference Citation Analysis]
|
| 58 |
Fu S, Huang H, Shang K, Tu G, Zhong P, Li S, Zhu X, Peng S, Liu Y, Lu Z, Chen L. Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer. Future Oncol 2023. [PMID: 36779488 DOI: 10.2217/fon-2022-0861] [Reference Citation Analysis]
|
| 59 |
Manning-Bennett AT, Cervesi J, Bandinelli PA, Sorich MJ, Hopkins AM. Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials. Biomedicines 2023;11. [PMID: 36831064 DOI: 10.3390/biomedicines11020528] [Reference Citation Analysis]
|
| 60 |
Nakamura A, Yamaguchi O, Mori K, Miura K, Tamiya M, Oba T, Yanagitani N, Mizutani H, Ninomiya T, Kajiwara T, Ito K, Miyanaga A, Arai D, Kodama H, Kobayashi K, Kaira K. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). Eur J Cancer 2023;184:62-72. [PMID: 36905770 DOI: 10.1016/j.ejca.2023.01.025] [Reference Citation Analysis]
|
| 61 |
Alessi JV, Elkrief A, Ricciuti B, Wang X, Cortellini A, Vaz VR, Lamberti G, Frias RL, Venkatraman D, Fulgenzi CAM, Pecci F, Recondo G, Di Federico A, Barrichello A, Park H, Nishino M, Hambelton GM, Egger JV, Ladanyi M, Digumarthy S, Johnson BE, Christiani DC, Lin X, Gainor JF, Lin JJ, Pinato DJ, Schoenfeld AJ, Awad MM. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. J Thorac Oncol 2023:S1556-0864(23)00121-1. [PMID: 36775193 DOI: 10.1016/j.jtho.2023.01.091] [Reference Citation Analysis]
|
| 62 |
Kandeel M, Althumairy D, El-sabagh IM, Shousha S, Hussin Y, Meligy AMA, Zabady MK, Zahran KM, Elkhair N, Hereba A, Elsebaei MG, Elamin A, Irshad F, Sufyan M, El-hassan EM, Albokhadaim I. The Interaction of Programmed Cell Death Protein and Its Ligands with Non-Coding RNAs in Neoplasms: Emerging Anticancer Immunotherapeutics. Processes 2023;11:538. [DOI: 10.3390/pr11020538] [Reference Citation Analysis]
|
| 63 |
Goh KY, Cheng TY, Tham SC, Lim DW. Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. Biomedicines 2023;11. [PMID: 36831044 DOI: 10.3390/biomedicines11020508] [Reference Citation Analysis]
|
| 64 |
Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 2023;14:695. [PMID: 36755027 DOI: 10.1038/s41467-023-36328-z] [Reference Citation Analysis]
|
| 65 |
Zhang X, Zhang J, Liu P, Wang J, Zhao K, Zhu Z, Gu K, Zhao W. Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer. Front Oncol 2023;13:1022042. [PMID: 36845690 DOI: 10.3389/fonc.2023.1022042] [Reference Citation Analysis]
|
| 66 |
Stămat LB, Dinescu S, Costache M. Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy. Int J Mol Sci 2023;24. [PMID: 36834660 DOI: 10.3390/ijms24043245] [Reference Citation Analysis]
|
| 67 |
Torresan S, Zussino G, Cortiula F, Follador A, Fasola G, Girometti R, Cereser L. Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer. J Clin Med 2023;12. [PMID: 36835802 DOI: 10.3390/jcm12041266] [Reference Citation Analysis]
|
| 68 |
Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, Bei R, Buonomo OC, Roselli M, Mauriello A, Barillari G. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. Int J Mol Sci 2023;24. [PMID: 36834641 DOI: 10.3390/ijms24043226] [Reference Citation Analysis]
|
| 69 |
Zhao J, Stephan-Falkenau S, Schuler M, Arndt B. Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2023;15. [PMID: 36765942 DOI: 10.3390/cancers15030988] [Reference Citation Analysis]
|
| 70 |
Long Y, Chen R, Yu X, Tong Y, Peng X, Li F, Hu C, Sun J, Gong L. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner. Cancer Immunol Res 2023;11:241-60. [PMID: 36484740 DOI: 10.1158/2326-6066.CIR-22-0439] [Reference Citation Analysis]
|
| 71 |
Meri-Abad M, Moreno-Manuel A, García SG, Calabuig-Fariñas S, Pérez RS, Herrero CC, Jantus-Lewintre E. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer. Crit Rev Oncol Hematol 2023;182:103891. [PMID: 36565893 DOI: 10.1016/j.critrevonc.2022.103891] [Reference Citation Analysis]
|
| 72 |
Zhou Y, Chen H, Tang L, Feng Y, Tao Y, Huang L, Lou N, Shi Y. Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Immunotherapy 2023;15:209-20. [PMID: 36710655 DOI: 10.2217/imt-2022-0028] [Reference Citation Analysis]
|
| 73 |
Gu T, Jiang A, Zhou C, Lin A, Cheng Q, Liu Z, Zhang J, Luo P. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. Int J Cancer 2023;152:480-95. [PMID: 36274626 DOI: 10.1002/ijc.34332] [Reference Citation Analysis]
|
| 74 |
Berlin, 7. Dezember 2022 – Aktuelle Empfehlungen zum Lieferengpass von Nanopartikel-Albumin-gebundenem Paclitaxel (nab-Paclitaxel). Geburtshilfe Frauenheilkd 2023;83:158-159. [DOI: 10.1055/a-1998-7964] [Reference Citation Analysis]
|
| 75 |
Ni JJ, Zhang ZZ, Ge MJ, Chen JY, Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. Acta Pharmacol Sin 2023;44:288-307. [PMID: 35927312 DOI: 10.1038/s41401-022-00953-z] [Reference Citation Analysis]
|
| 76 |
Sun C, Liu Y, Zhang P, Wang X, Xu Y, Lin X, Ma X, Guo Y, Qiu S, Shao G, Yang Z, Ma K. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. J Cancer Res Clin Oncol 2023;149:819-31. [PMID: 35192053 DOI: 10.1007/s00432-021-03896-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 77 |
Kwok WC, Cheong TF, Chiang KY, Ho JCM, Lam DCL, Ip MSM, Tam TCC. Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non-small cell carcinoma. Asia Pac J Clin Oncol 2023;19:87-95. [PMID: 35445527 DOI: 10.1111/ajco.13658] [Reference Citation Analysis]
|
| 78 |
Bourreau C, Treps L, Faure S, Fradin D, Clere N. Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies. Pharmacol Ther 2023;242:108347. [PMID: 36642389 DOI: 10.1016/j.pharmthera.2023.108347] [Reference Citation Analysis]
|
| 79 |
Cheng Y, Zhou Q, Han B, Fan Y, Shan L, Chang J, Sun S, Fang J, Chen Y, Sun J, Wu G, Mann H, Naicker K, Shire N, Mok T, de Castro G Jr. NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. Lung Cancer 2023;178:87-95. [PMID: 36806898 DOI: 10.1016/j.lungcan.2023.01.013] [Reference Citation Analysis]
|
| 80 |
Borghaei H, Ciuleanu TE, Lee JS, Pluzanski A, Caro RB, Gutierrez M, Ohe Y, Nishio M, Goldman J, Ready N, Spigel DR, Ramalingam SS, Paz-Ares LG, Gainor JF, Ahmed S, Reck M, Maio M, O'Byrne KJ, Memaj A, Nathan F, Tran P, Hellmann MD, Brahmer JR. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. Ann Oncol 2023;34:173-85. [PMID: 36414192 DOI: 10.1016/j.annonc.2022.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 81 |
Yan W, Zhong WZ, Liu YH, Chen Q, Xing W, Zhang Q, Liu L, Ge D, Chen K, Yang F, Lin X, Song L, Shi W, Wu YL. Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial. J Thorac Oncol 2023;18:194-203. [PMID: 36191882 DOI: 10.1016/j.jtho.2022.09.222] [Reference Citation Analysis]
|
| 82 |
Aggarwal H, Ndirangu K, Winfree KB, Muehlenbein CE, Zhu E, Tongbram V, Thom H. A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer. J Comp Eff Res 2023;12:e220016. [PMID: 36621905 DOI: 10.2217/cer-2022-0016] [Reference Citation Analysis]
|
| 83 |
liang L, Wang B, Wang C, Xie S. Gender is a non-negligible risk factor affecting the overall survival time of NSCLC patients: a nationwide population-based study.. [DOI: 10.21203/rs.3.rs-2382536/v1] [Reference Citation Analysis]
|
| 84 |
Hsu PC, Chen TD, Tsai TY, Yang CT. Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports. Clin Pract 2023;13:200-5. [PMID: 36826160 DOI: 10.3390/clinpract13010018] [Reference Citation Analysis]
|
| 85 |
Allmann V, Dyntar D, Lehnick D, Dressler M, Zeidler K, Niederberger P, Godau J, Diebold J, Gautschi O. Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. Swiss Med Wkly 2023;153:40039. [PMID: 36787492 DOI: 10.57187/smw.2023.40039] [Reference Citation Analysis]
|
| 86 |
Tang WF, Ye HY, Tang X, Su JW, Xu KM, Zhong WZ, Liang Y. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone. Front Oncol 2023;13:1063183. [PMID: 36776323 DOI: 10.3389/fonc.2023.1063183] [Reference Citation Analysis]
|
| 87 |
Jiménez Galán R, Prado-Mel E, Alvarez de Sotomayor M, Martin LA. Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. Biology (Basel) 2023;12. [PMID: 36829469 DOI: 10.3390/biology12020191] [Reference Citation Analysis]
|
| 88 |
Rizzo A, Mollica V, Tateo V, Tassinari E, Marchetti A, Rosellini M, De Luca R, Santoni M, Massari F. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunol Immunother 2023. [PMID: 36695827 DOI: 10.1007/s00262-023-03366-x] [Reference Citation Analysis]
|
| 89 |
Du X, Wen S, Shi R, Xia J, Wang R, Zhang Y, Pan B, Wu X, Zhu W, Feng J, Wang X, Shen B. Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study. BMC Cancer 2023;23:83. [PMID: 36698098 DOI: 10.1186/s12885-023-10502-4] [Reference Citation Analysis]
|
| 90 |
Vihinen H, Jokinen A, Laajala TD, Wahid N, Peltola L, Kettunen T, Rönkä A, Tiainen L, Skyttä T, Kohtamäki L, Tulokas S, Karhapää H, Hernberg M, Silvoniemi M, Mattila KE. Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy. Clin Lung Cancer 2023:S1525-7304(23)00002-5. [PMID: 36774235 DOI: 10.1016/j.cllc.2023.01.004] [Reference Citation Analysis]
|
| 91 |
Cheng S, Li J, Li B, Tang L, Yin T, Liu S. Atezolizumab versus Pembrolizumab for First-line Treatment in Non-small-cell Lung Cancer with High PD-L1 Expression: A Network Meta-analysis and Cost-effectiveness Analysis from Chinese Perspectives.. [DOI: 10.21203/rs.3.rs-2457024/v1] [Reference Citation Analysis]
|
| 92 |
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023:S0923-7534(22)04781-0. [PMID: 36872130 DOI: 10.1016/j.annonc.2022.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 93 |
Pang LL, Gan JD, Huang YH, Liao J, Zhuang WT, Ali WA, Hong SD, Zhang L, Fang WF. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. BMC Cancer 2023;23:72. [PMID: 36670414 DOI: 10.1186/s12885-022-10446-1] [Reference Citation Analysis]
|
| 94 |
Marin-Acevedo JA, Pellini B, Kimbrough EO, Hicks JK, Chiappori A. Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. Cancers (Basel) 2023;15. [PMID: 36765587 DOI: 10.3390/cancers15030629] [Reference Citation Analysis]
|
| 95 |
Yang SC, Ou HT, Su WC, Wang SY. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer. Cancer Med 2023. [PMID: 36653947 DOI: 10.1002/cam4.5632] [Reference Citation Analysis]
|
| 96 |
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023:S0923-7534(22)04785-8. [PMID: 36669645 DOI: 10.1016/j.annonc.2022.12.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 97 |
Khadela A, Chavda VP, Postwala H, Ephraim R, Apostolopoulos V, Shah Y. Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. Cancers (Basel) 2023;15. [PMID: 36672492 DOI: 10.3390/cancers15020543] [Reference Citation Analysis]
|
| 98 |
Liu L, Chen J. Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. Medical Review 2023;0. [DOI: 10.1515/mr-2022-0033] [Reference Citation Analysis]
|
| 99 |
Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, Zheng L, Pan CX. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol 2023;12:10. [PMID: 36647169 DOI: 10.1186/s40164-023-00372-8] [Reference Citation Analysis]
|
| 100 |
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Tai Y, Ma X, Shi W; CameL Study Group. Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial. J Thorac Oncol 2023:S1556-0864(22)01993-1. [PMID: 36646210 DOI: 10.1016/j.jtho.2022.12.017] [Reference Citation Analysis]
|
| 101 |
Wolf A, Stratmann JA, Shaid S, Niklas N, Calleja A, Ubhi H, Munro R, Waldenberger D, Carroll R, Daumont MJ, Penrod JR, Lacoin L, Rohde G. Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018. BMC Pulm Med 2023;23:16. [PMID: 36639770 DOI: 10.1186/s12890-022-02288-1] [Reference Citation Analysis]
|
| 102 |
Muto S, Enta A, Maruya Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, Watanabe M, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Hamada K, Suzuki H. Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. Biomedicines 2023;11. [PMID: 36672698 DOI: 10.3390/biomedicines11010190] [Reference Citation Analysis]
|
| 103 |
Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother 2023. [PMID: 36633661 DOI: 10.1007/s00262-022-03349-4] [Reference Citation Analysis]
|
| 104 |
Sonehara K, Ozawa R, Hama M, Nozawa S, Agatsuma T, Nishie K, Kato A, Matsuo A, Araki T, Komatsu M, Tateishi K, Hanaoka M. C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study. Thorac Cancer 2023;14:636-42. [PMID: 36635979 DOI: 10.1111/1759-7714.14798] [Reference Citation Analysis]
|
| 105 |
Yu L, Sun L, Liu X, Wang X, Yan H, Pu Q, Xie Y, Jiang Y, Du J, Yang Z. The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res 2023. [PMID: 36628564 DOI: 10.1111/hepr.13877] [Reference Citation Analysis]
|
| 106 |
Guo X, Tu P, Zhu L, Cheng C, Jiang W, Du C, Wang X, Qiu X, Luo Y, Wan L, Tang R, Ran H, Wang Z, Ren J. Nanoenabled Tumor Energy Metabolism Disorder via Sonodynamic Therapy for Multidrug Resistance Reversal and Metastasis Inhibition. ACS Appl Mater Interfaces 2023;15:309-26. [PMID: 36576435 DOI: 10.1021/acsami.2c16278] [Reference Citation Analysis]
|
| 107 |
Di Federico A, De Giglio A, Gelsomino F, Sperandi F, Melotti B, Ardizzoni A. Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis. J Natl Cancer Inst 2023;115:29-42. [PMID: 36322815 DOI: 10.1093/jnci/djac205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 108 |
Olateju OA, Zeng Z, Adenaiye OO, Varisco TJ, Zakeri M, Sujit SS. Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study. Front Oncol 2022;12:1092355. [PMID: 36698397 DOI: 10.3389/fonc.2022.1092355] [Reference Citation Analysis]
|
| 109 |
Wang X, Guo Z, Wu X, Chen D, Wang F, Yang L, Luo M, Wu S, Yang C, Huang L, Fu L. Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer. Immunotargets Ther 2023;12:1-16. [PMID: 36632330 DOI: 10.2147/ITT.S373866] [Reference Citation Analysis]
|
| 110 |
Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Clin Cancer Res 2023;29:30-9. [PMID: 35969170 DOI: 10.1158/1078-0432.CCR-22-1366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Gascón-Ruiz M, Ramírez-Labrada A, Lastra R, Martínez-Lostao L, Paño-Pardo JR, Sesma A, Zapata-García M, Moratiel A, Quílez E, Torres-Ramón I, Yubero A, Domingo MP, Esteban P, Gálvez EM, Pardo J, Isla D. A Subset of PD-1-Expressing CD56(bright) NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. Cancers (Basel) 2023;15. [PMID: 36672279 DOI: 10.3390/cancers15020329] [Reference Citation Analysis]
|
| 112 |
Lu S, Qin S, Zhou Z, Chen J, Gu K, Sun P, Pan Y, Yu G, Ma K, Shi J, Sun Y, Yang L, Chen P, Liu A, He J. Bevacizumab biosimilar candidate TAB008 compared to Avastin(®) in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study. J Cancer Res Clin Oncol 2023. [PMID: 36595042 DOI: 10.1007/s00432-022-04563-4] [Reference Citation Analysis]
|
| 113 |
Andric Z, Gálffy G, Cobo Dols M, Szima B, Stojanovic G, Petrovic M, Felip E, Vicente Baz D, Ponce Aix S, Juan-Vidal O, Szalai Z, Losonczy G, Calles Blanco A, Bernabe R, García Ledo G, Aguilar Hernández A, Duecker K, Zhou D, Schroeder A, Guezel G, Ciardiello F. Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC. JTO Clin Res Rep 2023;4:100461. [PMID: 36718142 DOI: 10.1016/j.jtocrr.2022.100461] [Reference Citation Analysis]
|
| 114 |
Creasman WT, Miller DS, Eskander RN, Powell M. Adenocarcinoma of the uterine corpus and sarcomas of the uterus. DiSaia and Creasman Clinical Gynecologic Oncology 2023. [DOI: 10.1016/b978-0-323-77684-4.00014-3] [Reference Citation Analysis]
|
| 115 |
de Castro G Jr, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V, Summers Y, Vynnychenko I, Lee SY, Bryl M, Zer A, Erman M, Timcheva C, Raja R, Naicker K, Scheuring U, Walker J, Mann H, Chand V, Mok T; NEPTUNE Investigators. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. J Thorac Oncol 2023;18:106-19. [PMID: 36240972 DOI: 10.1016/j.jtho.2022.09.223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 116 |
张 科. Research Progress in Prognostic Markers of Immunotherapy for Non-Small Cell Lung Cancer. ACM 2023;13:264-271. [DOI: 10.12677/acm.2023.131041] [Reference Citation Analysis]
|
| 117 |
Karhunen V, Gill D, Huang J, Bouras E, Malik R, Ponsford MJ, Ahola-Olli A, Papadopoulou A, Palaniswamy S, Sebert S, Wielscher M, Auvinen J, Veijola J, Herzig KH, Timonen M, Keinänen-Kiukaanniemi S, Dichgans M, Salmi M, Jalkanen S, Lehtimäki T, Salomaa V, Raitakari O, Jones SA, Hovingh GK, Tsilidis KK, Järvelin MR, Dehghan A. The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation study. BMJ Med 2023;2:e000157. [PMID: 36936266 DOI: 10.1136/bmjmed-2022-000157] [Reference Citation Analysis]
|
| 118 |
Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
|
| 119 |
Zhang CY, Sun H, Su JW, Chen YQ, Zhang SL, Zheng MY, Li YF, Huang J, Zhang C, Tai ZX, Cai M, Zhang XC, Su J, Xu CR, Yan HH, Chen HJ, Wu YL, Yang JJ. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival. Lung Cancer 2023;175:68-78. [PMID: 36473332 DOI: 10.1016/j.lungcan.2022.11.016] [Reference Citation Analysis]
|
| 120 |
He J, Li L, Lv L, Chen X, Ge M, Ren Y, Tang X, Liu P, Gao W. JAG1 is correlated to suppressive immune microenvironment and predicts immunotherapy resistance in lung adenocarcinoma. Front Oncol 2023;13:1091488. [PMID: 36923423 DOI: 10.3389/fonc.2023.1091488] [Reference Citation Analysis]
|
| 121 |
Kessler JE, Park KN, Grizzle AJ, Hurwitz JT. Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US. Expert Rev Pharmacoecon Outcomes Res 2023;23:55-61. [PMID: 36288082 DOI: 10.1080/14737167.2023.2140141] [Reference Citation Analysis]
|
| 122 |
Yang H, Miao Y, Yu Z, Wei M, Jiao X. Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. Front Oncol 2023;13:1107631. [PMID: 36895477 DOI: 10.3389/fonc.2023.1107631] [Reference Citation Analysis]
|
| 123 |
Hu X, Wang L, Shang B, Wang J, Sun J, Liang B, Su L, You W, Jiang S. Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. Front Immunol 2023;14:1094414. [PMID: 36949956 DOI: 10.3389/fimmu.2023.1094414] [Reference Citation Analysis]
|
| 124 |
Paz-Ares LG, Ciuleanu TE, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, Provencio M, Zurawski B, Lee KH, Kim SW, Caserta C, Ramalingam SS, Spigel DR, Brahmer JR, Reck M, O'Byrne KJ, Girard N, Popat S, Peters S, Memaj A, Nathan F, Aanur N, Borghaei H. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. J Thorac Oncol 2023;18:79-92. [PMID: 36049658 DOI: 10.1016/j.jtho.2022.08.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 125 |
Kapoor V, Kelly WJ. Biomarkers for immune checkpoint inhibitors in solid tumors. Clin Transl Oncol 2023;25:126-36. [PMID: 36103047 DOI: 10.1007/s12094-022-02942-4] [Reference Citation Analysis]
|
| 126 |
Kelner M, Carvalho da Silva B, Montella T, Aguiar PN Jr, Lopes G, Ferreira CG, De Marchi P. Discrepancies Between the Cost of Advanced Lung Cancer Treatment and How Much Is Reimbursed by the Brazilian Public Healthcare System. Value Health Reg Issues 2023;33:1-6. [PMID: 36162194 DOI: 10.1016/j.vhri.2022.08.004] [Reference Citation Analysis]
|
| 127 |
Singh G, Thakur N, Kumar U. RAS: Circuitry and therapeutic targeting. Cell Signal 2023;101:110505. [PMID: 36341985 DOI: 10.1016/j.cellsig.2022.110505] [Reference Citation Analysis]
|
| 128 |
刘 永. Clinical Observation of Immunotherapy Combined with Antiangiogenic Targeted Drugs in the Treatment of 20 Cases Advanced Hepatocellular Carcinoma. ACM 2023;13:2575-2580. [DOI: 10.12677/acm.2023.132364] [Reference Citation Analysis]
|
| 129 |
Liu H, Luo SX, Jie J, Peng L, Wang S, Song L. Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. Front Immunol 2023;14:1115305. [PMID: 36926326 DOI: 10.3389/fimmu.2023.1115305] [Reference Citation Analysis]
|
| 130 |
Cao Y, Lu M, Sun Y, Gong J, Li J, Lu Z, Li J, Zhang X, Li Y, Peng Z, Zhou J, Wang X, Shen L. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. J Cancer Res Clin Oncol 2023;149:779-89. [PMID: 35166929 DOI: 10.1007/s00432-021-03898-8] [Reference Citation Analysis]
|
| 131 |
Lin Y, Wilk U, Pöhmerer J, Hörterer E, Höhn M, Luo X, Mai H, Wagner E, Lächelt U. Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells. Small 2023;19:e2205318. [PMID: 36399647 DOI: 10.1002/smll.202205318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 132 |
Erasmus JJ, Nguyen Q, Stewart DJ, Swisher SG. Lung Cancer. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00007-0] [Reference Citation Analysis]
|
| 133 |
Safa H, Abu Rous F, Belani N, Borghaei H, Gadgeel S, Halmos B. Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. Target Oncol 2023;18:25-49. [PMID: 36577876 DOI: 10.1007/s11523-022-00937-3] [Reference Citation Analysis]
|
| 134 |
Li G, Cheng M, Hong K, Jiang Y. Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study. Onco Targets Ther 2023;16:157-63. [PMID: 36911534 DOI: 10.2147/OTT.S400376] [Reference Citation Analysis]
|
| 135 |
Vokes NI, Pan K, Le X. Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. Ther Adv Med Oncol 2023;15:17588359231161409. [PMID: 36950275 DOI: 10.1177/17588359231161409] [Reference Citation Analysis]
|
| 136 |
Neuwelt A, Camidge DR. The development and implementation of EGFR inhibitors in advanced NSCLC. Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC 2023. [DOI: 10.1016/b978-0-12-822833-3.00007-3] [Reference Citation Analysis]
|
| 137 |
Rossi S, Marinello A, Pagliaro A, Franceschini D, Navarria P, Finocchiaro G, Toschi L, Scorsetti M, Santoro A. Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer. Expert Rev Anticancer Ther 2023;23:29-41. [PMID: 36548111 DOI: 10.1080/14737140.2023.2162044] [Reference Citation Analysis]
|
| 138 |
Lengyel CG. Mechanisms of Resistance to Immunotherapies in Cancer. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_335-1] [Reference Citation Analysis]
|
| 139 |
Marriott M, Post B, Chablani L. A comparison of cancer vaccine adjuvants in clinical trials. Cancer Treat Res Commun 2023;34:100667. [PMID: 36516613 DOI: 10.1016/j.ctarc.2022.100667] [Reference Citation Analysis]
|
| 140 |
Chang Y, Lin WY, Chang YC, Huang CH, Tzeng HE, Abdul-Lattif E, Wang TH, Tseng TH, Kang YN, Chi KY. The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis. Cancers (Basel) 2022;15. [PMID: 36612290 DOI: 10.3390/cancers15010284] [Reference Citation Analysis]
|
| 141 |
Mougel A, Méjean F, Tran T, Adimi Y, Galy-fauroux I, Kaboré C, Mercier E, Urquia P, Terme M, Tartour E, Tanchot C. Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling. OncoImmunology 2022;11:2110218. [DOI: 10.1080/2162402x.2022.2110218] [Reference Citation Analysis]
|
| 142 |
Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, Arora M, Brufsky A, Dees EC, Santa-Maria CA, Connolly RM, Force J, Moreno-Aspitia A, Herndon JM, Carmody M, Davies SR, Larson S, Pfaff KL, Jones SM, Weirather JL, Giobbie-Hurder A, Rodig SJ, Liu Z, Hagemann IS, Sharon E, Gillanders WE. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ Breast Cancer 2022;8:134. [PMID: 36585404 DOI: 10.1038/s41523-022-00500-3] [Reference Citation Analysis]
|
| 143 |
Maugeais M, Péron J, Dalle S, Boespflug A, Duruissaux M, Corbaux P, Reverdy T, Sahin G, Rabier A, Lopez J, Freymond N, Maillet D. Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. Biomedicines 2022;11. [PMID: 36672591 DOI: 10.3390/biomedicines11010083] [Reference Citation Analysis]
|
| 144 |
Chen M, Xu Y, Zhao J, Liu X, Liu X, Zhang D, Shi Y, Zhang L, Zhong W, Wang M. Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients. Clin Lung Cancer 2022:S1525-7304(22)00291-1. [PMID: 36635116 DOI: 10.1016/j.cllc.2022.12.003] [Reference Citation Analysis]
|
| 145 |
Horita N. Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. Cancers (Basel) 2022;15. [PMID: 36612179 DOI: 10.3390/cancers15010185] [Reference Citation Analysis]
|
| 146 |
Roy R, Singh SK, Misra S. Advancements in Cancer Immunotherapies. Vaccines (Basel) 2022;11. [PMID: 36679904 DOI: 10.3390/vaccines11010059] [Reference Citation Analysis]
|
| 147 |
Basudan AM. The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clin Pract 2022;13:22-40. [PMID: 36648843 DOI: 10.3390/clinpract13010003] [Reference Citation Analysis]
|
| 148 |
Nakao A, Inoue H, Ikeuchi N, Igata F, Aoyama T, Hamasaki M, Arima H, Fujita M. Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer. J Clin Med 2022;12. [PMID: 36614938 DOI: 10.3390/jcm12010137] [Reference Citation Analysis]
|
| 149 |
Xu J, Xiong Y, Xu Z, Xing H, Zhou L, Zhang X. From targeted therapy to a novel way: Immunogenic cell death in lung cancer. Front Med (Lausanne) 2022;9:1102550. [PMID: 36619616 DOI: 10.3389/fmed.2022.1102550] [Reference Citation Analysis]
|
| 150 |
Samarth N, Gulhane P, Singh S. Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC - A systematic review. Front Oncol 2022;12:1089320. [PMID: 36620544 DOI: 10.3389/fonc.2022.1089320] [Reference Citation Analysis]
|
| 151 |
Tieri J, Harris B, Melikian L, Bullington S, Naville-cook C, Crawford B. Tolerability and efficacy of chemoimmunotherapy when administered with a corticosteroid-free anti-emetic regimen. J Oncol Pharm Pract 2022. [DOI: 10.1177/10781552221146528] [Reference Citation Analysis]
|
| 152 |
Tang Z, Zhang T, Yang B, Su J, Song Q. spaCI: deciphering spatial cellular communications through adaptive graph model. Brief Bioinform 2023;24. [PMID: 36545790 DOI: 10.1093/bib/bbac563] [Reference Citation Analysis]
|
| 153 |
Wengang Zhang, Xiaoling Shang, Ni Liu, Xinchun Ma, Rui Yang, Handai Xia, Yuqing Zhang, Qi Zheng, Xiuwen Wang, Yanguo Liu. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. BMC Pulm Med 2022;22:483. [PMID: 36539782 DOI: 10.1186/s12890-022-02279-2] [Reference Citation Analysis]
|
| 154 |
Raspe M, Frost N. Pneumologie meets Onkologie. Z Pneumologie 2022. [DOI: 10.1007/s10405-022-00481-x] [Reference Citation Analysis]
|
| 155 |
Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2022;4:579-97. [PMID: 36636451 DOI: 10.1016/j.jaccao.2022.09.004] [Reference Citation Analysis]
|
| 156 |
Kao CH, Liu CT, Lin H, Huang YC, Lan J, Ou YC, Fu HC, Wu CH. Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. Front Immunol 2022;13:1079253. [PMID: 36591227 DOI: 10.3389/fimmu.2022.1079253] [Reference Citation Analysis]
|
| 157 |
Nishimura T, Ichihara E, Yokoyama T, Inoue K, Tamura T, Sato K, Oda N, Kano H, Kishino D, Kawai H, Inoue M, Ochi N, Fujimoto N, Ichikawa H, Ando C, Hotta K, Maeda Y, Kiura K. The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. Cancers (Basel) 2022;14. [PMID: 36551668 DOI: 10.3390/cancers14246184] [Reference Citation Analysis]
|
| 158 |
Qi R, Yu Y, Shen M, Lv D, He S. Current status and challenges of immunotherapy in ALK rearranged NSCLC. Front Oncol 2022;12:1016869. [PMID: 36591504 DOI: 10.3389/fonc.2022.1016869] [Reference Citation Analysis]
|
| 159 |
Zhao ZR, Lin ZC, Shen JF, Xie ZH, Jiang L. Neoadjuvant Immunotherapy in Oncogene-Positive Non-Small Cell Lung Cancer: A Multicenter Study. Ann Thorac Surg 2022:S0003-4975(22)01541-7. [PMID: 36521526 DOI: 10.1016/j.athoracsur.2022.11.035] [Reference Citation Analysis]
|
| 160 |
Fujimoto A, Kotake Y, Hisamatsu D, Ookubo N, Yabuuchi Y, Kamimura G, Kai T, Kozono A, Ootsu T, Suzuki H, Matsuo K, Kuwahara K, Oiwane Y, Nagata Y, Tanimoto K, Sato E, Suenaga M, Uehara T, Ikari A, Endo S, Hiraki Y, Kawamata Y. Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: A multicenter retrospective study.. [DOI: 10.21203/rs.3.rs-2355931/v1] [Reference Citation Analysis]
|
| 161 |
Difoum F, Schernberg A, Vanquaethem H, Picchi H, Roy AL, Vuagnat P, Helissey C. Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study. Cancer Reports 2022. [DOI: 10.1002/cnr2.1760] [Reference Citation Analysis]
|
| 162 |
Eulberg D, Frömming A, Lapid K, Mangasarian A, Barak A. The prospect of tumor microenvironment-modulating therapeutical strategies. Front Oncol 2022;12:1070243. [PMID: 36568151 DOI: 10.3389/fonc.2022.1070243] [Reference Citation Analysis]
|
| 163 |
Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, Liu J, Yu X, Shi S. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol 2022;15:174. [PMID: 36482419 DOI: 10.1186/s13045-022-01392-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 164 |
Roe D, Rosoff H, Ruan DF, Khan Z, Dogra P, Carroll J, Hunkapiller J, Mohindra R, Srivastava MK, Nabet BY, Chandler GS, Albert ML, Mccarthy MI, Mellman I, Horowitz A, Hammer C. Natural killer cell educating KIR/HLA combinations impact survival in anti-PD-L1 treated cancer patients.. [DOI: 10.1101/2022.12.06.22282592] [Reference Citation Analysis]
|
| 165 |
Chen S, Wei H, Zhao W, Jiang W, Ning R, Zhou S, Tan L, Wang H, Su C, He J, Zeng A, Zhao Y, Yu Q. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. Front Immunol 2022;13:1059995. [PMID: 36569915 DOI: 10.3389/fimmu.2022.1059995] [Reference Citation Analysis]
|
| 166 |
Elkrief A, Victor Alessi JM, Ricciuti B, Brown S, Rizvi H, Preeshagul IR, Wang X, Pecci F, Federico AD, Lamberti G, Egger JV, Chaft JE, Rudin CM, Riely GJ, Kris MG, Ladanyi M, Chen Y, Hellmann MD, Shen R, Awad MM, Schoenfeld AJ. Efficacy of PD-(L)1 Blockade Monotherapy Compared to PD-(L)1 Blockade Plus Chemotherapy in First-Line PD-L1-Positive Advanced Lung Adenocarcinomas.. [DOI: 10.1101/2022.12.05.22283131] [Reference Citation Analysis]
|
| 167 |
Silva SB, Wanderley CWS, Gomes Marin JF, de Macedo MP, do Nascimento ECT, Antonacio FF, Figueiredo CS, Trinconi Cunha M, Cunha FQ, de Castro Junior G. Tumor glycolytic profiling through (18)F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Ther Adv Med Oncol 2022;14:17588359221138386. [PMID: 36506107 DOI: 10.1177/17588359221138386] [Reference Citation Analysis]
|
| 168 |
Nowak-sliwinska P, van Beijnum JR, Griffioen CJ, Huinen ZR, Sopesens NG, Schulz R, Jenkins SV, Dings RPM, Groenendijk FH, Huijbers EJM, Thijssen VLJL, Jonasch E, Vyth-dreese FA, Jordanova ES, Bex A, Bernards R, de Gruijl TD, Griffioen AW. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis 2022. [DOI: 10.1007/s10456-022-09863-4] [Reference Citation Analysis]
|
| 169 |
Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 2022;310:121138. [DOI: 10.1016/j.lfs.2022.121138] [Reference Citation Analysis]
|
| 170 |
Bu MT, Chandrasekhar P, Ding L, Hugo W. The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. Pharmacol Ther 2022;240:108211. [PMID: 35577211 DOI: 10.1016/j.pharmthera.2022.108211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 171 |
Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T. Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data in Brief 2022;45:108558. [DOI: 10.1016/j.dib.2022.108558] [Reference Citation Analysis]
|
| 172 |
Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol 2022;19:775-90. [PMID: 36216928 DOI: 10.1038/s41571-022-00689-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 173 |
Liu Y, Cheng X, Han X, Cheng X, Jiang S, Lin Y, Zhang Z, Lu L, Qu B, Chen Y, Zhang X. Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. Front Immunol 2022;13:1032747. [PMID: 36532038 DOI: 10.3389/fimmu.2022.1032747] [Reference Citation Analysis]
|
| 174 |
Leal JL, John T. Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options. Clin Lung Cancer 2022;23:643-58. [PMID: 36130865 DOI: 10.1016/j.cllc.2022.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 175 |
Wu N, Ge W, Quek RG, Gleeson M, Pouliot JF, Dietz H, Jalbert JJ, Harnett J, Antonia SJ. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer. Future Oncol 2022;18:4385-97. [PMID: 36656547 DOI: 10.2217/fon-2022-0540] [Reference Citation Analysis]
|
| 176 |
Miao XY, Wu H, Ye BC, Yi QW, Lin FN, Wang YL, Ren CL, Jiang YF, Li A. Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB. Sci Rep 2022;12:20734. [PMID: 36456601 DOI: 10.1038/s41598-022-25050-3] [Reference Citation Analysis]
|
| 177 |
Itchins M, Ainsworth H, Alexander M, Dean S, Dharmaraj D, Pavlakis N, Clarke SJ, Brown C, Torres J, Saqib A, Ladwa R, O'Byrne K, Moore M, Yip PY, Solomon B, John T, Kao S, Mitchell P, Parakh S. A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. Clin Lung Cancer 2022;23:702-8. [PMID: 36030187 DOI: 10.1016/j.cllc.2022.07.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 178 |
Wang Y, Wang Y, Yu J, Meng X. The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. Cancer Letters 2022;551:215947. [DOI: 10.1016/j.canlet.2022.215947] [Reference Citation Analysis]
|
| 179 |
Hatic H, Hearld KR, Das D, Deshane J. Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy. Cancers (Basel) 2022;14. [PMID: 36497435 DOI: 10.3390/cancers14235954] [Reference Citation Analysis]
|
| 180 |
Alhaddad H, Wong W, Abou-Gharbia M, Childers W, Melenski E, Bell RL, Sari Y. Effects of a Novel Beta Lactam Compound, MC-100093, on the Expression of Glutamate Transporters/Receptors and Ethanol Drinking Behavior of Alcohol-Preferring Rats. J Pharmacol Exp Ther 2022;383:208-16. [PMID: 36153003 DOI: 10.1124/jpet.122.001147] [Reference Citation Analysis]
|
| 181 |
Lin EP, Hsu CY, Chiou JF, Berry L, Horn L, Bunn P, Yang JC, Yang PC, Adjei AA, Shyr Y. Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit. J Thorac Oncol 2022;17:1365-74. [PMID: 36049656 DOI: 10.1016/j.jtho.2022.08.010] [Reference Citation Analysis]
|
| 182 |
Liang F, Peng L, Wu Z, Giamas G, Stebbing J. Design and reporting of phase III oncology trials with prospective biomarker validation. J Natl Cancer Inst 2023;115:174-80. [PMID: 36448689 DOI: 10.1093/jnci/djac210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 183 |
Wan Q, Wei R, Wei X, Deng YP. Crosstalk of four kinds of cell deaths defines subtypes of cutaneous melanoma for precise immunotherapy and chemotherapy. Front Immunol 2022;13:998454. [PMID: 36532053 DOI: 10.3389/fimmu.2022.998454] [Reference Citation Analysis]
|
| 184 |
Wang Y, He C, Liu J, Wu S, Huang X, Zhang L, Shu W, Gu C, Wang Y, Zhu L, Hu J. The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1758552] [Reference Citation Analysis]
|
| 185 |
Li J, Chen Y, Hu F, Qiang H, Chang Q, Qian J, Shen Y, Cai Y, Chu T. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1001503] [Reference Citation Analysis]
|
| 186 |
Lo Russo G, Sgambelluri F, Prelaj A, Galli F, Manglaviti S, Bottiglieri A, Di Mauro RM, Ferrara R, Galli G, Signorelli D, De Toma A, Occhipinti M, Brambilla M, Rulli E, Triulzi T, Torelli T, Agnelli L, Brich S, Martinetti A, Dumitrascu AD, Torri V, Pruneri G, Fabbri A, de Braud F, Anichini A, Proto C, Ganzinelli M, Mortarini R, Garassino MC. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. ESMO Open 2022;7:100645. [PMID: 36455507 DOI: 10.1016/j.esmoop.2022.100645] [Reference Citation Analysis]
|
| 187 |
Kushiya H, Hiraoka K, Suzuki T, Inoko K, Inagaki A, Niwa H, Sasaki K, Nakamura T, Tsuchikawa T, Shichinohe T, Jolly DJ, Kasahara N, Hirano S. Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer. Cancers (Basel) 2022;14. [PMID: 36497300 DOI: 10.3390/cancers14235820] [Reference Citation Analysis]
|
| 188 |
Laktionov KK, Artamonova EV, Borisova TN, Breder VV, Bychkov IM, Vladimirova LI, Volkov NM, Ergnian SM, Zhabina AS, Kononets PV, Kuzminov AE, Levchenko EV, Malikhova OA, Marinov DT, Miller SV, Moiseenko FV, Mochal’nikova VV, Novikov SN, Pikin OV, Reutova EV, Rodionov EO, Sakaeva DD, Sarantseva KA, Semenova AI, Smolin AV, Sotnikov VM, Tuzikov SA, Turkin IN, Tyurin IE, Chkhikvadze VD, Kolbanov KI, Chernykh MV, Chernichenko AV, Fedenko AA, Filonenko EV, Nevol’skikh AA, Ivanov SA, Khailova ZV, Gevorkian TG, Butenko AV, Gil’mutdinova IR, Gridneva IV, Eremushkin MA, Zernova MA, Kasparov BS, Kovlen DV, Kondrat’eva KO, Konchugova TV, Korotkova SB, Krutov AA, Obukhova OA, Ponomarenko GN, Semiglazova TI, Stepanova AM, Khulamkhanova MM. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. J Mod Onco 2022;24:269-304. [DOI: 10.26442/18151434.2022.3.201848] [Reference Citation Analysis]
|
| 189 |
Cohen IJ, Pareja F, Socci ND, Shen R, Doane AS, Schwartz J, Khanin R, Morris EA, Sutton EJ, Blasberg RG. Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. Front Immunol 2022;13:880959. [PMID: 36505421 DOI: 10.3389/fimmu.2022.880959] [Reference Citation Analysis]
|
| 190 |
Zalpoor H, Aziziyan F, Liaghat M, Bakhtiyari M, Akbari A, Nabi-Afjadi M, Forghaniesfidvajani R, Rezaei N. The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. Cell Commun Signal 2022;20:186. [PMID: 36419156 DOI: 10.1186/s12964-022-00951-y] [Reference Citation Analysis]
|
| 191 |
Lin J, Liu J, Hao SG, Lan B, Zheng XB, Xiong JN, Zhang YQ, Gao X, Chen CB, Chen L, Huang YF, Luo H, Yi YT, Yi X, Lu JP, Zheng XW, Chen G, Wang XF, Chen Y. An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. Front Immunol 2022;13:1022598. [PMID: 36505399 DOI: 10.3389/fimmu.2022.1022598] [Reference Citation Analysis]
|
| 192 |
Tanizaki S, Matsumoto K, Tamiya A, Taniguchi Y, Matsuda Y, Uchida J, Ueno K, Kawachi H, Tamiya M, Yanase T, Suzuki H, Okishio K. Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study.. [DOI: 10.21203/rs.3.rs-2281789/v1] [Reference Citation Analysis]
|
| 193 |
Noda-Narita S, Naito T, Udagawa H, Goto K, Miyawaki T, Mamesaya N, Nakashima K, Kenmotsu H, Shimokawaji T, Kato T, Hakozaki T, Okuma Y, Nakamura M, Nakayama Y, Watanabe H, Kusumoto M, Ohe Y, Horinouchi H. Nivolumab-induced radiation recall pneumonitis in non-small-cell lung cancer patients with thoracic radiation therapy. Cancer Sci 2023;114:630-9. [PMID: 36285515 DOI: 10.1111/cas.15621] [Reference Citation Analysis]
|
| 194 |
Zhang X, Ge N, Xiang Z, Liu T. Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. Cancer Cell Int 2022;22:363. [DOI: 10.1186/s12935-022-02760-2] [Reference Citation Analysis]
|
| 195 |
Inoue T, Narukawa M. Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Control 2022;29:10732748221140694. [PMID: 36748438 DOI: 10.1177/10732748221140694] [Reference Citation Analysis]
|
| 196 |
Melichar B. Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. Clinical Chemistry and Laboratory Medicine (CCLM) 2022;0. [DOI: 10.1515/cclm-2022-1108] [Reference Citation Analysis]
|
| 197 |
Liu Y, Gao Y, Wang Y, Zhao C, Zhang Z, Li B, Zhang T. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. BMC Cancer 2022;22:1175. [DOI: 10.1186/s12885-022-10236-9] [Reference Citation Analysis]
|
| 198 |
Nguyen NT, Mitsuhashi A, Ogino H, Kozai H, Yoneda H, Afroj T, Sato S, Nokihara H, Shinohara T, Nishioka Y. S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor. Cancer Sci 2023;114:384-98. [PMID: 36285504 DOI: 10.1111/cas.15620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 199 |
Ferreira M, Reckamp KL. Editorial: Impact of immunotherapy in lung cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1083524] [Reference Citation Analysis]
|
| 200 |
Li F, Zhai S, Lv Z, Yuan L, Wang S, Jin D, Yi H, Fu L, Mao Y. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.968517] [Reference Citation Analysis]
|
| 201 |
Li R, Jin C, Zhao W, Liang R, Xiong H. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. BMC Gastroenterol 2022;22:450. [DOI: 10.1186/s12876-022-02540-2] [Reference Citation Analysis]
|
| 202 |
Peng J, Zhang J, Zou D, Xiao L, Ma H, Zhang X, Li Y, Han L, Xie B. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.960459] [Reference Citation Analysis]
|
| 203 |
Wu F, Jiang T, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J, Bai X, Ren S, Zhou C; CameL Study Group. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy. Cancer Commun (Lond) 2022;42:1331-46. [PMID: 36331328 DOI: 10.1002/cac2.12383] [Reference Citation Analysis]
|
| 204 |
Liu K, Qin Z, Ge Y, Bian A, Xu X, Wu B, Xing C, Mao H. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04437-9] [Reference Citation Analysis]
|
| 205 |
Masatoshi Maki, Ryo Takada, Akihiko Taniguchi, Naoyuki Nomura, Seiichiro Kuramoto, Yuki Chiko, Toshiaki Okada, Seiji Saito, Koji Tamura. Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer. J Pharm Health Care Sci 2022;8:27. [PMID: 36316726 DOI: 10.1186/s40780-022-00259-6] [Reference Citation Analysis]
|
| 206 |
Ardeshir-Larijani F, Althouse SK, Leal T, Feldman LE, Hejleh TA, Patel M, Gentzler RD, Miller AR, Hanna NH. A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139. Clin Lung Cancer 2022;23:578-84. [PMID: 36041949 DOI: 10.1016/j.cllc.2022.07.001] [Reference Citation Analysis]
|
| 207 |
Varlotto JM, Sun Z, Ky B, Upshaw J, Fitzgerald TJ, Diehn M, Lovly C, Belani C, Oettel K, Masters G, Harkenrider M, Ross H, Ramalingam S, Pennell NA. A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. Clin Lung Cancer 2022;23:547-60. [PMID: 35882620 DOI: 10.1016/j.cllc.2022.06.005] [Reference Citation Analysis]
|
| 208 |
Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, Kristeleit R, Hiret S, Bajor DL, Cruz P, Beck JT, Ghosh S, Dabrowski C, Antony G, Duan T, Veneris J, Zografos E, Subramanian J. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. Clin Lung Cancer 2022;23:e415-27. [PMID: 35729005 DOI: 10.1016/j.cllc.2022.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 209 |
Murakami S, Yokose T, Shinada K, Isaka T, Katakura K, Ushio R, Kondo T, Kato T, Ito H, Saito H. Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. Thorac Cancer 2022;13:3217-24. [PMID: 36203199 DOI: 10.1111/1759-7714.14685] [Reference Citation Analysis]
|
| 210 |
Minegishi S, Kinguchi S, Horita N, Namkoong H, Briasoulis A, Ishigami T, Tamura K, Nishiyama A, Yano Y, Japanese Society of Hypertension working group “Onco-Hypertension”. Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis. Hypertension 2022;79:2611-2621. [DOI: 10.1161/hypertensionaha.122.19865] [Reference Citation Analysis]
|
| 211 |
Okuno T, Nakashima K, Mitarai Y, Kataoka M, Tobita H, Nagase M, Isobe T, Tsubata Y. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment. Respiratory Medicine Case Reports 2022. [DOI: 10.1016/j.rmcr.2022.101773] [Reference Citation Analysis]
|
| 212 |
Kandalaft LE, Dangaj Laniti D, Coukos G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer 2022;22:640-56. [PMID: 36109621 DOI: 10.1038/s41568-022-00503-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 213 |
Anderson TS, Wooster AL, Piersall SL, Okpalanwaka IF, Lowe DB. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Semin Cancer Biol 2022;86:981-96. [PMID: 35149179 DOI: 10.1016/j.semcancer.2022.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 214 |
Rizzo A, Ricci AD, Brandi G. Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. J Pers Med 2022;12. [PMID: 36579504 DOI: 10.3390/jpm12111788] [Reference Citation Analysis]
|
| 215 |
Tanizaki S, Matsumoto K, Tamiya A, Taniguchi Y, Matsuda Y, Uchida J, Ueno K, Kawachi H, Tamiya M, Yanase T, Suzuki H, Okishio K. Impact of prior immune checkpoint inhibitor and its tumor response on ramucirumab and docetaxel for advanced non-small cell lung cancer: a multicenter retrospective cohort study.. [DOI: 10.21203/rs.3.rs-2203249/v1] [Reference Citation Analysis]
|
| 216 |
Shao T, Zhao M, Liang L, Tang W. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.948597] [Reference Citation Analysis]
|
| 217 |
Liang Z, Hu X, Hu H, Wang P, Cai J. Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1017737] [Reference Citation Analysis]
|
| 218 |
Shoji F, Yamaguchi M, Okamoto M, Takamori S, Yamazaki K, Okamoto T, Maehara Y. Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer. Front Mol Biosci 2022;9. [DOI: 10.3389/fmolb.2022.1040424] [Reference Citation Analysis]
|
| 219 |
Liu X, Li L, Geng C, Wen S, Zhang C, Deng C, Gao X, Zhang G, He QY, Liu L. DDX17 promotes the growth and metastasis of lung adenocarcinoma. Cell Death Discov 2022;8:425. [PMID: 36273228 DOI: 10.1038/s41420-022-01215-x] [Reference Citation Analysis]
|
| 220 |
Heymach JV, Zurita‐saavedra A, Kopetz S, Cascone T, Nilsson M, Guijarro I. Tumor Angiogenesis. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm017.pub2] [Reference Citation Analysis]
|
| 221 |
Tsimberidou AM, Fountzilas E, Kurzrock R. Precision Medicine in Oncology Drug Development. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm052.pub3] [Reference Citation Analysis]
|
| 222 |
Rajasekaran K, Guan X, Tafazzol A, Hamidi H, Darwish M, Yadav M. Tetramer-aided sorting and single-cell RNA sequencing facilitate transcriptional profiling of antigen-specific CD8+ T cells. Transl Oncol 2022;27:101559. [PMID: 36279715 DOI: 10.1016/j.tranon.2022.101559] [Reference Citation Analysis]
|
| 223 |
Wu J, Bao C, Liu G, Meng S, Lu Y, Li P, Zhou J. Research Trends and Emerging Hotspots of Lung Cancer Surgery during 2012-2021: A 10-Year Bibliometric and Network Analysis. Health Data Science 2022;2022:1-10. [DOI: 10.34133/2022/9797842] [Reference Citation Analysis]
|
| 224 |
Morgensztern D, Boffa D, Chen A, Dhanasopon A, Goldberg SB, Decker RH, Devarakonda S, Ko JP, Solis Soto LM, Waqar SN, Wistuba II, Herbst RS. Cancer of the Lung. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm085.pub2] [Reference Citation Analysis]
|
| 225 |
Nishi T, Togashi Y. Translational Research in Cancer Immunotherapies. JJLC 2022;62:363-370. [DOI: 10.2482/haigan.62.363] [Reference Citation Analysis]
|
| 226 |
Bożyk A, Nicoś M. The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer. Life 2022;12:1640. [DOI: 10.3390/life12101640] [Reference Citation Analysis]
|
| 227 |
Zhang Q, Zheng T, Xu L, Gao J, Wang Z, Guo Y, Liang S, Qu K. Immune checkpoint inhibitor for different age patients with NSCLC in efficacy: a systematic review and Meta-analysis.. [DOI: 10.21203/rs.3.rs-2165411/v1] [Reference Citation Analysis]
|
| 228 |
Ou W, Liao P, Hsu Y, Chen K, Hsu K, Huang Y, Tseng J, Chang G, Yang T. Incidence, risk factors, and outcome of advanced NSCLC patients receiving antiangiogenic therapy with thromboembolic events: a retrospective cohort study.. [DOI: 10.21203/rs.3.rs-2164834/v1] [Reference Citation Analysis]
|
| 229 |
Kou W, Lin YY, Su F, Xiang Y, Qiao H, Wu X, Hou X. The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors. Front Pharmacol 2022;13:910722. [DOI: 10.3389/fphar.2022.910722] [Reference Citation Analysis]
|
| 230 |
Wang K, Liu Z, Yu H, Cheng Y, Xiang Y, Zhong J, Ni Q, Zhou L, Liang C, Zhou H, Pan W, Guo W, Shi J, Lau WY, Cheng S. Gemcitabine plus Oxaliplatin (GEMOX) combined with Atezolizumab and Bevacizumab for Advanced Biliary Tract Cancer: A Preliminary Observational Study.. [DOI: 10.21203/rs.3.rs-2149321/v1] [Reference Citation Analysis]
|
| 231 |
Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N, Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho A, Goto Y, Seike M, Okamoto H. A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630. Clin Cancer Res 2022;28:4402-9. [PMID: 35980349 DOI: 10.1158/1078-0432.CCR-22-1687] [Reference Citation Analysis]
|
| 232 |
Yang T, Xiong Y, Zeng Y, Wang Y, Zeng J, Liu J, Xu S, Li L. Current status of immunotherapy for non-small cell lung cancer. Front Pharmacol 2022;13:989461. [DOI: 10.3389/fphar.2022.989461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 233 |
Loureiro H, Kolben TM, Kiermaier A, Rüttinger D, Ahmidi N, Becker T, Bauer-mehren A. Longitudinal assessment of ROPRO as an early indicator of overall survival in oncology clinical trials: a retrospective analysis.. [DOI: 10.1101/2022.10.11.22280399] [Reference Citation Analysis]
|
| 234 |
Paratore C, Zichi C, Audisio M, Bungaro M, Caglio A, Di Liello R, Gamba T, Gargiulo P, Mariniello A, Reale ML, Perrone F, Di Maio M. Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020. ESMO Open 2022;7:100593. [PMID: 36228332 DOI: 10.1016/j.esmoop.2022.100593] [Reference Citation Analysis]
|
| 235 |
Isono T, Hasemi J, Hasegawa A, Nishida T, Hosoda C, Kawate E, Kobayashi Y, Ishiguro T, Kagiyama N, Kurashima K, Yanagisawa T, Takayanagi N. Outcomes of EGFR tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced EGFR-mutated non-small cell lung cancer.. [DOI: 10.21203/rs.3.rs-2128762/v1] [Reference Citation Analysis]
|
| 236 |
Hashimoto K, Kaira K. History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. The Journal of the Japan Broncho-esophagological Society 2022;73:325-331. [DOI: 10.2468/jbes.73.325] [Reference Citation Analysis]
|
| 237 |
Mestrallet G, Sone K, Bhardwaj N. Strategies to overcome DC dysregulation in the tumor microenvironment. Front Immunol 2022;13:980709. [DOI: 10.3389/fimmu.2022.980709] [Reference Citation Analysis]
|
| 238 |
Niu Z, Jin R, Zhang Y, Li H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduct Target Ther 2022;7:353. [PMID: 36198685 DOI: 10.1038/s41392-022-01200-x] [Reference Citation Analysis]
|
| 239 |
Lin Q, Wu HJ, Song QS, Tang YK. CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy. Front Oncol 2022;12:937277. [DOI: 10.3389/fonc.2022.937277] [Reference Citation Analysis]
|
| 240 |
Okuno T, Nakashima K, Mitarai Y, Kataoka M, Tobita H, Nagase M, Isobe T, Tsubata Y. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment. Respir Med Case Rep 2022;40:101753. [PMID: 36217354 DOI: 10.1016/j.rmcr.2022.101753] [Reference Citation Analysis]
|
| 241 |
Zhong Y, Yin K, Chen Y, Xie Z, Lv Z, Yang J, Yang X, Zhou Q, Wang B, Zhong W, Gao L, Zhou W, Chen J, Tu H, Liao R, Zhang D, Zhang S, Lu D, Zheng H, Zhang H, Wu Y, Zhang X. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma. Front Immunol 2022;13:951817. [DOI: 10.3389/fimmu.2022.951817] [Reference Citation Analysis]
|
| 242 |
Amini AP, Kirkpatrick JD, Wang CS, Jaeger AM, Su S, Naranjo S, Zhong Q, Cabana CM, Jacks T, Bhatia SN. Multiscale profiling of protease activity in cancer. Nat Commun 2022;13:5745. [PMID: 36192379 DOI: 10.1038/s41467-022-32988-5] [Reference Citation Analysis]
|
| 243 |
Veccia A, Kostine M, Tison A, Dipasquale M, Kinspergher S, Prokop L, Grandi G, Inchiostro S, Caffo O, Paolazzi G, Bortolotti R, Cornec D, Berti A. Effets indésirables rhumatologiques des inhibiteurs de point de contrôle PD-(L)1 dans le cancer du poumon : revue systématique et méta-analyse. Revue du Rhumatisme 2022;89:447-457. [DOI: 10.1016/j.rhum.2022.07.020] [Reference Citation Analysis]
|
| 244 |
Grohé C, Wehler T, Dechow T, Henschke S, Schuette W, Dittrich I, Hammerschmidt S, Müller-Huesmann H, Schumann C, Krüger S, Atz J, Kaiser R. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO. Transl Lung Cancer Res 2022;11:2010-21. [PMID: 36386456 DOI: 10.21037/tlcr-21-1018] [Reference Citation Analysis]
|
| 245 |
Dagogo-Jack I, Piotrowska Z. There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC. J Thorac Oncol 2022;17:1171-4. [PMID: 36192077 DOI: 10.1016/j.jtho.2022.08.003] [Reference Citation Analysis]
|
| 246 |
Wang F, Yang M, Luo W, Zhou Q. Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer. Journal of the National Cancer Center 2022. [DOI: 10.1016/j.jncc.2022.10.002] [Reference Citation Analysis]
|
| 247 |
Horiuchi M, Uemura T, Oguri T, Toda S, Yamamoto S, Suzuki Y, Kagawa Y, Sone K, Fukuda S, Mori Y, Fukumitsu K, Kanemitsu Y, Tajiri T, Ohkubo H, Takemura M, Ito Y, Maeno K, Niimi A. Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel. Invest New Drugs 2022;40:934-43. [PMID: 35759133 DOI: 10.1007/s10637-022-01275-x] [Reference Citation Analysis]
|
| 248 |
Shaikh FY, Gills JJ, Mohammad F, White JR, Stevens CM, Ding H, Fu J, Tam A, Blosser RL, Domingue JC, Larman TC, Chaft JE, Spicer JD, Reuss JE, Naidoo J, Forde PM, Ganguly S, Housseau F, Pardoll DM, Sears CL. Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. Cancer Immunol Immunother 2022;71:2405-2420. [DOI: 10.1007/s00262-022-03169-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 249 |
Chen B, Wang J, Pu X, Li J, Wang Q, Liu L, Xu Y, Xu L, Kong Y, Li K, Xu F, Liang S, Cardona AF, Wu L. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study. Transl Lung Cancer Res 2022;11:2111-24. [PMID: 36386462 DOI: 10.21037/tlcr-22-697] [Reference Citation Analysis]
|
| 250 |
Zheng Y, Mislang ARA, Coward J, Cosman R, Cooper A, Underhill C, Zhu J, Xiong J, Jiang O, Wang H, Xie Y, Zhou Y, Jin X, Li B, Wang ZM, Kwek KY, Xia D, Xia Y, Xu N. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Cancer Immunol Immunother 2022;71:2371-2379. [DOI: 10.1007/s00262-022-03160-1] [Reference Citation Analysis]
|
| 251 |
Fennell DA, Porter C, Lester J, Danson S, Blackhall F, Nicolson M, Nixon L, Gardner G, White A, Griffiths G, Casbard A. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 2022;52:101595. [PMID: 35990583 DOI: 10.1016/j.eclinm.2022.101595] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 252 |
Daly RJ, Scott AM, Klein O, Ernst M. Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. Mol Cancer 2022;21:189. [PMID: 36175961 DOI: 10.1186/s12943-022-01656-z] [Reference Citation Analysis]
|
| 253 |
Zhang X, Zhou Y, Chen H, Chen C, Lin Z, He L, Du W, Chen T, Hong S, Fu S. PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma. Front Immunol 2022;13:1015444. [DOI: 10.3389/fimmu.2022.1015444] [Reference Citation Analysis]
|
| 254 |
Altaf R, Jadoon SS, Muhammad SA, Ilyas U, Duan Y. Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. Front Oncol 2022;12:1014156. [DOI: 10.3389/fonc.2022.1014156] [Reference Citation Analysis]
|
| 255 |
. Lung Cancer. Fundamentals of Cancer Detection, Treatment, and Prevention 2022. [DOI: 10.1002/9783527838561.ch11] [Reference Citation Analysis]
|
| 256 |
Herzog BH, Waqar SN, Devarakonda S, Ward JP, Gao F, Govindan R, Morgensztern D. Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. Lung Cancer 2022;173:101-6. [PMID: 36179540 DOI: 10.1016/j.lungcan.2022.09.011] [Reference Citation Analysis]
|
| 257 |
Bolte FJ, Mctavish S, Wakefield N, Shantzer L, Hubbard C, Krishnaraj A, Novicoff W, Gentzler RD, Hall RD. Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. Front Oncol 2022;12:986236. [DOI: 10.3389/fonc.2022.986236] [Reference Citation Analysis]
|
| 258 |
Kim CM, Lee JB, Shin SJ, Ahn JB, Lee M, Kim HS. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. ESMO Open 2022;7:100577. [PMID: 36156450 DOI: 10.1016/j.esmoop.2022.100577] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 259 |
Han Y, Zhang Y, Tian Y, Zhang M, Xiang C, Zhen Q, Liu J, Shang Y, Zhao Y, Si H, Sui A, Zhang Z. The Interaction of the IFNγ/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells. Journal of Oncology 2022;2022:1-16. [DOI: 10.1155/2022/9016296] [Reference Citation Analysis]
|
| 260 |
Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, Chacon Castro MDC, Deese AR, Zhang L. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers 2022;14:4562. [DOI: 10.3390/cancers14194562] [Reference Citation Analysis]
|
| 261 |
Wu D, Huang L, Mao J, Liu J, Ye W, Xu J, Zhong W, Zhang X, Ying S, Kolla J. Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/6407344] [Reference Citation Analysis]
|
| 262 |
Chera A, Stancu AL, Bucur O. Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol 2022;13:1010279. [DOI: 10.3389/fendo.2022.1010279] [Reference Citation Analysis]
|
| 263 |
Irabor OC, Nelson N, Shah Y, Niazi MK, Poiset S, Storozynsky E, Singla DK, Hooper DC, Lu B. Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Front Oncol 2022;12:940127. [DOI: 10.3389/fonc.2022.940127] [Reference Citation Analysis]
|
| 264 |
Mountzios G, Banna GL, Rolfo C. Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. Front Oncol 2022;12:997404. [DOI: 10.3389/fonc.2022.997404] [Reference Citation Analysis]
|
| 265 |
Zhang Q, Ye M, Lin C, Hu M, Wang Y, Lou Y, Kong Q, Zhang J, Li J, Zhang Y, Yang T, Sun X, Yao W, Hua Y, Huang H, Xu M, Wang X, Yu X, Tao W, Liu R, Gao Y, Wang T, Wang J, Wei X, Wu J, Yu Z, Zhang C, Yu C, Bai X, Liang T. Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study. Gut 2022:gutjnl-2022-327496. [PMID: 36113977 DOI: 10.1136/gutjnl-2022-327496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 266 |
Li S, Chen K, Yang M, Hlaing SS, Chen M, Gu P, Meng Y, Yang H. Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis. Front Immunol 2022;13:991431. [DOI: 10.3389/fimmu.2022.991431] [Reference Citation Analysis]
|
| 267 |
Alves Pinto I, de Oliveira Cavagna R, Virginio da Silva AL, Dias JM, Santana IV, Souza LC, Ferreira da Silva FA, Biazotto Fernandes MF, Junqueira Pinto GD, Negreiros IS, Santiago Gonçalves MF, de Paula FE, Berardinelli GN, Casagrande GMS, Oliveira da Silva M, Albino da Silva EC, de Oliveira MA, Jacinto AA, Duval da Silva V, Reis RM, De Marchi P, Leal LF. EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil. Oncologist 2022;27:e899-907. [PMID: 36099421 DOI: 10.1093/oncolo/oyac167] [Reference Citation Analysis]
|
| 268 |
Le Tourneau C, Becker H, Claus R, Elez E, Ricci F, Fritsch R, Silber Y, Hennequin A, Tabernero J, Jayadeva G, Luedtke D, He M, Isambert N. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open 2022;7:100576. [PMID: 36108560 DOI: 10.1016/j.esmoop.2022.100576] [Reference Citation Analysis]
|
| 269 |
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP; LCMC study investigators. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med 2022. [PMID: 36097216 DOI: 10.1038/s41591-022-01962-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 270 |
Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond) 2022. [PMID: 36075878 DOI: 10.1002/cac2.12359] [Reference Citation Analysis]
|
| 271 |
Shiraishi Y, Kishimoto J, Shimose T, Toi Y, Sugawara S, Okamoto I. Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial. BMC Cancer 2022;22:964. [PMID: 36076179 DOI: 10.1186/s12885-022-10056-x] [Reference Citation Analysis]
|
| 272 |
Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Front Immunol 2022;13:982026. [DOI: 10.3389/fimmu.2022.982026] [Reference Citation Analysis]
|
| 273 |
Zhang B, Zeng J, Zhang H, Zhu S, Wang H, He J, Yang L, Zhou N, Zu L, Xu X, Song Z, Xu S. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Front Immunol 2022;13:974581. [DOI: 10.3389/fimmu.2022.974581] [Reference Citation Analysis]
|
| 274 |
Rebuzzi SE, Prelaj A, Friedlaender A, Cortellini A, Addeo A, Genova C, Naqash AR, Auclin E, Mezquita L, Banna GL. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Crit Rev Oncol Hematol 2022;179:103806. [PMID: 36087850 DOI: 10.1016/j.critrevonc.2022.103806] [Reference Citation Analysis]
|
| 275 |
Tozuka T, Noro R, Seike M, Honda K. Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability. Cancers 2022;14:4363. [DOI: 10.3390/cancers14184363] [Reference Citation Analysis]
|
| 276 |
Zhang Z, Lin Y, Liu J. Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Late Phase Oncology Drug Development. Statistics in Biopharmaceutical Research. [DOI: 10.1080/19466315.2022.2120532] [Reference Citation Analysis]
|
| 277 |
Zhang T, Wang Y, Shi C, Liu X, Lv S, Wang X, Li W. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Front Pharmacol 2022;13:955701. [DOI: 10.3389/fphar.2022.955701] [Reference Citation Analysis]
|
| 278 |
Yong J, Mellick AS, Whitelock J, Wang J, Liang K. A Biomolecular Toolbox for Precision Nanomotors. Adv Mater 2022;:e2205746. [PMID: 36055646 DOI: 10.1002/adma.202205746] [Reference Citation Analysis]
|
| 279 |
Zhang G, Liu A, Yang Y, Xia Y, Li W, Liu Y, Zhang J, Cui Q, Wang D, Liu X, Guo Y, Chen H, Yu J. Clinical predictive value of naïve and memory T cells in advanced NSCLC. Front Immunol 2022;13:996348. [DOI: 10.3389/fimmu.2022.996348] [Reference Citation Analysis]
|
| 280 |
Lu S, Fang J, Wang Z, Fan Y, Liu Y, He J, Zhou J, Hu J, Xia J, Liu W, Shi J, Yi J, Cao L. Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Med 2023;12:2666-76. [PMID: 36052772 DOI: 10.1002/cam4.5144] [Reference Citation Analysis]
|
| 281 |
Sa H, Xu Y, Ma X, Wang X, Sun C, Qiu S, Guo Y, Yang Z, Liu Y, Ma K. Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report. Current Oncology 2022;29:6334-6341. [DOI: 10.3390/curroncol29090498] [Reference Citation Analysis]
|
| 282 |
Bote H, Mesas A, Baena J, Herrera M, Paz-Ares L. Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer. Expert Opin Emerg Drugs 2022;27:289-300. [PMID: 36203360 DOI: 10.1080/14728214.2022.2113377] [Reference Citation Analysis]
|
| 283 |
Wang H, Gu D, Chen D, Mei J, Yang X, Ding J, Xu J, Wang M, Liu C, Hua D. The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma. IJGM 2022;Volume 15:7383-7393. [DOI: 10.2147/ijgm.s381530] [Reference Citation Analysis]
|
| 284 |
Zhao B, Li H, Ma W. Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic NSCLC. J Thorac Oncol 2022;17:e71-2. [PMID: 36031288 DOI: 10.1016/j.jtho.2022.04.015] [Reference Citation Analysis]
|
| 285 |
Liu J, Wei L, Hu N, Wang D, Ni J, Zhang S, Liu H, Lv T, Yin J, Ye M, Song Y. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer. J Immunother Cancer 2022;10:e005116. [PMID: 36104103 DOI: 10.1136/jitc-2022-005116] [Reference Citation Analysis]
|
| 286 |
Meng X, Chen Y, Xing L, Liu X, Zhao K, Jiang L, Zhang L, Zhou C, Yu J. PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials. BMJ Open Resp Res 2022;9:e001294. [DOI: 10.1136/bmjresp-2022-001294] [Reference Citation Analysis]
|
| 287 |
Kadono T, Yamamoto S, Kato K. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. Jpn J Clin Oncol 2022:hyac138. [PMID: 36047845 DOI: 10.1093/jjco/hyac138] [Reference Citation Analysis]
|
| 288 |
Akazawa Y, Yoshikawa A, Kanazu M, Yano Y, Yamaguchi T, Mori M. Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study. Thorac Cancer 2022;13:2450-8. [PMID: 35820673 DOI: 10.1111/1759-7714.14576] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 289 |
Conway JW, Rawson RV, Lo S, Ahmed T, Vergara IA, Gide TN, Attrill GH, Carlino MS, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Shivalingam B, Menzies AM, Wilmott JS, Long GV, Scolyer RA, Pires da Silva I. Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. J Immunother Cancer 2022;10:e004884. [PMID: 36096531 DOI: 10.1136/jitc-2022-004884] [Reference Citation Analysis]
|
| 290 |
Qi X, Guo J, Zhou X, Sun L, Lin J, Huang Z, Chen H, Lin L. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review. Heliyon 2022;8:e10581. [PMID: 36185140 DOI: 10.1016/j.heliyon.2022.e10581] [Reference Citation Analysis]
|
| 291 |
Li Z, Gu L, Gao Q, Li L, Sheng M, Ling Y, Hu C, He M, Zhang X, Shen X, Zhang X, Chen M. Mechanism investigation of Caspase-8/GSDMC dependent immunogenic cell death induced by Ophiopogonin B in NSCLC cells. Pharmacological Research - Modern Chinese Medicine 2022;4:100157. [DOI: 10.1016/j.prmcm.2022.100157] [Reference Citation Analysis]
|
| 292 |
Skorupan N, Palestino Dominguez M, Ricci SL, Alewine C. Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:4209. [DOI: 10.3390/cancers14174209] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 293 |
Corke LK, Li JJN, Leighl NB, Eng L. Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. Current Oncology 2022;29:6260-6276. [DOI: 10.3390/curroncol29090492] [Reference Citation Analysis]
|
| 294 |
Cui R, Yang Z, Liu L. What does radiomics do in PD-L1 blockade therapy of NSCLC patients? Thorac Cancer 2022. [PMID: 36039482 DOI: 10.1111/1759-7714.14620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 295 |
Ollila E, Kataja V, Sailas L. A David and Goliath set-up: a qualitative study of the challenges of ensuring the introduction of cost-effective new cancer medicines in Finland. J Pharm Policy Pract 2022;15:52. [PMID: 36038900 DOI: 10.1186/s40545-022-00449-5] [Reference Citation Analysis]
|
| 296 |
Li D, Xu L, Ji J, Bao D, Hu J, Qian Y, Zhou Y, Chen Z, Li D, Li X, Zhang X, Wang H, Yi C, Shi M, Pang Y, Liu S, Xu X. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. Front Immunol 2022;13:944062. [DOI: 10.3389/fimmu.2022.944062] [Reference Citation Analysis]
|
| 297 |
Chen W, Li L, Cheng S, Yu J, Yang Y. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. Disease Markers 2022;2022:1-11. [DOI: 10.1155/2022/2631852] [Reference Citation Analysis]
|
| 298 |
Mizuno T, Katsuya Y, Sato J, Koyama T, Shimizu T, Yamamoto N. Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. Front Oncol 2022;12:925938. [DOI: 10.3389/fonc.2022.925938] [Reference Citation Analysis]
|
| 299 |
Shen H, Huang F, Zhang X, Ojo OA, Li Y, Trummell HQ, Anderson JC, Fiveash J, Bredel M, Yang ES, Willey CD, Chong Z, Bonner JA, Shi LZ. Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling. Nat Commun 2022;13:5013. [PMID: 36008408 DOI: 10.1038/s41467-022-32754-7] [Reference Citation Analysis]
|
| 300 |
Cheng Y, Yang B, Ouyang W, Jie C, Zhang W, Chen G, Zhang J, Yu J, Xie C. Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation. Front Oncol 2022;12:920047. [DOI: 10.3389/fonc.2022.920047] [Reference Citation Analysis]
|
| 301 |
Kanazu M, Shimokawa M, Saito R, Mori M, Tamura A, Okano Y, Fujita Y, Endo T, Motegi M, Takata S, Kita T, Sukoh N, Takenoyama M, Atagi S. Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan. J Geriatr Oncol 2022:S1879-4068(22)00191-6. [PMID: 36008273 DOI: 10.1016/j.jgo.2022.07.011] [Reference Citation Analysis]
|
| 302 |
Abdelazeem B, Abbas KS, Labieb F, Arida AK, El-shahat NA, Shehata J, Kandah E, Malik B, Akanbi M, Rafae A, Wahab A, Ehsan H. The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized controlled trials. Expert Review of Anticancer Therapy. [DOI: 10.1080/14737140.2022.2116005] [Reference Citation Analysis]
|
| 303 |
You R, Zou X, Ding X, Zhang WJ, Zhang MX, Wang X, Xu HS, Liu YL, Ouyang YF, Duan CY, Gu CM, Wang ZQ, Liu YP, Hua YJ, Huang PY, Chen MY. Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma. Med (N Y) 2022:S2666-6340(22)00319-1. [PMID: 36041429 DOI: 10.1016/j.medj.2022.07.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 304 |
Hashimoto K, Kaira K, Imai H, Mouri A, Shiono A, Miura Y, Yamaguchi O, Kobayashi K, Kagamu H, Kuji I. Prognostic Potential of Metabolic Activity on 18F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade. J Immunother 2022. [PMID: 35980360 DOI: 10.1097/CJI.0000000000000434] [Reference Citation Analysis]
|
| 305 |
Offringa R, Kötzner L, Huck B, Urbahns K. The expanding role for small molecules in immuno-oncology. Nat Rev Drug Discov 2022. [PMID: 35982333 DOI: 10.1038/s41573-022-00538-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 306 |
Xiao Y. Clinical studies of Atezolizumab contributing to FDA approvals. HSET 2022;8:390-395. [DOI: 10.54097/hset.v8i.1183] [Reference Citation Analysis]
|
| 307 |
Hao Y, Zhang X, Yu L. Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. Front Oncol 2022;12:911906. [DOI: 10.3389/fonc.2022.911906] [Reference Citation Analysis]
|
| 308 |
Nakagawa N, Kawakami M. Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. Front Oncol 2022;12:952393. [DOI: 10.3389/fonc.2022.952393] [Reference Citation Analysis]
|
| 309 |
Gong L, Huang D, Shi Y, Liang Z, Bu H. Regulated cell death in cancer: from pathogenesis to treatment. Chin Med J (Engl) 2022. [PMID: 35950752 DOI: 10.1097/CM9.0000000000002239] [Reference Citation Analysis]
|
| 310 |
Attili I, Valenza C, Santoro C, Antonarelli G, Trillo Aliaga P, Del Signore E, Catania C, Spitaleri G, Passaro A, de Marinis F. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%. Front Oncol 2022;12:980765. [DOI: 10.3389/fonc.2022.980765] [Reference Citation Analysis]
|
| 311 |
Gao R, Song J, Sun L, Wu Z, Yi X, Zhang S, Huang L, Ma J, Han C. Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. Front Pharmacol 2022;13:920165. [DOI: 10.3389/fphar.2022.920165] [Reference Citation Analysis]
|
| 312 |
Tan AC, Pavlakis N. Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC). IJMS 2022;23:8863. [DOI: 10.3390/ijms23168863] [Reference Citation Analysis]
|
| 313 |
Feng Y, Huang L, Zhu H, Tang L, Hu X, Shi Y. The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study. Thoracic Cancer. [DOI: 10.1111/1759-7714.14603] [Reference Citation Analysis]
|
| 314 |
He Q, Qu M, Shen T, Xu Y, Luo J, Tan D, Xu C, Barkat MQ, Zeng L, Wu X. Suppression of VEGFD expression by S-nitrosylation promotes the development of lung adenocarcinoma. J Exp Clin Cancer Res 2022;41:239. [DOI: 10.1186/s13046-022-02453-8] [Reference Citation Analysis]
|
| 315 |
Zhang L, Zhou C, Zhang S, Chen X, Liu J, Xu F, Liang W. Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Front Oncol 2022;12:939249. [DOI: 10.3389/fonc.2022.939249] [Reference Citation Analysis]
|
| 316 |
Ma T, Jiao J, Huo R, Li X, Fang G, Zhao Q, Liu W, Han X, Xi C, Wang Y, Shang Y. PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. Front Oncol 2022;12:922899. [DOI: 10.3389/fonc.2022.922899] [Reference Citation Analysis]
|
| 317 |
Fan P, Qiang H, Liu Z, Zhao Q, Wang Y, Liu T, Wang X, Chu T, Huang Y, Xu W, Qin S. Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Front Immunol 2022;13:937924. [DOI: 10.3389/fimmu.2022.937924] [Reference Citation Analysis]
|
| 318 |
Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X, Hou R, Ma W, Liu D, Zheng J, Shi M. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. Front Immunol 2022;13:920021. [DOI: 10.3389/fimmu.2022.920021] [Reference Citation Analysis]
|
| 319 |
Kiss I, Kuhn M, Hrusak K, Buchler B, Boublikova L, Buchler T. Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. Front Oncol 2022;12:946307. [DOI: 10.3389/fonc.2022.946307] [Reference Citation Analysis]
|
| 320 |
Punekar SR, Shum E, Grello CM, Lau SC, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol 2022;12:877594. [DOI: 10.3389/fonc.2022.877594] [Reference Citation Analysis]
|
| 321 |
Vega DM, Nishimura KK, Zariffa N, Thompson JC, Hoering A, Cilento V, Rosenthal A, Anagnostou V, Baden J, Beaver JA, Chaudhuri AA, Chudova D, Fine AD, Fiore J, Hodge R, Hodgson D, Hunkapiller N, Klass DM, Kobie J, Peña C, Pennello G, Peterman N, Philip R, Quinn KJ, Raben D, Rosner GL, Sausen M, Tezcan A, Xia Q, Yi J, Young AG, Stewart MD, Carpenter EL, Aggarwal C, Allen J. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. JCO Precis Oncol 2022;6:e2100372. [PMID: 35952319 DOI: 10.1200/PO.21.00372] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 322 |
Pisapia P, Iaccarino A, De Luca C, Acanfora G, Bellevicine C, Bianco R, Daniele B, Ciampi L, De Felice M, Fabozzi T, Formisano L, Giordano P, Gridelli C, Ianniello GP, Libroia A, Maione P, Nacchio M, Pagni F, Palmieri G, Pepe F, Russo G, Salatiello M, Santaniello A, Scamarcio R, Seminati D, Troia M, Troncone G, Vigliar E, Malapelle U. Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. IJMS 2022;23:8541. [DOI: 10.3390/ijms23158541] [Reference Citation Analysis]
|
| 323 |
Kim DW, Gadgeel S, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A, Heist RS, Wozniak AJ, Singh J, Cha E, Spahn J, Ou SI. Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC. JTO Clin Res Rep 2022;3:100367. [PMID: 35875467 DOI: 10.1016/j.jtocrr.2022.100367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 324 |
Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD, Awad MM. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol 2022;8:1160-8. [PMID: 35708671 DOI: 10.1001/jamaoncol.2022.1981] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 325 |
Kato S, Fujiwara Y, Hong DS. Targeting KRAS: Crossroads of Signaling and Immune Inhibition. Journal of Immunotherapy and Precision Oncology 2022;5:68-78. [DOI: 10.36401/jipo-22-5] [Reference Citation Analysis]
|
| 326 |
Zhou L, Chen Q, Chen H, Wang L, Zhang J, Li Q. Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-11. [DOI: 10.1155/2022/4097576] [Reference Citation Analysis]
|
| 327 |
Möller M, Turzer S, Ganchev G, Wienke A, Schütte W, Seliger B, Riemann D. Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade. Cancers (Basel) 2022;14. [PMID: 35954354 DOI: 10.3390/cancers14153690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 328 |
Righini M, Mollica V, Rizzo A, La Manna G, Massari F. Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. J Clin Med 2022;11. [PMID: 35955989 DOI: 10.3390/jcm11154373] [Reference Citation Analysis]
|
| 329 |
Yudin DI, Laktionov KK. Is there a place for chemotherapy in first line of treatment for metastatic NSCLC in era of immunotherapy? Medicinskij alfavit 2022. [DOI: 10.33667/2078-5631-2022-13-18-21] [Reference Citation Analysis]
|
| 330 |
Li L, Wen Q, Ding R. Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials. Front Oncol 2022;12:905520. [DOI: 10.3389/fonc.2022.905520] [Reference Citation Analysis]
|
| 331 |
Florez MA, Kemnade JO, Chen N, Du W, Sabichi AL, Wang DY, Huang Q, Miller-Chism CN, Jotwani A, Chen AC, Hernandez D, Sandulache VC. Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. Cancer Res Commun 2022;2022:806-13. [PMID: 35966167 DOI: 10.1158/2767-9764.CRC-21-0143] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 332 |
Bylsma S, Yun K, Patel S, Dennis MJ. Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. Curr Treat Options Oncol 2022. [PMID: 35876957 DOI: 10.1007/s11864-022-00995-9] [Reference Citation Analysis]
|
| 333 |
Guo Y, Guo H, Zhang Y, Cui J. Anaplastic lymphoma kinase-special immunity and immunotherapy. Front Immunol 2022;13:908894. [DOI: 10.3389/fimmu.2022.908894] [Reference Citation Analysis]
|
| 334 |
Bredin P, Naidoo J. The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. Cancer Metastasis Rev 2022. [PMID: 35876944 DOI: 10.1007/s10555-022-10039-1] [Reference Citation Analysis]
|
| 335 |
Wu K, Xia B, Zhang J, Li X, Yang S, Zhang M, Zhu L, Wang B, Xu X, Ma S, Chen X. Positive Correlation of Peripheral CD8(+) T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers (Basel) 2022;14. [PMID: 35892826 DOI: 10.3390/cancers14153568] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 336 |
Shi C, Wang Y, Xue J, Zhou X. Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. Front Immunol 2022;13:940288. [DOI: 10.3389/fimmu.2022.940288] [Reference Citation Analysis]
|
| 337 |
Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Neal JW, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol 2022;40:2295-306. [PMID: 35658002 DOI: 10.1200/JCO.22.00912] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 338 |
Leal TA, Dahlberg SE, Ramalingam SS. Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. J Clin Oncol 2022;40:2285-7. [PMID: 35658027 DOI: 10.1200/JCO.22.01035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 339 |
Wu C, Liu F, Chen H, Liu Q, Song C, Cheng K, Gao Z, Fan C, Zhang Z. Identification of Ferroptosis-Related lncRNA Pairs for Predicting the Prognosis of Head and Neck Squamous Cell Carcinoma. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/7602482] [Reference Citation Analysis]
|
| 340 |
Li Y, Amaladas N, O’mahony M, Manro JR, Inigo I, Li Q, Rasmussen ER, Brahmachary M, Doman TN, Hall G, Kalos M, Novosiadly R, Puig O, Pytowski B, Schaer DA. Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. PLoS ONE 2022;17:e0268244. [DOI: 10.1371/journal.pone.0268244] [Reference Citation Analysis]
|
| 341 |
Miyawaki T, Kenmotsu H, Doshita K, Kodama H, Nishioka N, Iida Y, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy in non-small-cell lung cancer. Cancer Med 2023;12:1451-60. [PMID: 35848053 DOI: 10.1002/cam4.5035] [Reference Citation Analysis]
|
| 342 |
Zhang Q, Gong X, Sun L, Miao L, Zhou Y. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis. Front Oncol 2022;12:791496. [DOI: 10.3389/fonc.2022.791496] [Reference Citation Analysis]
|
| 343 |
Tian Y, Zhang C, Dang Q, Wang K, Liu Q, Liu H, Shang H, Zhao J, Xu Y, Wu T, Liu W, Yang X, Safi M, Wu YS. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/4976032] [Reference Citation Analysis]
|
| 344 |
Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel) 2022;14:3473. [PMID: 35884533 DOI: 10.3390/cancers14143473] [Reference Citation Analysis]
|
| 345 |
Lee JY, Kannan B, Lim BY, Li Z, Lim AH, Loh JW, Ko TK, Ng CC, Chan JY. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. Int J Mol Sci 2022;23:7839. [PMID: 35887186 DOI: 10.3390/ijms23147839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 346 |
Katakura S, Murakami S. Clinically-meaningful improvements in therapy for unresectable NSCLC. Expert Rev Anticancer Ther 2022. [PMID: 35838638 DOI: 10.1080/14737140.2022.2102483] [Reference Citation Analysis]
|
| 347 |
Shi K, Wang G, Pei J, Zhang J, Wang J, Ouyang L, Wang Y, Li W. Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J Hematol Oncol 2022;15:94. [PMID: 35840984 DOI: 10.1186/s13045-022-01311-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 348 |
Sun M, Ji H, Xu N, Jiang P, Qu T, Li Y. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. BMC Cancer 2022;22:762. [PMID: 35831785 DOI: 10.1186/s12885-022-09843-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 349 |
Huang Q, Kemnade J, Cornwell L, Kheradmand F, Sabichi AL, Das D. Non-small cell lung cancer in the era of immunotherapy. Semin Oncol 2022:S0093-7754(22)00049-5. [PMID: 35879123 DOI: 10.1053/j.seminoncol.2022.06.009] [Reference Citation Analysis]
|
| 350 |
Nakahama K, Kaneda H, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma. Thorac Cancer 2022. [PMID: 35808895 DOI: 10.1111/1759-7714.14560] [Reference Citation Analysis]
|
| 351 |
Elkrief A, Yu H. Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed? The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00449-1] [Reference Citation Analysis]
|
| 352 |
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00382-5] [Reference Citation Analysis]
|
| 353 |
Niho S. Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy. J Thorac Oncol 2022;17:865-6. [PMID: 35750453 DOI: 10.1016/j.jtho.2022.05.001] [Reference Citation Analysis]
|
| 354 |
Frost N, Reck M. Immuntherapie des nichtkleinzelligen Lungenkarzinoms (NSCLC). Innere Medizin 2022;63:709-716. [DOI: 10.1007/s00108-022-01363-3] [Reference Citation Analysis]
|
| 355 |
Liu SV, Nagasaka M, Stefaniak V, Gruver K, Lin Y, Ferry D, Socinski MA, Zhang L. The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. Front Oncol 2022;12:859892. [PMID: 35756655 DOI: 10.3389/fonc.2022.859892] [Reference Citation Analysis]
|
| 356 |
Banna GL, Cantale O, Muthuramalingam S, Cave J, Comins C, Cortellini A, Addeo A, Signori A, McKenzie H, Escriu C, Barone G, Chan S, Hicks A, Bainbridge H, Pinato DJ, Ottensmeier C, Gomes F. Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. Int Immunopharmacol 2022;110:108985. [PMID: 35777264 DOI: 10.1016/j.intimp.2022.108985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 357 |
Buriolla S, Pelizzari G, Corvaja C, Alberti M, Targato G, Bortolot M, Torresan S, Cortiula F, Fasola G, Follador A. Immunotherapy in NSCLC Patients with Brain Metastases. IJMS 2022;23:7068. [DOI: 10.3390/ijms23137068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 358 |
Freemantle N, Xu Y, Wilson FR, Guyot P, Chen CI, Keeping S, Konidaris G, Chan K, Kuznik A, Atsou K, Glowienka E, Pouliot JF, Gullo G, Rietschel P. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50. Ther Adv Med Oncol 2022;14:17588359221105024. [PMID: 35747163 DOI: 10.1177/17588359221105024] [Reference Citation Analysis]
|
| 359 |
Shi Y, Li Y, Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Lv C, Han S, Yu Y, Xu F, Tian Y. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. Int Immunopharmacol 2022;110:108968. [PMID: 35764018 DOI: 10.1016/j.intimp.2022.108968] [Reference Citation Analysis]
|
| 360 |
Conner M, Hance KW, Yadavilli S, Smothers J, Waight JD. Emergence of the CD226 Axis in Cancer Immunotherapy. Front Immunol 2022;13:914406. [DOI: 10.3389/fimmu.2022.914406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 361 |
Kim JM. Molecular Link between DNA Damage Response and Microtubule Dynamics. IJMS 2022;23:6986. [DOI: 10.3390/ijms23136986] [Reference Citation Analysis]
|
| 362 |
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 2022. [PMID: 35739268 DOI: 10.1038/s41591-022-01868-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 363 |
Ai Q, Chen W, Li Y, Li G. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis. Front Immunol 2022;13:840916. [PMID: 35720298 DOI: 10.3389/fimmu.2022.840916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 364 |
Liu W, Huo G, Chen P. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Front Immunol 2022;13:909027. [DOI: 10.3389/fimmu.2022.909027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 365 |
Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther 2022;7:196. [PMID: 35725836 DOI: 10.1038/s41392-022-01046-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 366 |
Zattarin E, Manglaviti S, Apollonio G, Beninato T, Mazzeo L, Massa G, Bottiglieri A, Galli E, De Toma A, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, Proto C, Garassino MC, de Braud F, Lo Russo G, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncol 2022. [PMID: 35722877 DOI: 10.2217/fon-2021-1454] [Reference Citation Analysis]
|
| 367 |
Shi Y, Ma X, Shen W, Liu T, Liang L, Liu S, Shen Z, Zhang Y, Zhang P. Evaluation of the EdgeSeq Precision Immuno-Oncology Panel for Gene Expression Profiling From Clinical Formalin-Fixed Paraffin-Embedded Tumor Specimens. Front Cell Dev Biol 2022;10:899353. [PMID: 35712667 DOI: 10.3389/fcell.2022.899353] [Reference Citation Analysis]
|
| 368 |
Yang R, He Q, Zhou H, Gong C, Wang X, Song X, Luo F, Lei Y, Ni Q, Wang Z, Xu S, Xue Y, Zhang M, Wen H, Fang L, Zeng L, Yan Y, Shi J, Zhang J, Yi J, Zhou P. Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell. Front Immunol 2022;13:923969. [DOI: 10.3389/fimmu.2022.923969] [Reference Citation Analysis]
|
| 369 |
Nishimura T, Fujimoto H, Okano T, Naito M, Tsuji C, Iwanaka S, Sakakura Y, Yasuma T, D'Alessandro-Gabazza CN, Oomoto Y, Gabazza EC, Kobayashi T, Ibata H. Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice? Cancers (Basel) 2022;14:2970. [PMID: 35740634 DOI: 10.3390/cancers14122970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 370 |
Li F, Liao B, Wang T, Qi T, Wang Y. Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment. Front Pharmacol 2022;13:918709. [DOI: 10.3389/fphar.2022.918709] [Reference Citation Analysis]
|
| 371 |
Goring S, Varol N, Waser N, Popoff E, Lozano-Ortega G, Lee A, Yuan Y, Eccles L, Tran P, Penrod JR. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis. Lung Cancer 2022;170:122-32. [PMID: 35767923 DOI: 10.1016/j.lungcan.2022.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 372 |
Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov 2022. [PMID: 35701637 DOI: 10.1038/s41573-022-00493-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 373 |
Ding K, Yi M, Liang H, Li Z, Zhang Y. Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression. Expert Rev Clin Immunol 2022;:1-13. [PMID: 35681264 DOI: 10.1080/1744666X.2022.2088510] [Reference Citation Analysis]
|
| 374 |
Liu J, Zhang Q, Yang D, Xie F, Wang Z. The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer. Mol Ther Nucleic Acids 2022;28:397-407. [PMID: 35505957 DOI: 10.1016/j.omtn.2022.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 375 |
Wu Q, Luo S, Xie X. Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75? J Immunother 2022. [PMID: 35674663 DOI: 10.1097/CJI.0000000000000426] [Reference Citation Analysis]
|
| 376 |
Song H, Huang XF, Hu SY, Lu LL, Yang XY. The LINC00261/MiR105-5p/SELL axis is involved in dysfunction of B cell and is associated with overall survival in hepatocellular carcinoma. PeerJ 2022;10:e12588. [PMID: 35702258 DOI: 10.7717/peerj.12588] [Reference Citation Analysis]
|
| 377 |
Li J, Wang M, Xu S, Li Y, Li J, Yu J, Zhu H. The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. Front Pharmacol 2022;13:841623. [PMID: 35656295 DOI: 10.3389/fphar.2022.841623] [Reference Citation Analysis]
|
| 378 |
Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. J Immunother Cancer 2022;10:e003956. [PMID: 35640927 DOI: 10.1136/jitc-2021-003956] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 379 |
Link H. G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei Krebserkrankung. best practice onkologie 2022;17:298-314. [DOI: 10.1007/s11654-022-00398-0] [Reference Citation Analysis]
|
| 380 |
Sanmamed MF, Berraondo P, Rodriguez-ruiz ME, Melero I. Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat Cancer 2022;3:665-680. [DOI: 10.1038/s43018-022-00401-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 381 |
Kiss I, Kuhn M, Hrusak K, Buchler T. Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. ESMO Open 2022;7:100474. [DOI: 10.1016/j.esmoop.2022.100474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 382 |
Guo L, Zhang J, Liu X, Liu H, Zhang Y, Liu J. Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report. OTT 2022;Volume 15:629-36. [DOI: 10.2147/ott.s346635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 383 |
Möller M, Adner J, Schütte W, Krüger M. 30- und 90-Tage-Letalität bei Patienten mit Lungenkarzinom im Stadium IV in Abhängigkeit der Primärtherapie. TumorDiagnostik & Therapie 2022;43:321-330. [DOI: 10.1055/a-1809-0389] [Reference Citation Analysis]
|
| 384 |
Chen Y, Kang S, Yan M. Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis. Pharmacol Res Perspect 2022;10:e00941. [PMID: 35568997 DOI: 10.1002/prp2.941] [Reference Citation Analysis]
|
| 385 |
Lepland A, Malfanti A, Haljasorg U, Asciutto EK, Pickholz M, Bringas M, Đorđević S, Salumäe L, Peterson P, Teesalu T, Vicent MJ, Scodeller P. Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice. Cancer Res Commun 2022;2:533-51. [PMID: 36923553 DOI: 10.1158/2767-9764.CRC-22-0043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 386 |
Fu C, Zhang K, Wang M, Qiu F. Casticin and chrysosplenol D from Artemisia annua L. induce apoptosis by inhibiting topoisomerase IIα in human non-small-cell lung cancer cells. Phytomedicine 2022;100:154095. [DOI: 10.1016/j.phymed.2022.154095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 387 |
Takenaka T, Yano T, Yamazaki K, Okamoto T, Hamatake M, Shimokawa M, Mori M. Survival after recurrence following surgical resected non-small cell lung cancer: A multicenter, prospective cohort study. JTCVS Open 2022;10:370-381. [DOI: 10.1016/j.xjon.2022.03.004] [Reference Citation Analysis]
|
| 388 |
Skribek M, Rounis K, Tsakonas G, Ekman S. Complications following novel therapies for non-small cell lung cancer. J Intern Med 2022;291:732-54. [PMID: 35032058 DOI: 10.1111/joim.13445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 389 |
Kano Y, Kataoka N, Kunimatsu Y, Tsutsumi R, Sato I, Tanimura M, Nakano T, Tanimura K, Takeda T. Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report. Medicina 2022;58:706. [DOI: 10.3390/medicina58060706] [Reference Citation Analysis]
|
| 390 |
Yang G, Yang Y, Liu R, Li W, Xu H, Hao X, Li J, Zhang S, Xu F, Lei S, Wang Y. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China. Cancer Med 2023;12:335-44. [PMID: 35608132 DOI: 10.1002/cam4.4852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 391 |
Peng J, Xiao L, Zou D, Han L. A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer. Front Med (Lausanne) 2022;9:808378. [PMID: 35592856 DOI: 10.3389/fmed.2022.808378] [Reference Citation Analysis]
|
| 392 |
Pozza DH, Andrade de Mello RB. Treatment Sequencing Strategies in Lung Cancer. Zhongguo Fei Ai Za Zhi 2022;25:323-36. [PMID: 35599008 DOI: 10.3779/j.issn.1009-3419.2022.104.01] [Reference Citation Analysis]
|
| 393 |
Kitadai R, Okuma Y. Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers 2022;14:2519. [DOI: 10.3390/cancers14102519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 394 |
Feng C, Yu H, Lei H, Cao H, Chen M, Liu S. A prognostic model using the neutrophil-albumin ratio and PG-SGA to predict overall survival in advanced palliative lung cancer. BMC Palliat Care 2022;21:81. [PMID: 35585628 DOI: 10.1186/s12904-022-00972-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 395 |
André L, Antherieu G, Boinet A, Bret J, Gilbert T, Boulahssass R, Falandry C. Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. Cancers (Basel) 2022;14:2470. [PMID: 35626074 DOI: 10.3390/cancers14102470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 396 |
Liu Y, Zhang T, Zhang L, Zhao C, Zhang Z, Wang Z, Gu M, Li W, Li B. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+ T cells in lung cancer. Immunotherapy 2022. [PMID: 35574588 DOI: 10.2217/imt-2021-0196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 397 |
Ye ZH, Long H, Zhao ZR. Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy. J Immunol Res 2022;2022:8513747. [PMID: 35528615 DOI: 10.1155/2022/8513747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 398 |
Wang C, Degnan‐morgenstern S, Martin JD, Stuber MD. Optimal therapy design with tumor microenvironment normalization. AIChE Journal. [DOI: 10.1002/aic.17747] [Reference Citation Analysis]
|
| 399 |
Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. [DOI: 10.1038/s41571-022-00639-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 400 |
Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Front Pharmacol 2022;13:835510. [PMID: 35517794 DOI: 10.3389/fphar.2022.835510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 401 |
Long Y, Chen R, Yu X, Tong Y, Peng X, Li F, Hu C, Sun J, Gong L. Suppression of tumor/host intrinsic CMTM6 drives anti-tumor cytotoxicity in a PD-L1 independent manner.. [DOI: 10.1101/2022.05.06.490847] [Reference Citation Analysis]
|
| 402 |
Nozawa K, Takatsuka D, Endo Y, Horisawa N, Ozaki Y, Kataoka A, Kotani H, Yoshimura A, Hattori M, Sawaki M, Iwata H. Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2022;:103703. [PMID: 35533814 DOI: 10.1016/j.critrevonc.2022.103703] [Reference Citation Analysis]
|
| 403 |
Wang X, He Z, Liu W, Han R, Li H, Dai S, Zhang L, Mao M, Silvestris N. Development of a Clinically Oriented Model to Predict Antitumor Effects after PD-1/PD-L1 Inhibitor Therapy. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/9030782] [Reference Citation Analysis]
|
| 404 |
Veluswamy R, Hirsch FR, Taioli E, Wisnivesky J, Strauss R, Harrough D, Tang B, Barnes G. Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States. Cancer Med 2022. [PMID: 35499294 DOI: 10.1002/cam4.4785] [Reference Citation Analysis]
|
| 405 |
Yang H, Zhu J, Xiao R, Liu Y, Yu F, Cai L, Qiu M, He F. EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis. Cancer Immunol Immunother 2022;71:1001-1016. [DOI: 10.1007/s00262-021-03030-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 406 |
Ruan S, Huang Y, He M, Gao H. Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. Adv Sci (Weinh) 2022;9:e2200027. [PMID: 35343112 DOI: 10.1002/advs.202200027] [Reference Citation Analysis]
|
| 407 |
Johnson M, Chiara Garassino M, Mok T, Mitsudomi T. Treatment Strategies and Outcomes for Patients with EGFR-mutant Non-Small Cell Lung Cancer Resistant to EGFR Tyrosine Kinase Inhibitors: Focus on Novel Therapies. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 408 |
Venina AR, Ivantsov AO, Iyevleva AG, Kuligina ES, Preobrazhenskaya EV, Yurlov DO, Rawlinson KE, Kosmin AV, Savelov NA, Raskin GA, Imyanitov EN. PCR-based analysis of PD-L1 RNA expression in lung cancer: comparison with commonly used immunohistochemical assays. Annals of Diagnostic Pathology 2022. [DOI: 10.1016/j.anndiagpath.2022.151968] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 409 |
Lim J, Murphy A, Wong S, Nagrial A, Karikios D, Daneshvar D, Mccloy R, Steinmann AM, O'toole S, Chin V. Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor-β as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer. Cancer Treatment and Research Communications 2022. [DOI: 10.1016/j.ctarc.2022.100576] [Reference Citation Analysis]
|
| 410 |
Griesinger F. Erstlinientherapie des metastasierten nichtkleinzelligen Lungenkarzinoms. best practice onkologie 2022;17:198-205. [DOI: 10.1007/s11654-022-00378-4] [Reference Citation Analysis]
|
| 411 |
Yoneda T, Sone T, Koba H, Shibata K, Suzuki J, Tani M, Nishitsuji M, Nishi K, Kobayashi T, Shirasaki H, Araya T, Kita T, Kase K, Yamamura K, Terada N, Nishikawa S, Tambo Y, Kimura H, Kasahara K. Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.03.008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 412 |
Ognerubov NA, Antipova TS. Atezolizumab in the first-line treatment of metastatic non-small cell lung cancer. Clinical experience of the drug application. Case report. J Mod Onco 2022;24:50-60. [DOI: 10.26442/18151434.2022.1.201478] [Reference Citation Analysis]
|
| 413 |
Rodrigues A, Chauhan J, Sagkriotis A, Aasaithambi S, Montrone M. Understanding the lived experience of lung cancer: a European social media listening study. BMC Cancer 2022;22:475. [PMID: 35490223 DOI: 10.1186/s12885-022-09505-4] [Reference Citation Analysis]
|
| 414 |
Masuda T, Fujitaka K, Suzuki T, Hamai K, Matsumoto N, Matsumura M, Isoyama S, Ueno S, Mito M, Yamaguchi K, Sakamoto S, Kawano R, Masuda K, Nishino R, Ishikawa N, Yamasaki M, Hattori N. Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1. Thorac Cancer 2022. [PMID: 35488720 DOI: 10.1111/1759-7714.14428] [Reference Citation Analysis]
|
| 415 |
Sunpaweravong P, Thongwatchara P, Chotipanvithayakul R, Sangkhathat S, Thongsuksai P. Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer. Clin Med Insights Oncol 2022;16:11795549221092747. [PMID: 35479767 DOI: 10.1177/11795549221092747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 416 |
Zhang W, Shang X, Yang F, Han W, Xia H, Liu N, Liu Y, Wang X. CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma. Front Oncol 2022;12:867788. [DOI: 10.3389/fonc.2022.867788] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 417 |
Kharagezov DA, Lazutin YN, Mirzoyan EA, Milakin AG, Stateshny ON, Leyman IA, Gappoeva MA, Vitkovskaya VN, Iozefi KD. Modern treatment of ALK-positive non-small cell lung cancer. jour 2022;3:41-51. [DOI: 10.37748/2686-9039-2022-3-2-5] [Reference Citation Analysis]
|
| 418 |
Yoshida K, Chan P, Marchand M, Zhang R, Wu B, Ballinger M, Sternheim N, Jin JY, Bruno R. Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study. AAPS J 2022;24:58. [PMID: 35484442 DOI: 10.1208/s12248-022-00710-4] [Reference Citation Analysis]
|
| 419 |
Wu HL, Gong Y, Ji P, Xie YF, Jiang YZ, Liu GY. Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. J Hematol Oncol 2022;15:45. [PMID: 35477416 DOI: 10.1186/s13045-022-01263-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 420 |
Chan DW, Choi HC, Lee VH. Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14:2157. [PMID: 35565285 DOI: 10.3390/cancers14092157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 421 |
Fujiwara Y, Horita N, Harrington M, Namkoong H, Miyashita H, Galsky MD. Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03203-7] [Reference Citation Analysis]
|
| 422 |
Choi SH, Yoo SS, Lee SY, Park JY. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Arch Pharm Res 2022. [PMID: 35449345 DOI: 10.1007/s12272-022-01382-6] [Reference Citation Analysis]
|
| 423 |
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol 2022;40:1312-22. [PMID: 35089812 DOI: 10.1200/JCO.21.01485] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 424 |
Yanagitani N. Combination Immunotherapy in the First-line Setting for Non-small-cell Lung Cancer. JJLC 2022;62:75-80. [DOI: 10.2482/haigan.62.75] [Reference Citation Analysis]
|
| 425 |
Furqan M, Abu-Hejleh T, Stephens LM, Hartwig SM, Mott SL, Pulliam CF, Petronek M, Henrich JB, Fath MA, Houtman JC, Varga SM, Bodeker KL, Bossler AD, Bellizzi AM, Zhang J, Monga V, Mani H, Ivanovic M, Smith BJ, Byrne MM, Zeitler W, Wagner BA, Buettner GR, Cullen JJ, Buatti JM, Spitz DR, Allen BG. Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer. Redox Biol 2022;53:102318. [PMID: 35525024 DOI: 10.1016/j.redox.2022.102318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 426 |
Bruijnen CP, Koldenhof JJ, Verheijden RJ, van den Bos F, Emmelot-Vonk MH, Witteveen PO, Suijkerbuijk KPM. Frailty and checkpoint inhibitor toxicity in older patients with melanoma. Cancer 2022. [PMID: 35439334 DOI: 10.1002/cncr.34230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 427 |
Li B, Zhang G, Jin C, Zhao Y, Hua P, Tong T. Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis. Indian J Surg. [DOI: 10.1007/s12262-022-03389-1] [Reference Citation Analysis]
|
| 428 |
Ma SC, Bai X, Guo XJ, Liu L, Xiao LS, Lin Y, Tan JL, Cai XT, Wen YX, Ma H, Fu QJ, Leng MX, Zhang YP, Long LL, Guo ZQ, Wu DH, Zhou JG, Dong ZY. Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. BMC Med 2022;20:120. [PMID: 35410334 DOI: 10.1186/s12916-022-02315-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 429 |
Meng LF, Huang JF, Luo PH, Huang SX, Wang HL. The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. Invest New Drugs 2022. [PMID: 35412172 DOI: 10.1007/s10637-022-01232-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 430 |
Liang H, Xu Y, Chen M, Zhao J, Zhong W, Liu X, Gao X, Li S, Li J, Guo C, Jia H, Wang M. Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. Front Immunol 2021;12:749461. [PMID: 35356154 DOI: 10.3389/fimmu.2021.749461] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 431 |
Hegi-Johnson F, Rudd S, Hicks RJ, De Ruysscher D, Trapani JA, John T, Donnelly P, Blyth B, Hanna G, Everitt S, Roselt P, MacManus MP. Imaging immunity in patients with cancer using positron emission tomography. NPJ Precis Oncol 2022;6:24. [PMID: 35393508 DOI: 10.1038/s41698-022-00263-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 432 |
Stares M, Ding TE, Stratton C, Thomson F, Baxter M, Cagney H, Cumming K, Swan A, Ross F, Barrie C, Maclennan K, Campbell S, Evans T, Tufail A, Harrow S, Lord H, Laird B, MacKean M, Phillips I. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. ESMO Open 2022;7:100445. [PMID: 35398717 DOI: 10.1016/j.esmoop.2022.100445] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 433 |
Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N, Sohrabi AD, Adili A, Noroozi-Aghideh A, Razeghian E. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 2022;20:44. [PMID: 35392976 DOI: 10.1186/s12964-022-00854-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 40.0] [Reference Citation Analysis]
|
| 434 |
Lu C, Zhang YC, Chen ZH, Zhou Q, Wu YL. Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. Front Oncol 2022;12:836891. [PMID: 35359372 DOI: 10.3389/fonc.2022.836891] [Reference Citation Analysis]
|
| 435 |
Wang Z, Kim J, Zhang P, Galvan Achi JM, Jiang Y, Rong L. Current therapy and development of therapeutic agents for lung cancer. Cell Insight 2022;1:100015. [DOI: 10.1016/j.cellin.2022.100015] [Reference Citation Analysis]
|
| 436 |
Tagliamento M, Frelaut M, Baldini C, Naigeon M, Nencioni A, Chaput N, Besse B. The use of immunotherapy in older patients with advanced non-small cell lung cancer. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 437 |
Yao Y, Zhou X, Zhang A, Ma X, Zhu H, Yang Z, Li N. The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring. European Journal of Radiology 2022;149:110200. [DOI: 10.1016/j.ejrad.2022.110200] [Reference Citation Analysis]
|
| 438 |
Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, Steen CB, Macaulay CW, Schultz A, Nesselbush MC, Soo J, Schroers-Martin JG, Chen B, Binkley MS, Stehr H, Chabon JJ, Sworder BJ, Hui AB, Frank MJ, Moding EJ, Liu CL, Newman AM, Isbell JM, Rudin CM, Li BT, Kurtz DM, Diehn M, Alizadeh AA. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol 2022;40:585-97. [PMID: 35361996 DOI: 10.1038/s41587-022-01222-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 439 |
Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 440 |
Nagasaka M, Molife C, Cui ZL, Stefaniak V, Li X, Kim S, Lee HY, Beyrer J, Blumenschein G. Generalizability of ORIENT-11 trial results to a US standard of care cohort with advanced non-small-cell lung cancer. Future Oncol 2022. [PMID: 35354280 DOI: 10.2217/fon-2022-0099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 441 |
Li Y, Guo R. Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study. J Oncol 2022;2022:7794840. [PMID: 35342409 DOI: 10.1155/2022/7794840] [Reference Citation Analysis]
|
| 442 |
Nel AE, Mei KC, Liao YP, Liu X. Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. ACS Nano 2022. [PMID: 35348320 DOI: 10.1021/acsnano.2c01252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 443 |
Miyawaki E, Kenmotsu H, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Kawaguchi T, Miyaoka E, Yoshino I, Date H. Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer 2022;22:342. [PMID: 35351059 DOI: 10.1186/s12885-022-09441-3] [Reference Citation Analysis]
|
| 444 |
Orillard E, Henriques J, Vernerey D, Almotlak H, Calcagno F, Fein F, Fratté S, Jary M, Klajer E, Vienot A, Borg C, Kim S. Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients. Front Oncol 2022;12:763926. [PMID: 35340264 DOI: 10.3389/fonc.2022.763926] [Reference Citation Analysis]
|
| 445 |
Ushio R, Murakami S, Saito H. Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. JCM 2022;11:1855. [DOI: 10.3390/jcm11071855] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 446 |
Schegoleva AA, Khozyainova AA, Gerashchenko TS, Zhuikova LD, Denisov EV. Metastasis prevention: targeting causes and roots. Clin Exp Metastasis 2022. [PMID: 35347574 DOI: 10.1007/s10585-022-10162-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 447 |
Yap TA, Bessudo A, Hamilton E, Sachdev J, Patel MR, Rodon J, Evilevitch L, Duncan M, Guo W, Kumar S, Lu S, Dezube BJ, Gabrail N. IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer. J Immunother Cancer 2022;10:e003924. [PMID: 35332062 DOI: 10.1136/jitc-2021-003924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 448 |
Wu SY, Xu Y, Chen L, Fan L, Ma XY, Zhao S, Song XQ, Hu X, Yang WT, Chai WJ, Guo XM, Chen XZ, Xu YH, Zhu XY, Zou JJ, Wang ZH, Jiang YZ, Shao ZM. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol Cancer 2022;21:84. [PMID: 35337339 DOI: 10.1186/s12943-022-01536-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 449 |
Fu Y, Liu J, Jiang Y. Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report. Front Endocrinol 2022;13:810747. [DOI: 10.3389/fendo.2022.810747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 450 |
Khimani K, Patel SP, Whyte A, Al-zubidi N. Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab. Front Oncol 2022;12:806501. [DOI: 10.3389/fonc.2022.806501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 451 |
Shen Y, Shen C, Chiang C, Huang H, Chou K, Chiu C, Chen Y, Luo Y. Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. Front Med 2022;9:860733. [DOI: 10.3389/fmed.2022.860733] [Reference Citation Analysis]
|
| 452 |
Panday SK, Alexov E. Protein-Protein Binding Free Energy Predictions with the MM/PBSA Approach Complemented with the Gaussian-Based Method for Entropy Estimation. ACS Omega 2022;7:11057-67. [PMID: 35415339 DOI: 10.1021/acsomega.1c07037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 453 |
Rojo F, Conde E, Torres H, Cabezón-Gutiérrez L, Bautista D, Ramos I, Carcedo D, Arrabal N, García JF, Galán R, Nadal E. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain. BMC Cancer 2022;22:292. [PMID: 35303812 DOI: 10.1186/s12885-022-09397-4] [Reference Citation Analysis]
|
| 454 |
Ueno T, Yamashita M, Yamashita N, Uomoto M, Kawamata O, Sano Y, Inokawa H, Hirayama S, Okazaki M, Toyooka S. Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer. Gen Thorac Cardiovasc Surg 2022. [PMID: 35304712 DOI: 10.1007/s11748-022-01798-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 455 |
Chai Y, Wu X, Bai H, Duan J. Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis. J Clin Med 2022;11. [PMID: 35329978 DOI: 10.3390/jcm11061655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 456 |
Hu H, Chen Y, Tan S, Wu S, Huang Y, Fu S, Luo F, He J. The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment. Front Immunol 2022;13:802846. [PMID: 35281003 DOI: 10.3389/fimmu.2022.802846] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 457 |
Patil NS, Nabet BY, Müller S, Koeppen H, Zou W, Giltnane J, Au-Yeung A, Srivats S, Cheng JH, Takahashi C, de Almeida PE, Chitre AS, Grogan JL, Rangell L, Jayakar S, Peterson M, Hsia AW, O'Gorman WE, Ballinger M, Banchereau R, Shames DS. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell 2022;40:289-300.e4. [PMID: 35216676 DOI: 10.1016/j.ccell.2022.02.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 51.0] [Reference Citation Analysis]
|
| 458 |
Rocco D, Della Gravara L, Maione P, Palazzolo G, Gridelli C. Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions. Expert Review of Precision Medicine and Drug Development 2022;7:29-38. [DOI: 10.1080/23808993.2022.2050369] [Reference Citation Analysis]
|
| 459 |
Carroll R, Bortolini M, Calleja A, Munro R, Kong S, Daumont MJ, Penrod JR, Lakhdari K, Lacoin L, Cheung WY. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. BMC Cancer 2022;22:255. [PMID: 35264135 DOI: 10.1186/s12885-022-09342-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 460 |
Pandey P, Khan F, Qari HA, Upadhyay TK, Alkhateeb AF, Oves M. Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals 2022;15:335. [DOI: 10.3390/ph15030335] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 461 |
Holmen Olofsson G, Mikkelsen MK, Ragle A, Christiansen AB, Olsen AP, Heide-ottosen L, Horsted CB, Pedersen CMS, Engell-noerregaard L, Lorentzen T, Persson GF, Vinther A, Nielsen DL, thor Straten P. High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI AIM)—a randomized controlled trial. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09349-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 462 |
Cheng Y, Shi D, Xu Z, Gao Z, Si Z, Zhao Y, Ye R, Fu Z, Fu W, Yang T, Xiu Y, Lin Q, Cheng D. 124I-Labeled Monoclonal Antibody and Fragment for the Noninvasive Evaluation of Tumor PD-L1 Expression In Vivo. Mol Pharm 2022. [PMID: 35244407 DOI: 10.1021/acs.molpharmaceut.2c00084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 463 |
Muhammed A, D'Alessio A, Enica A, Talbot T, Fulgenzi CAM, Nteliopoulos G, Goldin RD, Cortellini A, Pinato DJ. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35236211 DOI: 10.1080/14737159.2022.2049244] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 464 |
Salloum A, Habre M, Chebl JA, Chebl KA, Atallah C, Medawar G, Kourie HR. Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. Immunotherapy 2022. [PMID: 35232283 DOI: 10.2217/imt-2021-0244] [Reference Citation Analysis]
|
| 465 |
Chen Y, Chen Z, Chen R, Fang C, Zhang C, Ji M, Yang X. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC. Future Oncol 2022. [PMID: 35232247 DOI: 10.2217/fon-2021-0862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 466 |
Lin Y, Dong Y, Liu W, Fan X, Sun Y. Pan-Cancer Analyses Confirmed the Ferroptosis-Related Gene SLC7A11 as a Prognostic Biomarker for Cancer. IJGM 2022;Volume 15:2501-13. [DOI: 10.2147/ijgm.s341502] [Reference Citation Analysis]
|
| 467 |
Zhu Y, Chang X, Zhou R, Chen Y, Ma H, Xiao Z, Qu X, Liu Y, Liu L, Li Y, Yu Y, Zhang H. Bone Metastasis Attenuates Efficacy of Immune Checkpoint Inhibitors and Displays “Cold” Immune Characteristics in Non-small Cell Lung Cancer. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 468 |
Zhang W, Kong Y, Li Y, Shi F, Lyu J, Sheng C, Wang S, Wang Q. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. Front Immunol 2021;12:798474. [PMID: 35087523 DOI: 10.3389/fimmu.2021.798474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 469 |
Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, Gangemi R, Filaci G, Coco S, Croce M. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Front Immunol 2021;12:799455. [PMID: 35069581 DOI: 10.3389/fimmu.2021.799455] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 470 |
Butter R, Hondelink L, van Elswijk L, Blaauwgeers JL, Bloemena E, Britstra R, Bulkmans N, Lena van Gullik A, Monkhorst K, de Rooij M, Slavujevic-letic I, Smit V, Speel E, Thunnissen E, von der Thüsen J, Timens W, van de Vijver M, Yick D, Zwinderman A, Cohen D, 't Hart N, Radonic T. The impact of a pathologist’s personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 471 |
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front Immunol 2022;13:823618. [PMID: 35222404 DOI: 10.3389/fimmu.2022.823618] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 472 |
Faber MG, Wang C, Kommi Reddy S, Meagher A, Early A, Chen H, Dy GK. Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience. Lung Cancer 2022;165:49-53. [DOI: 10.1016/j.lungcan.2022.01.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 473 |
Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z. Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. Cancers (Basel) 2022;14:1253. [PMID: 35267561 DOI: 10.3390/cancers14051253] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 474 |
Lu S, Li Z. Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade. J Thorac Oncol 2022;17:341-4. [PMID: 35216727 DOI: 10.1016/j.jtho.2022.01.002] [Reference Citation Analysis]
|
| 475 |
Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer 2022;10:e003026. [PMID: 35217573 DOI: 10.1136/jitc-2021-003026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 476 |
Pérol M, Felip E, Dafni U, Polito L, Pal N, Tsourti Z, Ton TGN, Merritt D, Morris S, Stahel R, Peters S. Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data. Ann Oncol 2022:S0923-7534(22)00124-7. [PMID: 35218887 DOI: 10.1016/j.annonc.2022.02.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 477 |
West HJ, McCleland M, Cappuzzo F, Reck M, Mok TS, Jotte RM, Nishio M, Kim E, Morris S, Zou W, Shames D, Das Thakur M, Shankar G, Socinski MA. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J Immunother Cancer 2022;10:e003027. [PMID: 35190375 DOI: 10.1136/jitc-2021-003027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 478 |
Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol 2022;40:611-25. [PMID: 34985916 DOI: 10.1200/JCO.21.01626] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 479 |
Passaro A, Brahmer J, Antonia S, Mok T, Peters S. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol 2022;40:598-610. [PMID: 34985992 DOI: 10.1200/JCO.21.01845] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 480 |
John T, Sakai H, Ikeda S, Cheng Y, Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, Maemondo M, Minato K, Hisada T, Misumi Y, Satouchi M, Hotta K, Li A, Oukessou A, Lu S. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. Int J Clin Oncol 2022. [PMID: 35182247 DOI: 10.1007/s10147-022-02120-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 481 |
Maniar A, Haslam A, Prasad V. Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. Eur J Cancer 2022;164:95-104. [PMID: 35182927 DOI: 10.1016/j.ejca.2022.01.006] [Reference Citation Analysis]
|
| 482 |
Suárez GM, Catalá M, Peña Y, Portela S, Añé-Kourí AL, González A, Lorenzo-Luaces P, Díaz M, Molina MLA, Pereira K, Hernández JC, Ramos R, Reyes MC, Ledón N, Mazorra Z, Crombet T, Lage A, Saavedra D. Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Front Oncol 2022;12:823287. [PMID: 35155258 DOI: 10.3389/fonc.2022.823287] [Reference Citation Analysis]
|
| 483 |
Yadav D, Kwak M, Chauhan PS, Puranik N, Lee PCW, Jin JO. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Semin Cancer Biol 2022:S1044-579X(22)00044-X. [PMID: 35181474 DOI: 10.1016/j.semcancer.2022.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 484 |
Woodford R, Zhou D, Lord SJ, Marschner I, Cooper WA, Lewis CR, John T, Yang JC, Lee CK. PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncol 2022. [PMID: 35156837 DOI: 10.2217/fon-2021-1184] [Reference Citation Analysis]
|
| 485 |
Bossageon M, Swalduz A, Chouaïd C, Bylicki O. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. BioDrugs 2022. [PMID: 35147894 DOI: 10.1007/s40259-022-00515-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 486 |
Seto T, Nosaki K, Shimokawa M, Toyozawa R, Sugawara S, Hayashi H, Murakami H, Kato T, Niho S, Saka H, Oki M, Yoshioka H, Okamoto I, Daga H, Azuma K, Tanaka H, Nishino K, Tohnai R, Yamamoto N, Nakagawa K. Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). J Immunother Cancer 2022;10:e004025. [PMID: 35105689 DOI: 10.1136/jitc-2021-004025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 487 |
Leung JH, Chang CW, Chan AL, Lang HC. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. Future Oncol 2022. [PMID: 35105168 DOI: 10.2217/fon-2021-0785] [Reference Citation Analysis]
|
| 488 |
Yan W, Lang T, Zhu R, Zhu X, Li Y, Wu T, Yin Q, Li Y. Anti-hypoxia nanosized drug delivery systems improving cancer therapy. Nano Today 2022;42:101376. [DOI: 10.1016/j.nantod.2022.101376] [Reference Citation Analysis]
|
| 489 |
Kuznik A, Smare C, Chen C, Venkatachalam M, Keeping S, Atsou K, Xu Y, Wilson F, Guyot P, Chan K, Glowienka E, Konidaris G. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%. Value in Health 2022;25:203-14. [DOI: 10.1016/j.jval.2021.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 490 |
Tang M, Lee CK, Lewis CR, Boyer M, Brown B, Schaffer A, Pearson S, Simes RJ. Generalizability of Immune Checkpoint Inhibitor Trials to Real-world Patients with Advanced Non-Small Cell Lung Cancer. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.024] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 491 |
Villacampa G, Tolosa P, Salvador F, Sánchez-bayona R, Villanueva L, Dienstmann R, Ciruelos E, Pascual T. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: a systematic review and meta-analysis. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 492 |
Jain S, Chalif EJ, Aghi MK. Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. Front Oncol 2021;11:812916. [PMID: 35096619 DOI: 10.3389/fonc.2021.812916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 493 |
Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open 2022;5:e2149040. [PMID: 35179586 DOI: 10.1001/jamanetworkopen.2021.49040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 494 |
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2022;23:279-91. [PMID: 35033226 DOI: 10.1016/S1470-2045(21)00658-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 495 |
Pisano C, De Filippis M, Jacobs F, Novello S, Reale ML. Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. Cancers (Basel) 2022;14:718. [PMID: 35158987 DOI: 10.3390/cancers14030718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 496 |
Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, Rosen L, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Lin JJ. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. JCO Precis Oncol 2022;6:e2100418. [PMID: 35085007 DOI: 10.1200/PO.21.00418] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 497 |
Kong S, Heinzmann D, Lauer S, Tian L. Weighted Approach for Estimating Effects in Principal Strata With Missing Data for a Categorical Post-Baseline Variable in Randomized Controlled Trials. Statistics in Biopharmaceutical Research. [DOI: 10.1080/19466315.2021.2009020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 498 |
Muthusamy B, Pennell N. Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer. J Thorac Oncol 2022;17:179-81. [PMID: 35074223 DOI: 10.1016/j.jtho.2021.11.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 499 |
Gong J, Bao X, Wang T, Liu J, Peng W, Shi J, Wu F, Gu Y. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer. OncoImmunology 2022;11:2028962. [DOI: 10.1080/2162402x.2022.2028962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 500 |
Michielin O, Lalani A, Robert C, Sharma P, Peters S. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. J Immunother Cancer 2022;10:e003024. [DOI: 10.1136/jitc-2021-003024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 501 |
Ito N, Masuda T, Ooka I, Hosoya T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N. First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations. Thorac Cancer 2022. [PMID: 35076999 DOI: 10.1111/1759-7714.14288] [Reference Citation Analysis]
|
| 502 |
Andrini E, Lamberti G, Mazzoni F, Riccardi F, Bonetti A, Follador A, Artioli F, Genova C, Barbieri F, Frassoldati A, Brighenti M, Colantonio I, Pasello G, Ficorella C, Cinieri S, Tiseo M, Gelsomino F, Tognetto M, Rihawi K, Ardizzoni A. A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale. Future Oncology. [DOI: 10.2217/fon-2021-1027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 503 |
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21. [DOI: 10.1186/s12943-021-01489-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 47.0] [Reference Citation Analysis]
|
| 504 |
Kampoli K, Foukas PG, Ntavatzikos A, Arkadopoulos N, Koumarianou A. Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer. World J Methodol 2022; 12(1): 43-53 [DOI: 10.5662/wjm.v12.i1.43] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 505 |
Yamaguchi T, Shimizu J, Oya Y, Watanabe N, Hasegawa T, Horio Y, Inaba Y, Fujiwara Y. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis. Thorac Cancer 2022. [PMID: 35044093 DOI: 10.1111/1759-7714.14308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 506 |
Tang S, Qin C, Hu H, Liu T, He Y, Guo H, Yan H, Zhang J, Tang S, Zhou H. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells 2022;11:320. [DOI: 10.3390/cells11030320] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 507 |
Kujtan L, Kancha RK, Gustafson B, Douglass L, Ward CR, Buzard B, Subramanian J. Squamous cell carcinoma of the lung: Improving the detection and management of immune-related adverse events. Expert Rev Anticancer Ther 2022. [PMID: 35034561 DOI: 10.1080/14737140.2022.2029414] [Reference Citation Analysis]
|
| 508 |
Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022;15:6. [PMID: 35033167 DOI: 10.1186/s13045-021-01182-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 509 |
Corn BW, Feldman DB, Hull JG, O'Rourke MA, Bakitas MA. Dispositional hope as a potential outcome parameter among patients with advanced malignancy: An analysis of the ENABLE database. Cancer 2022;128:401-9. [PMID: 34613617 DOI: 10.1002/cncr.33907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 510 |
Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, Faloppi L, Battelli N, Massari F. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol 2022. [PMID: 35029519 DOI: 10.1080/17425255.2021.2029405] [Reference Citation Analysis]
|
| 511 |
Huijbers EJM, Khan KA, Kerbel RS, Griffioen AW. Tumors resurrect an embryonic vascular program to escape immunity. Sci Immunol 2022;7:eabm6388. [PMID: 35030032 DOI: 10.1126/sciimmunol.abm6388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 512 |
Ninomiya R, Kinehara Y, Tobita S, Konaka H, Jokoji R, Shintani T, Tachibana I. Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab. Intern Med 2022. [PMID: 35022350 DOI: 10.2169/internalmedicine.8688-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 513 |
Yang X, Jiang L, Jin Y, Li P, Hou Y, Yun J, Wu C, Sun W, Fan X, Kuang D, Wang W, Ni J, Mao A, Tang W, Liu Z, Wang J, Xiao S, Li Y, Lin D. PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. J Cancer 2021;12:7390-8. [PMID: 35003359 DOI: 10.7150/jca.63003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 514 |
Zhu C, Xing XX, Wu B, Liang G, Han G, Lin CX, Fang HM. Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China. Front Pharmacol 2021;12:735536. [PMID: 35002693 DOI: 10.3389/fphar.2021.735536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 515 |
Du Y, Peng Q, Cheng D, Pan T, Sun W, Wang H, Ma X, He R, Zhang H, Cui Z, Feng X, Liu Z, Zhao T, Hu W, Shen L, Jiang W, Gao N, Martin BN, Zhang CJ, Zhang Z, Wang C. Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells. Nat Commun 2022;13:231. [PMID: 35017553 DOI: 10.1038/s41467-021-27936-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 516 |
Principe DR, Kamath SD, Korc M, Munshi HG. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther 2022;236:108111. [PMID: 35016920 DOI: 10.1016/j.pharmthera.2022.108111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 517 |
Schlauch D, Fu X, Jones SF, Burris HA 3rd, Spigel DR, Reeves J, McKenzie AJ. Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precis Oncol 2021;5:1625-38. [PMID: 34994650 DOI: 10.1200/PO.21.00008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 518 |
Harvey MJ, Cunningham R, Sawchyn B, Montesion M, Reddy P, McBride A, Chawla AJ. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol 2021;5:1611-24. [PMID: 34994647 DOI: 10.1200/PO.20.00540] [Reference Citation Analysis]
|
| 519 |
Tjong MC, Ragulojan M, Poon I, Louie AV, Cheng SY, Doherty M, Zhang L, Ung Y, Cheung P, Cheema PK. Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience. Current Oncology 2022;29:221-30. [DOI: 10.3390/curroncol29010021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 520 |
Templeton AR, Jeffery PL, Thomas PB, Perera MPJ, Ng G, Calabrese AR, Nicholls C, Mackenzie NJ, Wood J, Bray LJ, Vela I, Thompson EW, Williams ED. Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management. Front Oncol 2021;11:767697. [PMID: 34988013 DOI: 10.3389/fonc.2021.767697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 521 |
Rocco D, Della Gravara L, Franzese N, Maione P, Gridelli C. Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going? Expert Rev Anticancer Ther 2022. [PMID: 34989305 DOI: 10.1080/14737140.2022.2026772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 522 |
Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (2020) 2021;2:692-729. [PMID: 34977873 DOI: 10.1002/mco2.105] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 523 |
Liu M, Yang J, Xu B, Zhang X. Tumor metastasis: Mechanistic insights and therapeutic interventions. MedComm (2020) 2021;2:587-617. [PMID: 34977870 DOI: 10.1002/mco2.100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 524 |
Goto Y, Arakawa S, Shirasawa M, Higashiyama R, Baba K, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Yoshida T, Horinouchi H, Yamamoto N, Ohe Y. Performance of Japanese patients in registrational studies. Jpn J Clin Oncol 2022;52:53-64. [PMID: 34978326 DOI: 10.1093/jjco/hyab171] [Reference Citation Analysis]
|
| 525 |
Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, Zamani M. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int 2022;22:2. [PMID: 34980128 DOI: 10.1186/s12935-021-02407-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 526 |
Kaen DL, Minatta N, Russo A, Malapelle U, de Miguel-Pérez D, Rolfo C. Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met? Adv Exp Med Biol 2021;1342:113-42. [PMID: 34972964 DOI: 10.1007/978-3-030-79308-1_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 527 |
Lee C, Seetharamu N. The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_63] [Reference Citation Analysis]
|
| 528 |
Satake T, Maruki Y, Kubo Y, Takahashi M, Ohba A, Nagashio Y, Kondo S, Hijioka S, Morizane C, Ueno H, Okusaka T. Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review. Intern Med . [DOI: 10.2169/internalmedicine.8919-21] [Reference Citation Analysis]
|
| 529 |
Kaulen LD, Lu B, Goldberg S, Baehring JM. Neurological complications of lung cancer. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 2022. [DOI: 10.1016/b978-0-12-821976-8.00027-x] [Reference Citation Analysis]
|
| 530 |
Lu L, Zhan M, Li X, Zhang H, Dauphars DJ, Jiang J, Yin H, Li S, Luo S, Li Y, He Y. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology 2022;3:118-27. [DOI: 10.1016/j.crimmu.2022.05.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 531 |
Hosseini M, Rezaei N. Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_52] [Reference Citation Analysis]
|
| 532 |
Alexander M, Shum E, Singh A, Halmos B. Chemotherapy for Lung Cancer. Medical Radiology 2022. [DOI: 10.1007/174_2022_311] [Reference Citation Analysis]
|
| 533 |
Alrifai D, Pastos DP. Current Role of Immunotherapy. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-08-102723-3.00185-2] [Reference Citation Analysis]
|
| 534 |
Rybkin I, Gadgeel SM. Immunotherapy of Lung Cancer. Medical Radiology 2022. [DOI: 10.1007/174_2022_313] [Reference Citation Analysis]
|
| 535 |
Das CK, Singh SK. Immune Checkpoint Inhibitors in Cancer Therapy: A Ray of Hope. Biomedical Translational Research 2022. [DOI: 10.1007/978-981-16-8845-4_20] [Reference Citation Analysis]
|
| 536 |
Jalal SI, Mamdani H, Turchi AM, Turchi JJ. Lung Cancer. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00063-3] [Reference Citation Analysis]
|
| 537 |
Friedlaender A, Naidoo J, Luigi Banna G, Metro G, Forde P, Addeo A. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 538 |
Qiu H, Cummings MA, Chen Y. Translational Research in Lung Cancer. Medical Radiology 2022. [DOI: 10.1007/174_2022_346] [Reference Citation Analysis]
|
| 539 |
Sanghavi N, Farwa U, Khurshid F, Husain H. Landscape of Immunotherapy in Lung Cancer. Cancer Metastasis Through the Lymphovascular System 2022. [DOI: 10.1007/978-3-030-93084-4_68] [Reference Citation Analysis]
|
| 540 |
Liu W, Liu C, Wang H, Xu L, Zhou J, Li S, Cheng Y, Zhou R, Zhao L. Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. Computational and Structural Biotechnology Journal 2022;20:5150-61. [DOI: 10.1016/j.csbj.2022.09.017] [Reference Citation Analysis]
|
| 541 |
Yuan C, Huang M, Wang H, Jiang W, Su C, Zhou S. Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy. CMAR 2022;Volume 14:377-86. [DOI: 10.2147/cmar.s347547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 542 |
Zhu H, Zeng B, Zou J, Su C. Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer. Food Sci Technol 2022;42:e33621. [DOI: 10.1590/fst.33621] [Reference Citation Analysis]
|
| 543 |
Gristina V, Iacono F, Lisanti C, La Mantia M, Galvano A. Available Immunotherapy Drugs in Oncology. Current Clinical Pathology 2022. [DOI: 10.1007/978-3-030-97744-3_2] [Reference Citation Analysis]
|
| 544 |
Casas F, Muñoz-guglielmetti D, Oses G, Cases C, Mollà M. Hematological Toxicity in Lung Cancer. Medical Radiology 2022. [DOI: 10.1007/174_2022_335] [Reference Citation Analysis]
|
| 545 |
Reuther S, Bassani N, Murphy MF, Dempke W. C-MET Inhibitors as New Members of the NSCLC Treatment Armamentarium—A Pooled Analysis. ALC 2022;11:1-13. [DOI: 10.4236/alc.2022.111001] [Reference Citation Analysis]
|
| 546 |
Yong C, Cambron-mellott MJ, Seal B, Will O, Maculaitis MC, Clapp K, Mulvihill E, Cotarla I, Mehra R. Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment. PPA 2022;Volume 16:123-35. [DOI: 10.2147/ppa.s338840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 547 |
Fu F, Deng C, Sun W, Zheng Q, Jin Y, Li Y, Zhang Y, Chen H. Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer. Respir Res 2022;23:302. [DOI: 10.1186/s12931-022-02201-8] [Reference Citation Analysis]
|
| 548 |
Gomes F, Banfill K, Bille A, Fraser S, Banna G. Non-Small Cell Lung Cancer in Older Adults with Frailty. Frailty in Older Adults with Cancer 2022. [DOI: 10.1007/978-3-030-89162-6_18] [Reference Citation Analysis]
|
| 549 |
Li M, Hou X, Chen J, Zhang B, Wang N, Han H, Chen L. ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 550 |
Li L, Selaru FM. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.01.011] [Reference Citation Analysis]
|
| 551 |
Elebiyo TC, Rotimi D, Evbuomwan IO, Maimako RF, Iyobhebhe M, Ojo OA, Oluba OM, Adeyemi OS. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treatment and Research Communications 2022;32:100620. [DOI: 10.1016/j.ctarc.2022.100620] [Reference Citation Analysis]
|
| 552 |
Davies A, Forster M. Management of Advanced Disease in NSCLC. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-08-102723-3.00265-1] [Reference Citation Analysis]
|
| 553 |
郭 文. Clinical Progress and Prospect of Traditional Chinese Medicine Combined with Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer. ACM 2022;12:11735-11739. [DOI: 10.12677/acm.2022.12121690] [Reference Citation Analysis]
|
| 554 |
Sawatari K, Izumi M, Sone R, Hattori T, Sugimoto A, Eguchi Y, Mamoto T. A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab. Respiratory Medicine Case Reports 2022;36:101579. [DOI: 10.1016/j.rmcr.2022.101579] [Reference Citation Analysis]
|
| 555 |
Lazzari C, Bulotta A, Damiano G, Mirabile A, Viganó M, Veronesi G, Gregorc V. Angiogenesis inhibition in lung cancer: emerging novel strategies. Curr Opin Oncol 2022;34:107-14. [PMID: 34812193 DOI: 10.1097/CCO.0000000000000807] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 556 |
Remon J, Facchinetti F, Besse B. The efficacy of immune checkpoint inhibitors in thoracic malignancies. Eur Respir Rev 2021;30:200387. [PMID: 34615702 DOI: 10.1183/16000617.0387-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 557 |
Lepland A, Malfanti A, Haljasorg U, Asciutto EK, Pickholz M, Bringas M, Đorđević S, Salumäe L, Peterson P, Teesalu T, Vicent MJ, Scodeller P. Depletion of CD206+ Tumour Macrophages via a Peptide-Targeted Star-Shaped Polyglutamate Inhibits Tumourigenesis and Metastatic Dissemination in Breast Cancer Models.. [DOI: 10.1101/2021.12.29.474487] [Reference Citation Analysis]
|
| 558 |
Yang SC, Kunst N, Gross CP, Wang JD, Su WC, Wang SY. Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. Front Oncol 2021;11:760686. [PMID: 34956882 DOI: 10.3389/fonc.2021.760686] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 559 |
Ishikura N, Sugimoto M, Yorozu K, Kurasawa M, Kondoh O. Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1low and immune desert‑like mouse tumors. Oncol Rep 2022;47:36. [PMID: 34958105 DOI: 10.3892/or.2021.8247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 560 |
De Mello RAB, Voscaboinik R, Luciano JVP, Cremonese RV, Amaral GA, Castelo-Branco P, Antoniou G. Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers (Basel) 2021;14:122. [PMID: 35008287 DOI: 10.3390/cancers14010122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 561 |
Tanaka I, Morise M. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. Int J Mol Sci 2021;23:245. [PMID: 35008669 DOI: 10.3390/ijms23010245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 562 |
Lang D, Brauner A, Huemer F, Rinnerthaler G, Horner A, Wass R, Brehm E, Kaiser B, Greil R, Lamprecht B. Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study. Cancers (Basel) 2021;14:93. [PMID: 35008255 DOI: 10.3390/cancers14010093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 563 |
Velez MA, Tsai HHC, Shackelford DB, Garon EB, Lisberg A. What is the current role of immunotherapy in EGFR mutant advanced NSCLC? Lung Cancer 2021:S0169-5002(21)00629-2. [PMID: 35031176 DOI: 10.1016/j.lungcan.2021.12.001] [Reference Citation Analysis]
|
| 564 |
Fennell DA, Dulloo S. Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. J Thorac Oncol 2022;17:34-7. [PMID: 34930610 DOI: 10.1016/j.jtho.2021.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 565 |
Seegobin K, Majeed U, Wiest N, Manochakian R, Lou Y, Zhao Y. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. Front Oncol 2021;11:750657. [PMID: 34926258 DOI: 10.3389/fonc.2021.750657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 566 |
Han F, Tian H, Jin B, Chen G. Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study. Clin Med Insights Oncol 2021;15:11795549211059146. [PMID: 34924779 DOI: 10.1177/11795549211059146] [Reference Citation Analysis]
|
| 567 |
Shi Y, Fang J, Zhou C, Liu A, Wang Y, Meng Q, Ding C, Ai B, Gu Y, Yao Y, Sun H, Guo H, Zhang C, Song X, Li J, Xu B, Han Z, Song M, Tang T, Chen P, Lu H, Shui Y, Lou G, Zhang D, Liu J, Liu X, Liu X, Gao X, Zhou Q, Chen M, Zhao J, Zhong W, Xu Y, Wang M. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. Thorac Cancer 2021. [PMID: 34935288 DOI: 10.1111/1759-7714.14274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 568 |
Blank CU, Wong DJ, Ho TH, Bauer TM, Lee CB, Bene-Tchaleu F, Zhu J, Zhang X, Cha E, Sznol M. Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Curr Oncol 2021;28:5466-79. [PMID: 34940094 DOI: 10.3390/curroncol28060455] [Reference Citation Analysis]
|
| 569 |
Zhai Y, Ma Y, Pang B, Zhang J, Li Y, Rui Y, Xu T, Zhao Y, Qian Z, Gu Y, Li S. A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy. J Nanobiotechnology 2021;19:434. [PMID: 34930285 DOI: 10.1186/s12951-021-01193-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 570 |
Gridelli C, Peters S, Mok T, Forde PM, Reck M, Attili I, de Marinis F. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology. ESMO Open 2021;7:100355. [PMID: 34922299 DOI: 10.1016/j.esmoop.2021.100355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 571 |
Xiong A, Wang J, Zhou C. Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China. Front Oncol 2021;11:757993. [PMID: 34900707 DOI: 10.3389/fonc.2021.757993] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 572 |
Haskins C, Cohen J, Kotecha R, Kaiser A. Low Carbohydrate Diets in Cancer Therapeutics: Current Evidence. Front Nutr 2021;8:662952. [PMID: 34901101 DOI: 10.3389/fnut.2021.662952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 573 |
Waibl Polania J, Lerner EC, Wilkinson DS, Hoyt-Miggelbrink A, Fecci PE. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. Front Immunol 2021;12:777073. [PMID: 34868044 DOI: 10.3389/fimmu.2021.777073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 574 |
Zhou CH, Yang F, Jiang WJ, Zhang YC, Yang HY, Zeng L, Liu L, Xiong Y, Zeng FX, Wang Z, Yang N. Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study. Front Pharmacol 2021;12:727102. [PMID: 34867332 DOI: 10.3389/fphar.2021.727102] [Reference Citation Analysis]
|
| 575 |
Wiest N, Majeed U, Seegobin K, Zhao Y, Lou Y, Manochakian R. Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Front Oncol 2021;11:751209. [PMID: 34868953 DOI: 10.3389/fonc.2021.751209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 576 |
Zouein J, Haddad FG, Eid R, Kourie HR. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy 2021. [PMID: 34865502 DOI: 10.2217/imt-2021-0014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 577 |
Matsumoto H, Kobayashi N, Somekawa K, Fukuda N, Kaneko A, Kamimaki C, Kubo S, Tanaka K, Tagami Y, Teranishi S, Watanabe K, Horita N, Hara Y, Yamamoto M, Kudo M, Koizumi H, Miura K, Miyazawa N, Kaneko T. Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial. Thorac Cancer 2021. [PMID: 34866339 DOI: 10.1111/1759-7714.14252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 578 |
Shi J, Li J, Wang Q, Cheng X, Du H, Han R, Li X, Zhao C, Gao G, He Y, Chen X, Su C, Ren S, Wu F, Zhang Z, Zhou C. The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. Transl Lung Cancer Res 2021;10:3929-42. [PMID: 34858782 DOI: 10.21037/tlcr-21-524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 579 |
Bongiovanni A, Foca F, Menis J, Stucci SL, Artioli F, Guadalupi V, Forcignanò MR, Fantini M, Recine F, Mercatali L, Spadazzi C, Burgio MA, Fausti V, Miserocchi A, Ibrahim T. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio. Front Immunol 2021;12:697298. [PMID: 34858389 DOI: 10.3389/fimmu.2021.697298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 580 |
Lang D, Ritzberger L, Rambousek V, Horner A, Wass R, Akbari K, Kaiser B, Kronbichler J, Lamprecht B, Gabriel M. First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes. Cancers (Basel) 2021;13:6096. [PMID: 34885206 DOI: 10.3390/cancers13236096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 581 |
Luo W, Wang Z, Zhang T, Yang L, Xian J, Li Y, Li W. Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. Precision Clinical Medicine 2021;4:258-70. [DOI: 10.1093/pcmedi/pbab027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 582 |
Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov 2021;20:899-919. [PMID: 33686237 DOI: 10.1038/s41573-021-00155-y] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 46.0] [Reference Citation Analysis]
|
| 583 |
Wakuda K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Shimizu T, Gon Y, Takahashi T. Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors. Jpn J Clin Oncol 2021;51:1736-43. [PMID: 34642738 DOI: 10.1093/jjco/hyab158] [Reference Citation Analysis]
|
| 584 |
Filleron T, Bachelier M, Mazieres J, Pérol M, Meyer N, Martin E, Mathevet F, Dauxois JY, Porcher R, Delord JP. Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review. JAMA Netw Open 2021;4:e2139573. [PMID: 34932105 DOI: 10.1001/jamanetworkopen.2021.39573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 585 |
Di Federico A, Rizzo A, Carloni R, De Giglio A, Bruno R, Ricci D, Brandi G. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs 2021;:1-9. [PMID: 34798793 DOI: 10.1080/13543784.2022.2009455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 586 |
Yoshimura N, Sawa K, Nakai T, Matsumoto Y, Mitsuoka S, Kimura T, Asai K, Yana T, Kawaguchi T, Hirata K. Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer. Am J Clin Oncol 2021;44:613-8. [PMID: 34753884 DOI: 10.1097/COC.0000000000000876] [Reference Citation Analysis]
|
| 587 |
Souquet PJ, Audigier-Valette C, Molinier O, Cortot A, Margery J, Moreau L, Gervais R, Barlesi F, Pichon E, Zalcman G, Dumont P, Girard N, Poudenx M, Mazières J, Cadranel J, Debieuvre D, Dauba J, Langlais A, Morin F, Moro-Sibilot D, Westeel V, Pérol M. Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial. Lung Cancer 2021;164:84-90. [PMID: 35051725 DOI: 10.1016/j.lungcan.2021.11.014] [Reference Citation Analysis]
|
| 588 |
Florez M, Kemnade J, Chen N, Du W, Sabichi AL, Wang D, Huang Q, Miller-chism C, Jotwani A, Chen A, Hernandez D, Sandulache V. Persistent racial/ethnic associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.. [DOI: 10.1101/2021.11.26.21266821] [Reference Citation Analysis]
|
| 589 |
Alessi JV, Ricciuti B, Alden SL, Bertram AA, Lin JJ, Sakhi M, Nishino M, Vaz VR, Lindsay J, Turner MM, Pfaff K, Sharma B, Felt KD, Rodig SJ, Gainor JF, Awad MM. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J Immunother Cancer 2021;9:e003536. [PMID: 34824161 DOI: 10.1136/jitc-2021-003536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 590 |
Nakamura R, Yamada T, Morimoto K, Nakao A, Goto Y, Ogura Y, Takeda T, Takumi C, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Tanaka S, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Uchino J, Takayama K. Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. J Cancer Res Clin Oncol 2021. [PMID: 34825950 DOI: 10.1007/s00432-021-03866-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 591 |
Seto T, Nosaki K. ICI Monotherapy or Combination Therapy in the Treatment of NSCLC: How to Choose Among Multiple Options. JJLC 2021;61:847-849. [DOI: 10.2482/haigan.61.847] [Reference Citation Analysis]
|
| 592 |
Matsumoto K, Shiroyama T, Kuge T, Miyake K, Yamamoto Y, Yoneda M, Yamamoto M, Naito Y, Suga Y, Fukushima K, Koyama S, Iwahori K, Hirata H, Nagatomo I, Takeda Y, Kumanogoh A. Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer 2021;162:175-84. [PMID: 34823108 DOI: 10.1016/j.lungcan.2021.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 593 |
Bilger G, Girard N, Doubre H, Levra MG, Giroux-Leprieur E, Giraud F, Decroisette C, Carton M, Massiani MA. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. Cancer Immunol Immunother 2021. [PMID: 34821950 DOI: 10.1007/s00262-021-03114-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 594 |
Luna J, Zafra J, Areses Manrique MC, Rodríguez A, Sotoca A, Fírvida JL, Chicas-Sett R, Mielgo X, Reyes JCT, Couñago F. New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World J Clin Oncol 2021; 12(11): 983-999 [PMID: 34909394 DOI: 10.5306/wjco.v12.i11.983] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 595 |
Wang C, Cui A, Bukenya M, Aung A, Pradhan D, Whittaker CA, Agarwal Y, Thomas A, Liang S, Amlashi P, Suh H, Spranger S, Hacohen N, Irvine DJ. Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Cell Rep 2021;37:110021. [PMID: 34818534 DOI: 10.1016/j.celrep.2021.110021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 596 |
Cusano E, Wong C, Taguedong E, Vaska M, Abedin T, Nixon N, Karim S, Tang P, Heng DYC, Ezeife D. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Curr Oncol 2021;28:4894-928. [PMID: 34898590 DOI: 10.3390/curroncol28060412] [Reference Citation Analysis]
|
| 597 |
Huang C, Yang X. [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:777-83. [PMID: 34802209 DOI: 10.3779/j.issn.1009-3419.2021.102.40] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 598 |
Yudin DI, Laktionov KK, Laktionova LV, Breder VV. Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives. J Mod Onco 2021;23:428-435. [DOI: 10.26442/18151434.2021.3.201189] [Reference Citation Analysis]
|
| 599 |
Laktionov KK, Artamonova EV, Borisova TN, Breder VV, Bychkov IM, Vladimirova LI, Volkov NM, Ergnian SM, Zhabina AS, Kononets PV, Kuz’minov AE, Levchenko EV, Malikhova OA, Marinov DT, Miller SV, Moiseenko FV, Mochal’nikova VV, Novikov SN, Pikin OV, Reutova EV, Rodionov EO, Sakaeva DD, Semenova AI, Smolin AV, Sotnikov VM, Tuzikov SA, Turkin IN, Tiurin IE, Chkhikvadze VD, Kolbanov KI, Chernichenko AV, Fedenko AA, Filonenko EV, Nevol’skikh AA, Ivanov SA, Khailova ZV, Gevorkian TG, Butenko AV, Gil’mutdinova IR, Gridneva IV, Eremushkin MA, Zernova MA, Kasparov BS, Kovlen DV, Kondrat’eva KO, Konchugova TV, Korotkova SB, Krutov AA, Obukhova OA, Ponomarenko GN, Semiglazova TI, Stepanova AM, Tkachenko GA, Khulamkhanova MM. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. J Mod Onco 2021;23:369-402. [DOI: 10.26442/18151434.2021.3.201048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 600 |
Insa A, Martín-Martorell P, Di Liello R, Fasano M, Martini G, Napolitano S, Vicidomini G, Cappabianca S, Franco R, Morgillo F, Della Corte CM. Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? Crit Rev Oncol Hematol 2021;169:103538. [PMID: 34801700 DOI: 10.1016/j.critrevonc.2021.103538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 601 |
Malapelle U, Pilotto S, Reale ML, Passiglia F, Pisapia P, Pepe F, Belluomini L, Galetta D, Cortinovis D, Tiseo M, Passaro A, Seminati D, Pagni F, Parra HS, Migliorino MR, Rocco D, Troncone G, Novello S. Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. Crit Rev Oncol Hematol 2021;169:103536. [PMID: 34801697 DOI: 10.1016/j.critrevonc.2021.103536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 602 |
Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, Chung HC, Mileham K, Vaishampayan U, Rasco D, Golan T, Bauer TM, Jimeno A, Chung V, Chartash E, Lala M, Chen Q, Healy JA, Ahn MJ. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer. Ann Oncol 2021:S0923-7534(21)04776-1. [PMID: 34800678 DOI: 10.1016/j.annonc.2021.11.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 603 |
Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Takeda T, Takayama K. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study. Thorac Cancer 2021. [PMID: 34791812 DOI: 10.1111/1759-7714.14236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 604 |
Kwan TY, Chowdhury EH. Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. Medicina (Kaunas) 2021;57:1252. [PMID: 34833470 DOI: 10.3390/medicina57111252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 605 |
Shi LZ, Bonner JA. Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis. Int J Mol Sci 2021;22:12295. [PMID: 34830176 DOI: 10.3390/ijms222212295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 606 |
Ott PA, Nazzaro M, Pfaff KL, Gjini E, Felt KD, Wolff JO, Buchbinder EI, Haq R, Sullivan RJ, Lawrence DP, McDermott DF, Severgnini M, Giobbie-Hurder A, Rodig SJ, Stephen Hodi F. Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. J Immunother Cancer 2021;9:e003318. [PMID: 34772758 DOI: 10.1136/jitc-2021-003318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 607 |
Crockett C, Belderbos J, Levy A, McDonald F, Le Péchoux C, Faivre-Finn C. Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand? Lung Cancer 2021;162:96-105. [PMID: 34768007 DOI: 10.1016/j.lungcan.2021.10.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 608 |
Soleimany AP, Kirkpatrick JD, Wang CS, Jaeger AM, Su S, Naranjo S, Zhong Q, Cabana CM, Jacks T, Bhatia SN. Multiscale profiling of enzyme activity in cancer.. [DOI: 10.1101/2021.11.11.468288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 609 |
Fitzpatrick O, Naidoo J. Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. Lung Cancer (Auckl) 2021;12:123-31. [PMID: 34754256 DOI: 10.2147/LCTT.S305466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 610 |
White MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, Neal JW, Das M, Padda SK, Ramchandran K, Chen TT, Sequist LV, Piotrowska Z, Wakelee HA. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clin Lung Cancer 2021:S1525-7304(21)00278-3. [PMID: 34887193 DOI: 10.1016/j.cllc.2021.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 611 |
Bellone M, Bregni M, Bronte V, Ugel S, Ferrucci PF, Di Nicola M, Nisticò P, Zuccolotto G, Rosato A, Russo V, Sica A, Colombo MP. Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. Cancer Immunol Immunother 2021. [PMID: 34755203 DOI: 10.1007/s00262-021-03104-1] [Reference Citation Analysis]
|
| 612 |
Kesireddy M, Ganti AK. Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter? Transl Lung Cancer Res 2021;10:3705-8. [PMID: 34733621 DOI: 10.21037/tlcr-21-718] [Reference Citation Analysis]
|
| 613 |
Denault MH, Melosky B. Immunotherapy in the First-Line Setting in Wild-Type NSCLC. Curr Oncol 2021;28:4457-70. [PMID: 34898579 DOI: 10.3390/curroncol28060378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 614 |
Hilser T, Virchow I, Grünwald V. Immunkombinationstherapien. Onkologe 2021;27:1085-1093. [DOI: 10.1007/s00761-021-01033-3] [Reference Citation Analysis]
|
| 615 |
Horton BJ, Wages NA, Gentzler RD. Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer. Int J Environ Res Public Health 2021;18:11452. [PMID: 34769970 DOI: 10.3390/ijerph182111452] [Reference Citation Analysis]
|
| 616 |
Song X, Rao H, Guo C, Yang B, Ren Y, Wang M, Li Y, Cao Z, Pei J. Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo. Phytomedicine 2021;93:153802. [PMID: 34710755 DOI: 10.1016/j.phymed.2021.153802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 617 |
Ayuso-Íñigo B, Méndez-García L, Pericacho M, Muñoz-Félix JM. The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement? Cancers (Basel) 2021;13:5412. [PMID: 34771575 DOI: 10.3390/cancers13215412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 618 |
Hopkins AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, Logan JM, Badaoui S, Karapetis CS, Rowland A, Sorich MJ. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer 2021. [PMID: 34711947 DOI: 10.1038/s41416-021-01606-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 619 |
Loh JS, Tan LKS, Lee WL, Ming LC, How CW, Foo JB, Kifli N, Goh BH, Ong YS. Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids? Cancers (Basel) 2021;13:5346. [PMID: 34771511 DOI: 10.3390/cancers13215346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 620 |
Shiraishi Y, Hakozaki T, Nomura S, Kataoka T, Tanaka K, Miura S, Sekino Y, Ando M, Horinouchi H, Ohe Y, Okamoto I. A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). Clin Lung Cancer 2021:S1525-7304(21)00271-0. [PMID: 34802879 DOI: 10.1016/j.cllc.2021.10.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 621 |
Akhbariyoon H, Azizpour Y, Esfahani MF, Firoozabad MSM, Rad MR, Esfahani KS, Khoshavi N, Karimi N, Shirinisaz A, Abedi F, Rad MR, Sharifi P. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clin Immunol 2021;232:108873. [PMID: 34688855 DOI: 10.1016/j.clim.2021.108873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 622 |
Kauffmann-Guerrero D, Taugner J, Eze C, Käsmann L, Li M, Tufman A, Manapov F. Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer-A Prospective Longitudinal Assessment. Diagnostics (Basel) 2021;11:1968. [PMID: 34829315 DOI: 10.3390/diagnostics11111968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 623 |
Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M. Immunotherapeutic Advances for NSCLC. Biologics 2021;15:399-417. [PMID: 34675481 DOI: 10.2147/BTT.S295406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 624 |
Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD. Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight 2021;6:e151035. [PMID: 34676831 DOI: 10.1172/jci.insight.151035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 625 |
Baldessari C, Pecchi A, Marcheselli R, Guaitoli G, Bonacini R, Valoriani F, Torricelli P, Reverberi L, Menozzi R, Pugliese G, Vitale MG, Sabbatini R, Bertolini F, Barbieri F, Dominici M. Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy. Immunotherapy 2021;13:1501-19. [PMID: 34670403 DOI: 10.2217/imt-2021-0038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 626 |
Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Chiabudini M, Fischer von Weikersthal L, Budweiser S, Nacke A, Taeuscher D, Welslau M, Potthoff K. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study. Cancer Med 2021;10:8127-37. [PMID: 34668662 DOI: 10.1002/cam4.4310] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 627 |
Huang L, Qin Y, Zhao F, Zhou S, Shi Y. [Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib]. Zhongguo Fei Ai Za Zhi 2021;24:739-42. [PMID: 34628779 DOI: 10.3779/j.issn.1009-3419.2021.102.25] [Reference Citation Analysis]
|
| 628 |
Liao J, Liu C, Long Q, Wu X, Wang H, Yu H, Sun S, Zhang Y, Lin Y, Zhao X, Wang J. Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations. Front Oncol 2021;11:752545. [PMID: 34660317 DOI: 10.3389/fonc.2021.752545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 629 |
Cheng Y, Zhang L, Hu J, Wang D, Hu C, Zhou J, Wu L, Cao L, Liu J, Zhang H, Sun H, Wang Z, Gao H, Sun Y, Li B, Hu X, Schwarzenberger P, Paz-Ares L. Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407. JTO Clin Res Rep 2021;2:100225. [PMID: 34661177 DOI: 10.1016/j.jtocrr.2021.100225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 630 |
Gerard CL, Delyon J, Wicky A, Homicsko K, Cuendet MA, Michielin O. Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treat Rev 2021;101:102227. [PMID: 34656019 DOI: 10.1016/j.ctrv.2021.102227] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 631 |
Singh T, Fatehi Hassanabad M, Fatehi Hassanabad A. Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochim Biophys Acta Rev Cancer 2021;1876:188636. [PMID: 34655692 DOI: 10.1016/j.bbcan.2021.188636] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 632 |
He M, Zheng T, Zhang X, Peng Y, Jiang X, Huang Y, Tan B, Yang Z. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis. Cancer Immunol Immunother 2021. [PMID: 34657171 DOI: 10.1007/s00262-021-03089-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 633 |
Janopaul-Naylor JR, Shen Y, Qian DC, Buchwald ZS. The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. Int J Mol Sci 2021;22:11061. [PMID: 34681719 DOI: 10.3390/ijms222011061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 634 |
Takamori S, Shimokawa M, Komiya T. Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Real-world data from 86 173 patients. Thorac Cancer 2021;12:2943-8. [PMID: 34612011 DOI: 10.1111/1759-7714.14178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 635 |
Garg G, Prasad KT, Singh N, Gupta P, Muthu V, Das A, Bal A. Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters. J Pathol Transl Med 2021;55:398-405. [PMID: 34610234 DOI: 10.4132/jptm.2021.08.08] [Reference Citation Analysis]
|
| 636 |
Nagaoka K, Shirai M, Taniguchi K, Hosoi A, Sun C, Kobayashi Y, Maejima K, Fujita M, Nakagawa H, Nomura S, Kakimi K. Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. J Immunother Cancer 2020;8:e001358. [PMID: 33093158 DOI: 10.1136/jitc-2020-001358] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 637 |
Chambers AM, Lupo KB, Wang J, Cao J, Toregrosa-allen S, Elzey BD, Pine SR, Jalal S, Utturkar S, Lanman NA, Bernal-crespo V, Matosevic S. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.. [DOI: 10.1101/2021.10.05.463201] [Reference Citation Analysis]
|
| 638 |
Lin J, Sabath BF. Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small Cell Lung Cancer. Am J Case Rep 2021;22:e933396. [PMID: 34606491 DOI: 10.12659/AJCR.933396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 639 |
García Campelo MR, Arriola E, Campos Balea B, López-Brea M, Fuentes-Pradera J, de Castro Carpeno J, Aguado C, Pérez Parente D, de Oro Pulido F, Ruiz-Gracia P, Rodríguez-Abreu D. PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis. J Clin Med 2021;10:4583. [PMID: 34640601 DOI: 10.3390/jcm10194583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 640 |
Han MG, Jang BS, Kang MH, Na D, Kim IA. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. Eur J Cancer 2021;157:450-63. [PMID: 34601286 DOI: 10.1016/j.ejca.2021.08.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 641 |
Roulleaux Dugage M, Brosseau S. [Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression]. Bull Cancer 2021;108:904-6. [PMID: 34598788 DOI: 10.1016/j.bulcan.2021.06.011] [Reference Citation Analysis]
|
| 642 |
Miyashita K, Karayama M, Inoue Y, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kono M, Matsui T, Niwa M, Koda K, Toyoshima M, Matsushima S, Matsuura S, Asada K, Fujii M, Kusagaya H, Matsuda H, Inui N, Suda T. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. BMC Pulm Med 2021;21:309. [PMID: 34600514 DOI: 10.1186/s12890-021-01681-6] [Reference Citation Analysis]
|
| 643 |
Ma LR, Li JX, Tang L, Li RZ, Yang JS, Sun A, Leung EL, Yan PY. Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions. Oncol Lett 2021;22:787. [PMID: 34594428 DOI: 10.3892/ol.2021.13048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 644 |
Di Federico A, De Giglio A, Parisi C, Gelsomino F, Boni L, Ardizzoni A. Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis. JTO Clin Res Rep 2021;2:100214. [PMID: 34590054 DOI: 10.1016/j.jtocrr.2021.100214] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 645 |
Hensing TA, Wang X, Stinchcombe TE, Gao J, Knopp MV, Watson M, Dudek AZ, Graziano SL, Patel JD, Faller BA, Dragnev KH, Kozono D, Vokes EE. Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. JTO Clin Res Rep 2021;2:100208. [PMID: 34590049 DOI: 10.1016/j.jtocrr.2021.100208] [Reference Citation Analysis]
|
| 646 |
Lemaire V, Shemesh CS, Rotte A. Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. J Exp Clin Cancer Res 2021;40:311. [PMID: 34598713 DOI: 10.1186/s13046-021-02111-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 647 |
Yang JC, Mok TSK, Lu S, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Morita S, Tamura T. Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. JTO Clin Res Rep 2021;2:100142. [PMID: 34590001 DOI: 10.1016/j.jtocrr.2021.100142] [Reference Citation Analysis]
|
| 648 |
Wang B, Guo H, Xu H, Yu H, Chen Y, Zhao G. Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. Cells 2021;10:2620. [PMID: 34685600 DOI: 10.3390/cells10102620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 649 |
Reinmuth N, Merk M, Duell T. NSCLC und SCLC*. InFo Hämatol Onkol 2021;24:44-52. [DOI: 10.1007/s15004-021-8835-z] [Reference Citation Analysis]
|
| 650 |
Kinoshita T, Terai H, Yaguchi T. Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life (Basel) 2021;11:1029. [PMID: 34685400 DOI: 10.3390/life11101029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 651 |
Fukuda N, Horita N, Katakura S, Namkoong H, Kaneko A, Somekawa K, Tagami Y, Watanabe K, Hara Y, Kobayashi N, Kaneko T. The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1-49%: a network meta-analysis. Transl Lung Cancer Res 2021;10:3550-66. [PMID: 34584856 DOI: 10.21037/tlcr-21-419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 652 |
Walsh RJ, Tan DSP. The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. J Clin Med 2021;10:4523. [PMID: 34640541 DOI: 10.3390/jcm10194523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 653 |
Lee D, Park J, Choi H, Gim G, Cho S, Kim L, Oh Y, Kang CY, Kim Y, Tan D, de Viveiros PAH, Chae YK. Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy. Heliyon 2021;7:e07916. [PMID: 34568594 DOI: 10.1016/j.heliyon.2021.e07916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 654 |
Wan Q, Bao Y, Xia X, Liu J, Wang P, Peng Y, Xie X, He J, Li X. Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Predicting and Monitoring the Response of Anti-Angiogenic Treatment in the Orthotopic Nude Mouse Model of Lung Adenocarcinoma. J Magn Reson Imaging 2021. [PMID: 34570394 DOI: 10.1002/jmri.27920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 655 |
Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 2021;14:156. [PMID: 34579759 DOI: 10.1186/s13045-021-01164-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 656 |
Baysal H, De Pauw I, Zaryouh H, Peeters M, Vermorken JB, Lardon F, De Waele J, Wouters A. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. Front Immunol 2021;12:737311. [PMID: 34557197 DOI: 10.3389/fimmu.2021.737311] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 657 |
Xu Y, Wang Q, Xie J, Chen M, Liu H, Zhan P, Lv T, Song Y. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Front Oncol 2021;11:732214. [PMID: 34557415 DOI: 10.3389/fonc.2021.732214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 658 |
Montisci A, Vietri MT, Palmieri V, Sala S, Donatelli F, Napoli C. Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. Cancers (Basel) 2021;13:4797. [PMID: 34638281 DOI: 10.3390/cancers13194797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 659 |
Awad MM, Le Bruchec Y, Lu B, Ye J, Miller J, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Front Oncol 2021;11:696512. [PMID: 34552864 DOI: 10.3389/fonc.2021.696512] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 660 |
Peng TR, Lin HH, Tsai FP, Wu TW. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis. Thorac Cancer 2021;12:2873-85. [PMID: 34545685 DOI: 10.1111/1759-7714.14148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 661 |
Miyawaki T, Naito T, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Takahashi K, Takahashi T. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. Support Care Cancer 2021. [PMID: 34550461 DOI: 10.1007/s00520-021-06572-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 662 |
Yang X, Jin X, Xu R, Yu Z, An N. ER expression associates with poor prognosis in male lung squamous carcinoma after radical resection. BMC Cancer 2021;21:1043. [PMID: 34548052 DOI: 10.1186/s12885-021-08777-6] [Reference Citation Analysis]
|
| 663 |
Morita C, Yoshida T, Shirasawa M, Masuda K, Matsumoto Y, Shinno Y, Yagishita S, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Motoi N, Yatabe Y, Ohe Y. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Sci Rep 2021;11:18762. [PMID: 34548567 DOI: 10.1038/s41598-021-98275-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 664 |
Leem G, Park J, Jeon M, Kim ES, Kim SW, Lee YJ, Choi SJ, Choi B, Park S, Ju YS, Jung I, Kim S, Shin EC, Lee JY, Park SH. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. J Immunother Cancer 2020;8:e001650. [PMID: 33335029 DOI: 10.1136/jitc-2020-001650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 665 |
Xia J, Chen Y, Wen S, Du X, Shen B. [Peripheral Blood Inflammation Indicators as Predictive Indicators in
Immunotherapy of Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:632-45. [PMID: 34521188 DOI: 10.3779/j.issn.1009-3419.2021.103.10] [Reference Citation Analysis]
|
| 666 |
Wang F, Gao J, Ren Y, Su H, She Y, Xie D, Chen C. Predicted outcomes of subdividing M1-stage metastatic lung cancer based on the prognosis and the response to local consolidative therapy. Ann Transl Med 2021;9:1293. [PMID: 34532430 DOI: 10.21037/atm-21-1383] [Reference Citation Analysis]
|
| 667 |
Zhang K, Wang H, Fang J, Xu Q. Immune checkpoint inhibitor combined with anti-angiogenesis agent inhibits metastasis of advanced adenoid cystic carcinoma of the tongue base to the lung: a case report. Ann Transl Med 2021;9:1353. [PMID: 34532490 DOI: 10.21037/atm-21-3426] [Reference Citation Analysis]
|
| 668 |
Kong F, Wang Z, Liao D, Zuo J, Xie H, Li X, Jia Y. Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance. Front Oncol 2021;11:739191. [PMID: 34532293 DOI: 10.3389/fonc.2021.739191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 669 |
Wang H, Wang Z, Hou Z, Yang X, Zhu K, Cao M, Zhu X, Li H, Zhang T. The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib. Cancer Manag Res 2021;13:6989-98. [PMID: 34522141 DOI: 10.2147/CMAR.S311526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 670 |
Yamaguchi Y, Aso M, Nagasawa H, Wada M. Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma. Intern Med 2021;60:3025-9. [PMID: 33776010 DOI: 10.2169/internalmedicine.6917-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 671 |
Alessi JV, Ricciuti B, Jiménez-Aguilar E, Hong F, Wei Z, Nishino M, Plodkowski AJ, Sawan P, Luo J, Rizvi H, Carter BW, Heymach JV, Altan M, Hellmann M, Awad M. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer 2020;8:e001007. [PMID: 32753547 DOI: 10.1136/jitc-2020-001007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 672 |
Larbouret C, Gros L, Pèlegrin A, Chardès T. Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures. Cancers (Basel) 2021;13:4620. [PMID: 34572847 DOI: 10.3390/cancers13184620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 673 |
Kemper M, Evers G, Schulze AB, Sperveslage J, Schülke C, Lenz G, Herold T, Hartmann W, Schildhaus HU, Bleckmann A. Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition. Oncotarget 2021;12:1946-52. [PMID: 34548910 DOI: 10.18632/oncotarget.28062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 674 |
Wang L, Liu F, Li J, Ma L, Feng H, Liu Q, Cho WC, Chen H, Chen H, Guo H, Li Z, Howard SC, Li M, Shan B, Gu W, Ji J. From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific? J Pers Med 2021;11:914. [PMID: 34575691 DOI: 10.3390/jpm11090914] [Reference Citation Analysis]
|
| 675 |
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. J Cancer Res Clin Oncol 2021. [PMID: 34510271 DOI: 10.1007/s00432-021-03782-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 676 |
Liberini V, Mariniello A, Righi L, Capozza M, Delcuratolo MD, Terreno E, Farsad M, Volante M, Novello S, Deandreis D. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. Cancers (Basel) 2021;13:4543. [PMID: 34572771 DOI: 10.3390/cancers13184543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 677 |
Jiménez Galán R, Prado-Mel E, Pérez-Moreno MA, Caballano-Infantes E, Flores Moreno S. Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population. Biology (Basel) 2021;10:890. [PMID: 34571767 DOI: 10.3390/biology10090890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 678 |
Xiong W, Zhao Y, Du H, Guo X. Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. Front Oncol 2021;11:704336. [PMID: 34490104 DOI: 10.3389/fonc.2021.704336] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 679 |
Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, Athanasiadis I, Gaissmaier L, Elshiaty M, Daniello L, Christopoulou A, Pentheroudakis G, Lianos E, Linardou H, Kriegsmann K, Kosmidis P, El Shafie R, Kriegsmann M, Psyrri A, Andreadis C, Fountzilas E, Heussel CP, Herth FJ, Winter H, Emmanouilides C, Oikonomopoulos G, Meister M, Muley T, Bischoff H, Saridaki Z, Razis E, Perdikouri EI, Stenzinger A, Boukovinas I, Reck M, Syrigos K, Thomas M, Christopoulos P. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open 2021;6:100254. [PMID: 34481329 DOI: 10.1016/j.esmoop.2021.100254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 680 |
Tian W, Sun Y, Cheng Y, Ma X, Du W, Shi W, Guo Q. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1. Thorac Cancer 2021;12:2551-63. [PMID: 34469060 DOI: 10.1111/1759-7714.14136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 681 |
Evangelista L, Sepulcri M, Pasello G. PET/CT and the Response to Immunotherapy in Lung Cancer. Curr Radiopharm 2020;13:177-84. [PMID: 31858908 DOI: 10.2174/1874471013666191220105449] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 682 |
Mojsak D, Kuklińska B, Minarowski Ł, Mróz RM. Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review. Adv Med Sci 2021;66:381-7. [PMID: 34315013 DOI: 10.1016/j.advms.2021.07.005] [Reference Citation Analysis]
|
| 683 |
Zhang L, Zhang T, Shang B, Li Y, Cao Z, Wang H. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Scand J Immunol 2021;94:e13087. [PMID: 35226388 DOI: 10.1111/sji.13087] [Reference Citation Analysis]
|
| 684 |
Hirata T, Sugimoto K, Kakegawa T, Takahashi H, Tomita Y, Wada T, Abe M, Yoshimasu Y, Takeuchi H, Saito K, Terashi H, Itoi T. A case of suspected autoimmune encephalitis after the introduction of atezolizumab + bevacizumab therapy for hepatocellular carcinoma. Acta hepatologica Japonica 2021;62:590-592. [DOI: 10.2957/kanzo.62.590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 685 |
Reinmuth N, Merk M, Duell T. NSCLC und SCLC. Pneumo News 2021;13:35-43. [DOI: 10.1007/s15033-021-2728-6] [Reference Citation Analysis]
|
| 686 |
Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol 2021;7:1368-77. [PMID: 34264316 DOI: 10.1001/jamaoncol.2021.2209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 687 |
Makunts T, Saunders IM, Cohen IV, Li M, Moumedjian T, Issa MA, Burkhart K, Lee P, Patel SP, Abagyan R. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep 2021;11:17324. [PMID: 34462476 DOI: 10.1038/s41598-021-96467-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 688 |
Ge Y, Zhang H, Weygant N, Yao J. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Front Pharmacol 2021;12:640099. [PMID: 34447305 DOI: 10.3389/fphar.2021.640099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 689 |
Sierra-Rodero B, Cruz-Bermúdez A, Nadal E, Garitaonaindía Y, Insa A, Mosquera J, Casal-Rubio J, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, García-Grande A, Romero A, Franco F, Provencio M. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. J Immunother Cancer 2021;9:e002804. [PMID: 34446577 DOI: 10.1136/jitc-2021-002804] [Reference Citation Analysis]
|
| 690 |
Wang C, Li J, Zhang Q, Wu J, Xiao Y, Song L, Gong H, Li Y. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer. BMC Cancer 2021;21:968. [PMID: 34454455 DOI: 10.1186/s12885-021-08662-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 691 |
Udagawa H, Sugiyama E, Harada T, Atagi S, Koyama R, Watanabe S, Nakamura Y, Harada D, Hataji O, Tanaka F, Kida H, Satouchi M, Maeno K, Inoue A, Yoh K, Yamane Y, Urata Y, Yoshioka H, Yamanaka T, Goto K. Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR). Transl Lung Cancer Res 2021;10:3059-70. [PMID: 34430347 DOI: 10.21037/tlcr-21-240] [Reference Citation Analysis]
|
| 692 |
Ren S, Xu A, Lin Y, Camidge DR, Di Maio M, Califano R, Hida T, Rossi A, Guibert N, Zhu C, Shen J. A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future. Transl Lung Cancer Res 2021;10:3264-75. [PMID: 34430363 DOI: 10.21037/tlcr-21-259] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 693 |
Tanaka I, Furukawa T, Morise M. The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. Cancer Cell Int 2021;21:454. [PMID: 34446006 DOI: 10.1186/s12935-021-02165-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 694 |
Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Stenzinger A, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Transl Lung Cancer Res 2021;10:3093-105. [PMID: 34430350 DOI: 10.21037/tlcr-21-197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 695 |
Tjong MC, Louie AV, Iyengar P, Solomon BJ, Palma DA, Siva S. Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review. Transl Lung Cancer Res 2021;10:3446-56. [PMID: 34430379 DOI: 10.21037/tlcr-20-994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 696 |
Passiglia F, Galvano A, Gristina V, Barraco N, Castiglia M, Perez A, La Mantia M, Russo A, Bazan V. Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?-a trial-level meta-analysis in PD-L1 selected subgroups. Transl Lung Cancer Res 2021;10:3106-19. [PMID: 34430351 DOI: 10.21037/tlcr-21-52] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 697 |
Du J, Zhang Y, Dong Y, Duan J, Bai H, Wang J, Xu J, Wang Z. Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. Thorac Cancer 2021;12:2732-9. [PMID: 34432361 DOI: 10.1111/1759-7714.14114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 698 |
Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, Tolaney SM. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer 2021;7:110. [PMID: 34433812 DOI: 10.1038/s41523-021-00287-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 699 |
Bironzo P, Passiglia F, Novello S. Winds From the ORIENT: New Data to Inform RATIONAL Choice? J Thorac Oncol 2021;16:1434-6. [PMID: 34425995 DOI: 10.1016/j.jtho.2021.07.003] [Reference Citation Analysis]
|
| 700 |
Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Shinomiya S, Imai H, Kobayashi K, Kagamu H. Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. J Clin Med 2021;10:3744. [PMID: 34442054 DOI: 10.3390/jcm10163744] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 701 |
Higuchi M, Kawamata T, Oshibe I, Soeta N, Saito T, Hojo H, Matsumura Y, Suzuki H. Pathological Complete Response after Immune-Checkpoint Inhibitor Followed by Salvage Surgery for Clinical Stage IV Pulmonary Adenocarcinoma with Continuous Low Neutrophil-to-Lymphocyte Ratio: A Case Report. Case Rep Oncol 2021;14:1124-33. [PMID: 34413743 DOI: 10.1159/000515509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 702 |
Lim JU, Kim SH, Kang HS, Kim SK, Kim JS, Kim JW, Kim SJ, Yeo CD, Choi CM. Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy. J Clin Med 2021;10:3719. [PMID: 34442015 DOI: 10.3390/jcm10163719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 703 |
Seguchi K, Nakashima K, Terao T, Takeshita G, Nagai T, Tanaka Y. Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report. Respir Med Case Rep 2021;33:101439. [PMID: 34401279 DOI: 10.1016/j.rmcr.2021.101439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 704 |
Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E, Fumagalli C, Pisapia P, Pepe F, De Luca C, Cucchiara F, Troncone G, Danesi R, Spaggiari L, De Marinis F, Rolfo C. Understanding EGFR heterogeneity in lung cancer. ESMO Open 2020;5:e000919. [PMID: 33067323 DOI: 10.1136/esmoopen-2020-000919] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 705 |
Chen Q, Zhang L, Mo X, You J, Chen L, Fang J, Wang F, Jin Z, Zhang B, Zhang S. Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021. [PMID: 34402924 DOI: 10.1007/s00259-021-05509-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 706 |
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021;27:1345-56. [PMID: 34385702 DOI: 10.1038/s41591-021-01450-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 36.5] [Reference Citation Analysis]
|
| 707 |
Saez de Gordoa K, Lopez I, Marginet M, Coloma B, Frigola G, Vega N, Martinez D, Teixido C. PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain. Diagnostics (Basel) 2021;11:1452. [PMID: 34441386 DOI: 10.3390/diagnostics11081452] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 708 |
Shen CI, Chao HS, Shiao TH, Chiang CL, Huang HC, Luo YH, Chiu CH, Chen YM. Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. Sci Rep 2021;11:16122. [PMID: 34373555 DOI: 10.1038/s41598-021-95628-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 709 |
Lyadova MA, Lyadov VK. Immunotherapy in elderly patients. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-9-26-32] [Reference Citation Analysis]
|
| 710 |
Xu X, Li R, Zhu P, Zhang P, Chen J, Lin Y, Chen Y. Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study. World J Surg Oncol 2021;19:231. [PMID: 34362384 DOI: 10.1186/s12957-021-02340-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 711 |
Li CL, Song Y. Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges. Chin Med J (Engl) 2021;134:1908-19. [PMID: 34343148 DOI: 10.1097/CM9.0000000000001610] [Reference Citation Analysis]
|
| 712 |
Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol 2021;18:527-40. [PMID: 33833434 DOI: 10.1038/s41571-021-00496-y] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 37.5] [Reference Citation Analysis]
|
| 713 |
Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 714 |
Yang Z, Yu R, Deng W, Wang W. Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer. J Cancer Res Clin Oncol 2021. [PMID: 34324065 DOI: 10.1007/s00432-021-03740-1] [Reference Citation Analysis]
|
| 715 |
Dart SJ, Cook AM, Millward MJ, McDonnell AM, Chin WL, Hakeem MU, Meniawy TM, Bowyer SE. Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. Sci Rep 2021;11:15312. [PMID: 34321489 DOI: 10.1038/s41598-021-93479-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 716 |
Bienia A, Wiecheć-Cudak O, Murzyn AA, Krzykawska-Serda M. Photodynamic Therapy and Hyperthermia in Combination Treatment-Neglected Forces in the Fight against Cancer. Pharmaceutics 2021;13:1147. [PMID: 34452108 DOI: 10.3390/pharmaceutics13081147] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 717 |
Liu SR, Yan Q, Lin HM, Shi GZ, Cao Y, Zeng H, Liu C, Zhang R. Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World J Clin Cases 2021; 9(21): 5988-5998 [PMID: 34368318 DOI: 10.12998/wjcc.v9.i21.5988] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 718 |
Wu D, Wei C, Li Y, Yang X, Zhou S. Pyroptosis, a New Breakthrough in Cancer Treatment. Front Oncol 2021;11:698811. [PMID: 34381721 DOI: 10.3389/fonc.2021.698811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 719 |
Moeller M, Adner J, Schuette W, Krueger M. [30- and 90-day Lethality in Patients with Stage IV Lung Cancer Depending on the Primary Therapy]. Pneumologie 2021;75:950-9. [PMID: 34298565 DOI: 10.1055/a-1534-1339] [Reference Citation Analysis]
|
| 720 |
Maio M, Lahn M, Di Giacomo AM, Covre A, Calabrò L, Ibrahim R, Fox B; Siena Think Tank. A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. J Exp Clin Cancer Res 2021;40:240. [PMID: 34301276 DOI: 10.1186/s13046-021-02023-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 721 |
Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, Ni C, Chen Z. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res 2021;9:59. [PMID: 34294146 DOI: 10.1186/s40364-021-00312-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 722 |
Vernieri C, Ganzinelli M, Rulli E, Farina G, Bettini AC, Bareggi C, Rosso L, Signorelli D, Galli G, Lo Russo G, Proto C, Moro M, Indraccolo S, Busico A, Sozzi G, Torri V, Marabese M, Massimo B, Garassino MC. LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open 2020;5:e000748. [PMID: 32467099 DOI: 10.1136/esmoopen-2020-000748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 723 |
Kang BW, Chau I. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. ESMO Open 2020;5:e000791. [PMID: 32817133 DOI: 10.1136/esmoopen-2020-000791] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 724 |
Xu Z, Li T, Hu X, Hao X, Xing P, Li J. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). Thorac Cancer 2021;12:2360-8. [PMID: 34268872 DOI: 10.1111/1759-7714.14078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 725 |
Toi Y, Kobayashi T, Harada T, Nakagawa T, Mori Y, Kuda T, Sugawara S. Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204. Front Oncol 2021;11:685320. [PMID: 34336670 DOI: 10.3389/fonc.2021.685320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 726 |
He MY, Halford MM, Liu R, Roy JP, Grant ZL, Coultas L, Thio N, Gilan O, Chan YC, Dawson MA, Achen MG, Stacker SA. Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy. Commun Biol 2021;4:878. [PMID: 34267311 DOI: 10.1038/s42003-021-02397-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 727 |
Shi H, Li K, Ni Y, Liang X, Zhao X. Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Front Cell Dev Biol 2021;9:707198. [PMID: 34336860 DOI: 10.3389/fcell.2021.707198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 728 |
Von CE, Fuang HG. A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma. Respir Med Case Rep 2021;34:101478. [PMID: 34336591 DOI: 10.1016/j.rmcr.2021.101478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 729 |
Tian Y, Li R, Liu Y, Li M, Song Y, Zheng Y, Gao A, Wen Q, Su G, Sun Y. The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:667650. [PMID: 34322382 DOI: 10.3389/fonc.2021.667650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 730 |
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. Oncoimmunology 2021;10:1950411. [PMID: 34290909 DOI: 10.1080/2162402X.2021.1950411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 731 |
Baroz AR, Mambetsariev I, Fricke J, Pharaon R, Tan T, Kidambi T, Sandhu KS, Koczywas M, Salgia R. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. Cureus 2021;13:e16266. [PMID: 34377604 DOI: 10.7759/cureus.16266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 732 |
Hsu JC, Nguyen PA, Chen YT, Yang SC, Lin CC, Yang YH, Lin YC, Hsia TC, Hsieh HC, Wu JS, Chang CP, Feng YH, Lin PC, Hsu PC, Tzeng HE, Chien SC, Chang WC, Chang CC, Yang HC, Lee CM, Lu CY. The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study. Front Oncol 2021;11:671127. [PMID: 34307141 DOI: 10.3389/fonc.2021.671127] [Reference Citation Analysis]
|
| 733 |
Liapis V, Tieu W, Wittwer NL, Gargett T, Evdokiou A, Takhar P, Rudd SE, Donnelly PS, Brown MP, Staudacher AH. Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models. Mol Imaging Biol 2021. [PMID: 34231102 DOI: 10.1007/s11307-021-01620-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 734 |
Rzhevskiy A, Kapitannikova A, Malinina P, Volovetsky A, Aboulkheyr Es H, Kulasinghe A, Thiery JP, Maslennikova A, Zvyagin AV, Ebrahimi Warkiani M. Emerging role of circulating tumor cells in immunotherapy. Theranostics 2021;11:8057-75. [PMID: 34335980 DOI: 10.7150/thno.59677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 735 |
Petrelli F, Morelli AM, Luciani A, Ghidini A, Solinas C. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Targ Oncol. [DOI: 10.1007/s11523-021-00824-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 736 |
Guckenberger M. Systemischer Effekt einer lokalen Strahlentherapie: Erste klinische Evidenz. InFo Hämatol Onkol 2021;24:27-28. [DOI: 10.1007/s15004-021-8731-6] [Reference Citation Analysis]
|
| 737 |
Vellanki PJ, Mulkey F, Jaigirdar AA, Rodriguez L, Wang Y, Xu Y, Zhao H, Liu J, Howe G, Wang J, Choo Q, Golding SJ, Mansell V, Korsah K, Spillman D, de Claro RA, Pazdur R, Beaver JA, Singh H. FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. Clin Cancer Res 2021;27:3522-7. [PMID: 33632925 DOI: 10.1158/1078-0432.CCR-20-4338] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 738 |
Xie X, Lin J, Kang M, Guo Y. Effects of MicroRNA-22 (miR-222) on Non-Small-Cell Lung Carcinoma (NSCLC) Cells Apoptosis and Proliferation Through Protein Kinase B/Mammalian Target of Rapamycin (AKT/mTOR) Signaling Pathway. j biomater tissue eng 2021;11:1346-51. [DOI: 10.1166/jbt.2021.2693] [Reference Citation Analysis]
|
| 739 |
Eichbaum M, Eichbaum C. Bislang kein zusätzlicher Nutzen durch eine Checkpointinhibition mit Atezolizumab. InFo Hämatol Onkol 2021;24:29-30. [DOI: 10.1007/s15004-021-8727-2] [Reference Citation Analysis]
|
| 740 |
Garon EB, Scagliotti GV, Gautschi O, Reck M, Thomas M, Iglesias Docampo L, Kalofonos H, Kim JH, Gans S, Brustugun OT, Orlov SV, Cuyun Carter G, Zimmermann AH, Oton AB, Alexandris E, Lee P, Wolff K, Stefaniak VJ, Socinski MA, Pérol M. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. ESMO Open 2020;5:e000567. [PMID: 31958290 DOI: 10.1136/esmoopen-2019-000567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 741 |
Presley CJ, Gomes F, Burd CE, Kanesvaran R, Wong ML. Immunotherapy in Older Adults With Cancer. J Clin Oncol 2021;39:2115-27. [PMID: 34043444 DOI: 10.1200/JCO.21.00138] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 742 |
Suazo-Zepeda E, Bokern M, Vinke PC, Hiltermann TJN, de Bock GH, Sidorenkov G. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Immunol Immunother 2021. [PMID: 34195862 DOI: 10.1007/s00262-021-02996-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 743 |
Russell BL, Sooklal SA, Malindisa ST, Daka LJ, Ntwasa M. The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Front Oncol 2021;11:641428. [PMID: 34268109 DOI: 10.3389/fonc.2021.641428] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 744 |
He F, Wang G, Xu Z, Huang Z. Nelfinavir restricts A549 cell growth by inhibiting STAT3 signaling. J Int Med Res 2021;49:3000605211014989. [PMID: 34167351 DOI: 10.1177/03000605211014989] [Reference Citation Analysis]
|
| 745 |
Popovic LS, Matovina-Brko G, Popovic M, Popovic M, Cvetanovic A, Nikolic I, Kukic B, Petrovic D. Immunotherapy in the treatment of lymphoma. World J Stem Cells 2021;13:503-20. [PMID: 34249225 DOI: 10.4252/wjsc.v13.i6.503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 746 |
Li S, Zhang H, Liu T, Chen J, Dang J. The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis. Front Oncol 2021;11:702924. [PMID: 34249764 DOI: 10.3389/fonc.2021.702924] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 747 |
Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF, Kadel E 3rd, Baldwin N, Jhunjhunwala S, Nickles D, Assaf ZJ, Bower D, Patil N, McCleland M, Shames D, Molinero L, Huseni M, Sanjabi S, Cummings C, Mellman I, Mariathasan S, Hegde P, Powles T. Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun 2021;12:3969. [PMID: 34172722 DOI: 10.1038/s41467-021-24112-w] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 748 |
Khaddour K, Jonna S, Deneka A, Patel JD, Abazeed ME, Golemis E, Borghaei H, Boumber Y. Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers (Basel) 2021;13:3164. [PMID: 34202748 DOI: 10.3390/cancers13133164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 749 |
Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 2021. [PMID: 34168333 DOI: 10.1038/s41571-021-00520-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 750 |
Shionoya Y, Hattori A, Hanada T, Fujino M. Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma. Front Oncol 2021;11:693279. [PMID: 34249743 DOI: 10.3389/fonc.2021.693279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 751 |
Chiu LC, Lin SM, Lo YL, Kuo SC, Yang CT, Hsu PC. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines (Basel) 2021;9:689. [PMID: 34201650 DOI: 10.3390/vaccines9070689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 752 |
Ferreira M, Secher T, Heuze-Vourc'H N, Reckamp KL. Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics 2021;13:912. [PMID: 34205484 DOI: 10.3390/pharmaceutics13060912] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 753 |
Saito S, Toyokawa G, Momosaki S, Kozuma Y, Shoji F, Yamazaki K, Takeo S. Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient. Thorac Cancer 2021;12:2217-20. [PMID: 34151529 DOI: 10.1111/1759-7714.14051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 754 |
Hayashi K, Tokui K, Inomata M, Azechi K, Mizushima I, Takata N, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Nomura S, Tobe K. Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors. In Vivo 2021;35:1687-92. [PMID: 33910853 DOI: 10.21873/invivo.12428] [Reference Citation Analysis]
|
| 755 |
Crombet Ramos T, Santos Morales O, Dy GK, León Monzón K, Lage Dávila A. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Front Oncol 2021;11:639745. [PMID: 34211836 DOI: 10.3389/fonc.2021.639745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 756 |
Higuera Gómez O, Moreno Paul A, Ortega Granados AL, Ros Martínez S, Pérez Parente D, Ruiz Gracia P, Sáenz Cuervo-Arango L, Vilà L. "High Tumor Burden" in Metastatic Non-Small Cell Lung Cancer: Defining the Concept. Cancer Manag Res 2021;13:4665-70. [PMID: 34163241 DOI: 10.2147/CMAR.S302928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 757 |
Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Mol Med 2021;13:e08253. [PMID: 34125494 DOI: 10.15252/emmm.201708253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 758 |
Saito S, Abe T, Iino M, Aoshika T, Ryuno Y, Ohta T, Igari M, Hirai R, Kumazaki Y, Yamaguchi O, Kaira K, Kagamu H, Noda SE, Kato S. Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy. J Radiat Res 2021;62:669-75. [PMID: 34121123 DOI: 10.1093/jrr/rrab051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 759 |
Dong N, Moreno-Manuel A, Calabuig-Fariñas S, Gallach S, Zhang F, Blasco A, Aparisi F, Meri-Abad M, Guijarro R, Sirera R, Camps C, Jantus-Lewintre E. Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients. Cancers (Basel) 2021;13:2950. [PMID: 34204662 DOI: 10.3390/cancers13122950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 760 |
Dantoing E, Piton N, Salaün M, Thiberville L, Guisier F. Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. Int J Mol Sci 2021;22:6288. [PMID: 34208111 DOI: 10.3390/ijms22126288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 761 |
Chi A, He X, Hou L, Nguyen NP, Zhu G, Cameron RB, Lee JM. Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. Cancers (Basel) 2021;13:2924. [PMID: 34208113 DOI: 10.3390/cancers13122924] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 762 |
Passaro A, Novello S, Giannarelli D, Bria E, Galetta D, Gelibter A, Reale ML, Carnio S, Vita E, Stefani A, Pizzutilo P, Stati V, Attili I, de Marinis F. Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. Cancers (Basel) 2021;13:2935. [PMID: 34208253 DOI: 10.3390/cancers13122935] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 763 |
Niu X, Sun Y, Planchard D, Chiu L, Bai J, Ai X, Lu S. Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. Front Oncol 2021;11:634920. [PMID: 34178624 DOI: 10.3389/fonc.2021.634920] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 764 |
Della Gravara L, Battiloro C, Letizia A, Cantile R, D'agnano V, Sica G, Rocco D. Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients. JMP 2021;2:197-206. [DOI: 10.3390/jmp2020017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 765 |
Zheng Y, Hao S, Xiang C, Han Y, Shang Y, Zhen Q, Zhao Y, Zhang M, Zhang Y. The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis. Front Oncol 2021;11:592854. [PMID: 34178613 DOI: 10.3389/fonc.2021.592854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 766 |
Konstantinopoulos PA, Cannistra SA. Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality? J Clin Oncol 2021;39:1833-8. [PMID: 33891471 DOI: 10.1200/JCO.21.00571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 767 |
Cui W, Popat S. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. Drugs 2021;81:971-84. [PMID: 34106454 DOI: 10.1007/s40265-021-01506-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 768 |
Khan Z, Hammer C, Carroll J, Di Nucci F, Acosta SL, Maiya V, Bhangale T, Hunkapiller J, Mellman I, Albert ML, McCarthy MI, Chandler GS. Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nat Commun 2021;12:3355. [PMID: 34099659 DOI: 10.1038/s41467-021-23661-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 769 |
Mao S, Zhou F, Liu Y, Yang S, Chen B, Xu J, Wu F, Li X, Zhao C, Wang W, Liu Q, Yu X, Jia K, Shao C, Zhou C, Gao G, Ren S. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. Cancer Immunol Immunother 2021. [PMID: 34097116 DOI: 10.1007/s00262-021-02974-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 770 |
Wojas-Krawczyk K, Krawczyk P, Gil M, Strzemski M. Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients-Mechanism of Action and Future Concepts. Cancers (Basel) 2021;13:2836. [PMID: 34200219 DOI: 10.3390/cancers13112836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 771 |
Lai LT, Gu WG, Hu MB, Wang WJ, Wang SS, Huai YJ, Mei JH, Wang CL. Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. Aging (Albany NY) 2021;13:15413-32. [PMID: 34086601 DOI: 10.18632/aging.203100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 772 |
Zhang T, Yang X, Zhao J, Xia L, Wang Q, Jin R, Zhou L, Zhang B, Zhao J, Li H, Li W, Xia Y. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. Front Oncol 2021;11:690093. [PMID: 34150659 DOI: 10.3389/fonc.2021.690093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 773 |
Ferro A, Filoni A, Pavan A, Pasello G, Guarneri V, Conte P, Alaibac M, Bonanno L. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Front Med (Lausanne) 2021;8:570921. [PMID: 34179028 DOI: 10.3389/fmed.2021.570921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 774 |
Li DN, Lu WQ, Yang BW, Zhang LY, Jin B, Wang S, Che XF, Li C, Liu YP, Qu XJ. Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis. Front Immunol 2021;12:666909. [PMID: 34149702 DOI: 10.3389/fimmu.2021.666909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 775 |
Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S. Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. PLoS One 2021;16:e0252537. [PMID: 34061904 DOI: 10.1371/journal.pone.0252537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 776 |
Akanda ZZ, Neeson PJ, John T, Barnett S, Hanna GG, Miller A, Jennens R, Siva S. A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Transl Lung Cancer Res 2021;10:2766-78. [PMID: 34295676 DOI: 10.21037/tlcr-20-1117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 777 |
Guaitoli G, Tiseo M, Di Maio M, Friboulet L, Facchinetti F. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res 2021;10:2890-916. [PMID: 34295687 DOI: 10.21037/tlcr-20-941] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 778 |
Hendriks LEL, Remon J, Menis J, Besse B. Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases? Transl Lung Cancer Res 2021;10:2868-75. [PMID: 34295685 DOI: 10.21037/tlcr-20-343] [Reference Citation Analysis]
|
| 779 |
Inoue H, Tsutsumi H, Tanaka K, Iwama E, Shiraishi Y, Hirayama A, Nakanishi T, Ando H, Nakajima M, Shinozaki S, Ogata H, Uryu K, Okamura K, Kimura S, Ogawa T, Ota K, Yoneshima Y, Hamada N, Nakanishi Y, Okamoto I. Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer. Transl Lung Cancer Res 2021;10:2475-86. [PMID: 34295655 DOI: 10.21037/tlcr-21-92] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 780 |
Geng N, Su J, Liu Z, Ding C, Xie S, Hu W. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen. Technol Cancer Res Treat 2021;20:15330338211019433. [PMID: 34060368 DOI: 10.1177/15330338211019433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 781 |
Naltet C, Besse B. Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. Transl Lung Cancer Res 2021;10:3014-28. [PMID: 34295694 DOI: 10.21037/tlcr-20-1239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 782 |
Gantner LF. Immuntherapien - Hoffnungsträger in der Therapie des Zervixkarzinoms. InFo Hämatol Onkol 2021;24:16-22. [DOI: 10.1007/s15004-021-8694-7] [Reference Citation Analysis]
|
| 783 |
Zhou C, Li S, Liu J, Chu Q, Miao L, Cai L, Cai X, Chen Y, Cui F, Dong Y, Dong W, Fang W, He Y, Li W, Li M, Liang W, Lin G, Lin J, Lin X, Liu H, Liu M, Mu X, Hu Y, Hu J, Jin Y, Li Z, Qin Y, Ren S, Sun G, Shen Y, Su C, Tang K, Wu L, Wang M, Wang H, Wang K, Wang Y, Wang P, Wang H, Wang Q, Wang Z, Xie X, Xie Z, Xu X, Xu F, Yang M, Yang B, Yi X, Ye X, Ye F, Yu Z, Yue D, Zhang B, Zhang J, Zhang J, Zhang X, Zhang W, Zhao W, Zhu B, Zhu Z, Zhong W, Bai C, Chen L, Han B, Hu C, Lu S, Li W, Song Y, Wang J, Zhou C, Zhou J, Zhou Y, Saito Y, Ichiki Y, Igai H, Watanabe S, Bravaccini S, Fiorelli A, Petrella F, Nakada T, Solli P, Tsoukalas N, Kataoka Y, Goto T, Berardi R, He J, Zhong N. International consensus on severe lung cancer-the first edition. Transl Lung Cancer Res 2021;10:2633-66. [PMID: 34295668 DOI: 10.21037/tlcr-21-467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 784 |
McLean L, Leal JL, Solomon BJ, John T. Immunotherapy in oncogene addicted non-small cell lung cancer. Transl Lung Cancer Res 2021;10:2736-51. [PMID: 34295674 DOI: 10.21037/tlcr-20-772] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 785 |
Passiglia F, Cetoretta V, De Filippis M, Napoli V, Novello S. Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease. Transl Lung Cancer Res 2021;10:2876-89. [PMID: 34295686 DOI: 10.21037/tlcr-20-635] [Reference Citation Analysis]
|
| 786 |
Lee YJ, Lee JB, Ha SJ, Kim HR. Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer. Mol Cells 2021;44:363-73. [PMID: 34001680 DOI: 10.14348/molcells.2021.0044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 787 |
Li T, Pang X, Wang J, Wang S, Guo Y, He N, Xing P, Li J. Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma. Front Oncol 2021;11:591922. [PMID: 34136375 DOI: 10.3389/fonc.2021.591922] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 788 |
Kataoka N, Kunimatsu Y, Tsutsumi R, Tani N, Sato I, Tanimura M, Nakano T, Tanimura K, Kato D, Takeda T. Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report. Medicina (Kaunas) 2021;57:547. [PMID: 34072448 DOI: 10.3390/medicina57060547] [Reference Citation Analysis]
|
| 789 |
Sheng L, Gao J, Xu Q, Zhang X, Huang M, Dai X, Li S, Liu L. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol 2021;13:17588359211018537. [PMID: 34104227 DOI: 10.1177/17588359211018537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 790 |
Tanimura K, Yamada T, Omura A, Shiotsu S, Kataoka N, Takeda T, Taniguchi R, Yamada T, Takeuchi M, Chihara Y, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. Front Oncol 2021;11:663612. [PMID: 34123822 DOI: 10.3389/fonc.2021.663612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 791 |
Montanino A, Manzo A, Carillio G, Palumbo G, Esposito G, Sforza V, Costanzo R, Sandomenico C, Botti G, Piccirillo MC, Cascetta P, Pascarella G, La Manna C, Normanno N, Morabito A. Angiogenesis Inhibitors in Small Cell Lung Cancer. Front Oncol 2021;11:655316. [PMID: 34123809 DOI: 10.3389/fonc.2021.655316] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 792 |
Zhang Q, Tang L, Zhou Y, He W, Li W. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. Front Immunol 2021;12:663986. [PMID: 34122422 DOI: 10.3389/fimmu.2021.663986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 793 |
Feng Y, Zhu G, Lang S, Hao P, Li G, Chen F, Zhuo W, Duan Y, Zhang A, Chen Z, Sun J. The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations. Front Oncol 2021;11:659065. [PMID: 34123814 DOI: 10.3389/fonc.2021.659065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 794 |
Zhao D, Li H, Mambetsariev I, Chen C, Pharaon R, Fricke J, Baroz AR, Kulkarni P, Xing Y, Massarelli E, Koczywas M, Reckamp KL, Margolin K, Salgia R. Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:2653. [PMID: 34071259 DOI: 10.3390/cancers13112653] [Reference Citation Analysis]
|
| 795 |
Kato R, Hayashi H, Chiba Y, Miyawaki E, Shimizu J, Ozaki T, Fujimoto D, Toyozawa R, Nakamura A, Kozuki T, Tanaka K, Teraoka S, Usui K, Nishino K, Hataji O, Ota K, Ebi N, Saeki S, Akazawa Y, Okuno M, Yamamoto N, Nakagawa K. Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L). J Immunother Cancer 2020;8:e000350. [PMID: 32066647 DOI: 10.1136/jitc-2019-000350] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 796 |
Alsina-Sanchis E, Mülfarth R, Fischer A. Control of Tumor Progression by Angiocrine Factors. Cancers (Basel) 2021;13:2610. [PMID: 34073394 DOI: 10.3390/cancers13112610] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 797 |
To KKW, Fong W, Cho WCS. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Front Oncol 2021;11:635007. [PMID: 34113560 DOI: 10.3389/fonc.2021.635007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 798 |
Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L, Dong L, Zhang C, Zheng X, Deng S, Kuai J, Liu Z, Jiang W, Wang X, Wu D, Huang Y. DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression. Proc Natl Acad Sci U S A 2021;118:e2020057118. [PMID: 34035167 DOI: 10.1073/pnas.2020057118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 799 |
Xia T, Du WL, Chen XY, Zhang YN. Organoid models of the tumor microenvironment and their applications. J Cell Mol Med 2021. [PMID: 34033245 DOI: 10.1111/jcmm.16578] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 800 |
Tian Y, Huang A, Yang Y, Dang Q, Wen Q, Wang L, Sun Y. Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:662392. [PMID: 34109117 DOI: 10.3389/fonc.2021.662392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 801 |
Ai B, Yang Y. [Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:626-30. [PMID: 32702797 DOI: 10.3779/j.issn.1009-3419.2020.101.34] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 802 |
Giroux Leprieur E, Hélias-Rodzewicz Z, Takam Kamga P, Costantini A, Julie C, Corjon A, Dumenil C, Dumoulin J, Giraud V, Labrune S, Garinet S, Chinet T, Emile JF. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. J Immunother Cancer 2020;8:e000527. [PMID: 32581058 DOI: 10.1136/jitc-2020-000527] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 803 |
Kockx MM, McCleland M, Koeppen H. Microenvironmental regulation of tumour immunity and response to immunotherapy. J Pathol 2021;254:374-83. [PMID: 33846997 DOI: 10.1002/path.5681] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 804 |
Marchal C, Orillard E, Calais F, Westeel V. Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. Cochrane Database of Systematic Reviews 2021. [DOI: 10.1002/14651858.cd014907] [Reference Citation Analysis]
|
| 805 |
Tong J 3rd, Mao Y, Yang Z, Xu Q, Zheng Z, Zhang H, Wang J, Zhang S, Rong W, Zheng L 3rd. Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment. Cancer Manag Res 2021;13:4041-53. [PMID: 34040444 DOI: 10.2147/CMAR.S304022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 806 |
Dyrka K, Witasik D, Czarnywojtek A, Łącka K. The influence of monoclonal antibodies for cancer treatment on the endocrine system. Postepy Hig Med Dosw 2021;75:317-27. [DOI: 10.5604/01.3001.0014.8889] [Reference Citation Analysis]
|
| 807 |
Chen Y, Wen S, Xia J, Du X, Wu Y, Pan B, Zhu W, Shen B. Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer. Front Immunol 2021;12:672271. [PMID: 34054853 DOI: 10.3389/fimmu.2021.672271] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 808 |
Lee D, Park J, Choi H, Gim G, Cho S, Kim L, Oh Y, Kang CY, Kim Y, Tan D, de Viveiros PAH, Chae YK. Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapy.. [DOI: 10.1101/2021.05.10.21256924] [Reference Citation Analysis]
|
| 809 |
Tian Y, Wang J, Wen Q, Su G, Sun Y. Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis. Aging (Albany NY) 2021;13:12691-709. [PMID: 33973529 DOI: 10.18632/aging.202941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 810 |
Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, Yan L, Xiong B, Liang B, Zheng C. Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Front Oncol 2021;11:621639. [PMID: 34046338 DOI: 10.3389/fonc.2021.621639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 811 |
Ayers KL, Mullaney T, Zhou X, Liu JJ, Lee K, Ma M, Jones S, Li L, Redfern A, Jappe W, Liu Z, Goldsweig H, Yadav KK, Hahner N, Dietz M, Zimmerman M, Prentice T, Newman S, Veluswamy R, Wisnivesky J, Hirsch FR, Oh WK, Li SD, Schadt EE, Chen R. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. Oncologist 2021;26:e1226-39. [PMID: 33829580 DOI: 10.1002/onco.13780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 812 |
Lee G. Current advances in the treatment of lung cancer with immune checkpoint inhibitors. J Korean Med Assoc 2021;64:333-41. [DOI: 10.5124/jkma.2021.64.5.333] [Reference Citation Analysis]
|
| 813 |
Akaba T, Shiota Y, Onizawa F, Isaka T, Nagashima Y, Tagaya E. Recurrent spindle cell carcinoma of the lung successfully treated by chemoimmunotherapy. Respirol Case Rep 2021;9:e00757. [PMID: 33976886 DOI: 10.1002/rcr2.757] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 814 |
Mair MJ, Ilhan-Mutlu A, Pajenda S, Kiesel B, Wöhrer A, Widhalm G, Dieckmann K, Marosi C, Wagner L, Preusser M, Berghoff AS. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. Cancer Immunol Immunother 2021. [PMID: 33956203 DOI: 10.1007/s00262-021-02951-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 815 |
Truong NTH, Gargett T, Brown MP, Ebert LM. Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. Cancers (Basel) 2021;13:2225. [PMID: 34066414 DOI: 10.3390/cancers13092225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 816 |
Fang L, Zhao W, Ye B, Chen D. Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer. Front Oncol 2021;11:670313. [PMID: 34017689 DOI: 10.3389/fonc.2021.670313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 817 |
Hammer C, Ruppel J, Hunkapiller J, Mellman I, Quarmby V. Allelic Variation in HLA-DRB1 is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing in Vitro.. [DOI: 10.1101/2021.04.29.21256008] [Reference Citation Analysis]
|
| 818 |
Lim JU, Kang HS, Yeo CD, Kim JS, Park CK, Kim JW, Kim SJ, Lee SH. Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. J Thorac Dis 2021;13:2824-32. [PMID: 34164174 DOI: 10.21037/jtd-20-3416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 819 |
Cervantez SR, Karnad AB. Recognition and Management of Toxicities from Immunotherapy and Targeted Therapy in Elderly Patients with Lung Cancer. Advances in Oncology 2021;1:73-84. [DOI: 10.1016/j.yao.2021.02.007] [Reference Citation Analysis]
|
| 820 |
Park CK, Oh HJ, Kim MS, Koh BG, Cho HJ, Kim YC, Yang HJ, Lee JY, Chun SM, Oh IJ. Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 2021;10:2103-17. [PMID: 34164263 DOI: 10.21037/tlcr-21-100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 821 |
Hu R, Zhao Z, Shi Y, Shi M, Xia G, Yu S, Feng J. Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis. J Thorac Dis 2021;13:2959-67. [PMID: 34164187 DOI: 10.21037/jtd-20-3520] [Reference Citation Analysis]
|
| 822 |
Kalita B, Coumar MS. Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics. Cell Oncol (Dordr) 2021;44:751-75. [PMID: 33914273 DOI: 10.1007/s13402-021-00611-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 823 |
Trukhin D, Poddubskaya E, Andric Z, Makharadze T, Bellala RS, Charoentum C, Yañez Ruiz EP, Fulop A, Hyder Ali IA, Syrigos K, Katgi N, Lopez Chuken YA, Rumyana I, Reyes-Igama J, Costamilan RC, Del Campo García A, Florez A, Paravisini A, Millan S; STELLA Investigators. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). BioDrugs 2021;35:429-44. [PMID: 33914256 DOI: 10.1007/s40259-021-00483-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 824 |
Korphaisarn K, Danchaivijitr P, Reungwetwattana T, Chewaskulyong B, Thongthieang L, Chindaprasirt J, Maneenil K, Sathitruangsak C, Vinayanuwattikun C. Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study. Front Oncol 2021;11:572740. [PMID: 33996532 DOI: 10.3389/fonc.2021.572740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 825 |
Liu G, Kang S, Wang X, Shang F. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status. Front Oncol 2021;11:669195. [PMID: 33987103 DOI: 10.3389/fonc.2021.669195] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 826 |
Zhong Q, Tao Y, Chen H, Zhou Y, Huang L, Han X, Shi Y. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. Lancet Reg Health West Pac 2021;11:100151. [PMID: 34327360 DOI: 10.1016/j.lanwpc.2021.100151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 827 |
Zhou C, Wang J, Wang B, Cheng Y, Wang Z, Han B, Lu Y, Wu G, Zhang L, Song Y, Zhu B, Hu Y, Wang Z, Song Q, Ren S, He Y, Hu X, Zhang J, Yao Y, Zhao H, Wang Z, Chu Q, Duan J, Liu J, Qin S. [Chinese Experts Consensus on Immune Checkpoint Inhibitors
for Non-small Cell Lung Cancer (2020 Version)]. Zhongguo Fei Ai Za Zhi 2021;24:217-35. [PMID: 33896153 DOI: 10.3779/j.issn.1009-3419.2021.101.13] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 828 |
Fares J, Ulasov I, Timashev P, Lesniak MS. Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. Brain 2021;144:1046-66. [PMID: 33893488 DOI: 10.1093/brain/awab012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 829 |
De Wispelaere W, Annibali D, Tuyaerts S, Lambrechts D, Amant F. Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types? Cancers (Basel) 2021;13:2040. [PMID: 33922556 DOI: 10.3390/cancers13092040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 830 |
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol 2021;39:1842-55. [PMID: 33891472 DOI: 10.1200/JCO.21.00306] [Cited by in Crossref: 75] [Cited by in F6Publishing: 87] [Article Influence: 37.5] [Reference Citation Analysis]
|
| 831 |
Gu M, Xu T, Chang P. KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Ther Adv Med Oncol 2021;13:17588359211006950. [PMID: 33995590 DOI: 10.1177/17588359211006950] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 832 |
Zhang Z, Gu Y, Su X, Bai J, Guan W, Ma J, Luo J, He J, Zhang B, Geng M, Xia X, Guan Y, Shen C, Chen C. Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC. Front Oncol 2021;11:659321. [PMID: 33968765 DOI: 10.3389/fonc.2021.659321] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 833 |
Shereen A, Jack A K, Mahmoud L. Current medical and surgical management of lung cancer. J Surg Surgical Res 2021. [DOI: 10.17352/2455-2968.000137] [Reference Citation Analysis]
|
| 834 |
Daga H. First-line Immunotherapy for Advanced Non-small-cell Lung Cancer. JJLC 2021;61:88-94. [DOI: 10.2482/haigan.61.88] [Reference Citation Analysis]
|
| 835 |
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol 2021;39:2339-49. [PMID: 33872070 DOI: 10.1200/JCO.21.00174] [Cited by in Crossref: 139] [Cited by in F6Publishing: 156] [Article Influence: 69.5] [Reference Citation Analysis]
|
| 836 |
Huang LT, Cao R, Wang YR, Sun L, Zhang XY, Guo YJ, Zhao JZ, Zhang SL, Jing W, Song J, Han CB, Ma J. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials. BMC Cancer 2021;21:426. [PMID: 33865364 DOI: 10.1186/s12885-021-08136-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 837 |
Chen Y, Yang Z, Wang Y, Hu M, Zhang B, Zhang Y, Qian F, Zhang W, Han B. Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC. Front Oncol 2021;11:671228. [PMID: 33937084 DOI: 10.3389/fonc.2021.671228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 838 |
Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Cui P, Huang D, Huang Z, Wu Z, Hu Y. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:562315. [PMID: 33937012 DOI: 10.3389/fonc.2021.562315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 839 |
Kuehl PJ, Yingling CM, Dubose D, Burke M, Revelli DA, Chen W, Dye WW, Belinsky SA, Tessema M. Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. Drug Deliv 2021;28:767-75. [PMID: 33860729 DOI: 10.1080/10717544.2021.1912209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 840 |
Roubec J. What a general practitioner should know about bronchogenic carcinoma. Med Pro Praxi 2021;18:63-67. [DOI: 10.36290/med.2021.010] [Reference Citation Analysis]
|
| 841 |
Lopes-Coelho F, Martins F, Pereira SA, Serpa J. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Int J Mol Sci 2021;22:3765. [PMID: 33916438 DOI: 10.3390/ijms22073765] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 842 |
Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov 2021;11:1368-97. [PMID: 33811048 DOI: 10.1158/2159-8290.CD-20-1209] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 19.5] [Reference Citation Analysis]
|
| 843 |
Deng H, Zhou C. From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era-chemo-free or chemo-reform? Transl Lung Cancer Res 2021;10:1924-7. [PMID: 34012802 DOI: 10.21037/tlcr-21-179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 844 |
Matsumoto K, Tamiya A, Matsuda Y, Taniguchi Y, Atagi S, Kawachi H, Tamiya M, Tanizaki S, Uchida J, Ueno K, Yanase T, Suzuki H, Hirashima T. Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. Transl Lung Cancer Res 2021;10:1642-52. [PMID: 34012781 DOI: 10.21037/tlcr-20-1263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 845 |
Alemany M, Domènech M, Argyriou AA, Vilariño N, Majós C, Naval-Baudin P, Lucas A, Palmero R, Simó M, Nadal E, Bruna J. Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. Ann Transl Med 2021;9:648. [PMID: 33987346 DOI: 10.21037/atm-20-6497] [Reference Citation Analysis]
|
| 846 |
Sebastian M, Stratmann JA, Eberhardt WEE. Too Good to be True? J Thorac Oncol 2021;16:507-8. [PMID: 33781437 DOI: 10.1016/j.jtho.2021.01.1606] [Reference Citation Analysis]
|
| 847 |
Rounis K, Skribek M, Makrakis D, De Petris L, Agelaki S, Ekman S, Tsakonas G. Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy. Cancers (Basel) 2021;13:1562. [PMID: 33805335 DOI: 10.3390/cancers13071562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 848 |
Shao J, Wang C, Ren P, Jiang Y, Tian P, Li W. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep 2020;40:BSR20192347. [PMID: 32315071 DOI: 10.1042/BSR20192347] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 849 |
Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D. Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:1569. [PMID: 33805461 DOI: 10.3390/cancers13071569] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 850 |
Shang M, Yang H, Yang R, Chen T, Fu Y, Li Y, Fang X, Zhang K, Zhang J, Li H, Cao X, Gu J, Xiao J, Zhang Q, Liu X, Yu Q, Wang T. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. Nat Commun 2021;12:1940. [PMID: 33782411 DOI: 10.1038/s41467-021-22173-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 851 |
Tani T, Kitajima S, Conway EB, Knelson EH, Barbie DA. KRAS G12C inhibition and innate immune targeting. Expert Opin Ther Targets 2021;25:167-74. [PMID: 33703985 DOI: 10.1080/14728222.2021.1902991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 852 |
Stroh GR, Peikert T, Escalante P. Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area. Cancer Immunol Immunother 2021. [PMID: 33770211 DOI: 10.1007/s00262-021-02905-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 853 |
Majem M, Cobo M, Isla D, Marquez-Medina D, Rodriguez-Abreu D, Casal-Rubio J, Bueno TM, Bernabé-Caro R, Parente DP, Ruiz-Gracia P, Arroyo MM, Paz-Ares L. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. J Clin Med 2021;10:1365. [PMID: 33810441 DOI: 10.3390/jcm10071365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 854 |
Momozane T, Shigetsu K, Kimura Y, Kishima H, Kodama K. The histological diagnosis and molecular testing of lung cancer by surgical biopsy for intrathoracic lesions. Gen Thorac Cardiovasc Surg 2021;69:1185-91. [PMID: 33768496 DOI: 10.1007/s11748-021-01600-w] [Reference Citation Analysis]
|
| 855 |
Sankar K, Nagrath S |
